Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer</title><author><name sortKey="Gavalas, Nikos G" sort="Gavalas, Nikos G" uniqKey="Gavalas N" first="Nikos G." last="Gavalas">Nikos G. Gavalas</name></author><author><name sortKey="Liontos, Michalis" sort="Liontos, Michalis" uniqKey="Liontos M" first="Michalis" last="Liontos">Michalis Liontos</name></author><author><name sortKey="Trachana, Sofia Paraskevi" sort="Trachana, Sofia Paraskevi" uniqKey="Trachana S" first="Sofia-Paraskevi" last="Trachana">Sofia-Paraskevi Trachana</name></author><author><name sortKey="Bagratuni, Tina" sort="Bagratuni, Tina" uniqKey="Bagratuni T" first="Tina" last="Bagratuni">Tina Bagratuni</name></author><author><name sortKey="Arapinis, Calliope" sort="Arapinis, Calliope" uniqKey="Arapinis C" first="Calliope" last="Arapinis">Calliope Arapinis</name></author><author><name sortKey="Liacos, Christine" sort="Liacos, Christine" uniqKey="Liacos C" first="Christine" last="Liacos">Christine Liacos</name></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name></author><author><name sortKey="Bamias, Aristotle" sort="Bamias, Aristotle" uniqKey="Bamias A" first="Aristotle" last="Bamias">Aristotle Bamias</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23903048</idno><idno type="pmc">3759892</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759892</idno><idno type="RBID">PMC:3759892</idno><idno type="doi">10.3390/ijms140815885</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000195</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000195</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer</title><author><name sortKey="Gavalas, Nikos G" sort="Gavalas, Nikos G" uniqKey="Gavalas N" first="Nikos G." last="Gavalas">Nikos G. Gavalas</name></author><author><name sortKey="Liontos, Michalis" sort="Liontos, Michalis" uniqKey="Liontos M" first="Michalis" last="Liontos">Michalis Liontos</name></author><author><name sortKey="Trachana, Sofia Paraskevi" sort="Trachana, Sofia Paraskevi" uniqKey="Trachana S" first="Sofia-Paraskevi" last="Trachana">Sofia-Paraskevi Trachana</name></author><author><name sortKey="Bagratuni, Tina" sort="Bagratuni, Tina" uniqKey="Bagratuni T" first="Tina" last="Bagratuni">Tina Bagratuni</name></author><author><name sortKey="Arapinis, Calliope" sort="Arapinis, Calliope" uniqKey="Arapinis C" first="Calliope" last="Arapinis">Calliope Arapinis</name></author><author><name sortKey="Liacos, Christine" sort="Liacos, Christine" uniqKey="Liacos C" first="Christine" last="Liacos">Christine Liacos</name></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name></author><author><name sortKey="Bamias, Aristotle" sort="Bamias, Aristotle" uniqKey="Bamias A" first="Aristotle" last="Bamias">Aristotle Bamias</name></author></analytic><series><title level="j">International Journal of Molecular Sciences</title><idno type="eISSN">1422-0067</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Ovarian Cancer represents the most fatal type of gynecological malignancies. A number of processes are involved in the pathogenesis of ovarian cancer, especially within the tumor microenvironment. Angiogenesis represents a hallmark phenomenon in cancer, and it is responsible for tumor spread and metastasis in ovarian cancer, among other tumor types, as it leads to new blood vessel formation. In recent years angiogenesis has been given considerable attention in order to identify targets for developing effective anti-tumor therapies. Growth factors have been identified to play key roles in driving angiogenesis and, thus, the formation of new blood vessels that assist in “feeding” cancer. Such molecules include the vascular endothelial growth factor (VEGF), the platelet derived growth factor (PDGF), the fibroblast growth factor (FGF), and the angiopoietin/Tie2 receptor complex. These proteins are key players in complex molecular pathways within the tumor cell and they have been in the spotlight of the development of anti-angiogenic molecules that may act as stand-alone therapeutics, or in concert with standard treatment regimes such as chemotherapy. The pathways involved in angiogenesis and molecules that have been developed in order to combat angiogenesis are described in this paper.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Siegel, R" uniqKey="Siegel R">R. Siegel</name></author><author><name sortKey="Naishadham, D" uniqKey="Naishadham D">D. Naishadham</name></author><author><name sortKey="Jemal, A" uniqKey="Jemal A">A. Jemal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yabroff, K R" uniqKey="Yabroff K">K.R. Yabroff</name></author><author><name sortKey="Lamont, E B" uniqKey="Lamont E">E.B. Lamont</name></author><author><name sortKey="Mariotto, A" uniqKey="Mariotto A">A. Mariotto</name></author><author><name sortKey="Warren, J L" uniqKey="Warren J">J.L. Warren</name></author><author><name sortKey="Topor, M" uniqKey="Topor M">M. Topor</name></author><author><name sortKey="Meekins, A" uniqKey="Meekins A">A. Meekins</name></author><author><name sortKey="Brown, M L" uniqKey="Brown M">M.L. Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilks, C B" uniqKey="Gilks C">C.B. Gilks</name></author><author><name sortKey="Prat, J" uniqKey="Prat J">J. Prat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vaughan, S" uniqKey="Vaughan S">S. Vaughan</name></author><author><name sortKey="Coward, J I" uniqKey="Coward J">J.I. Coward</name></author><author><name sortKey="Bast, R C" uniqKey="Bast R">R.C. Bast</name></author><author><name sortKey="Berchuck, A" uniqKey="Berchuck A">A. Berchuck</name></author><author><name sortKey="Berek, J S" uniqKey="Berek J">J.S. Berek</name></author><author><name sortKey="Brenton, J D" uniqKey="Brenton J">J.D. Brenton</name></author><author><name sortKey="Coukos, G" uniqKey="Coukos G">G. Coukos</name></author><author><name sortKey="Crum, C C" uniqKey="Crum C">C.C. Crum</name></author><author><name sortKey="Drapkin, R" uniqKey="Drapkin R">R. Drapkin</name></author><author><name sortKey="Etemadmoghadam, D" uniqKey="Etemadmoghadam D">D. Etemadmoghadam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liliac, L" uniqKey="Liliac L">L. Liliac</name></author><author><name sortKey="Amalinei, C" uniqKey="Amalinei C">C. Amalinei</name></author><author><name sortKey="Balan, R" uniqKey="Balan R">R. Balan</name></author><author><name sortKey="Grigoras, A" uniqKey="Grigoras A">A. Grigoras</name></author><author><name sortKey="Caruntu, I D" uniqKey="Caruntu I">I.D. Caruntu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, W" uniqKey="Cheng W">W. Cheng</name></author><author><name sortKey="Liu, J" uniqKey="Liu J">J. Liu</name></author><author><name sortKey="Yoshida, H" uniqKey="Yoshida H">H. Yoshida</name></author><author><name sortKey="Rosen, D" uniqKey="Rosen D">D. Rosen</name></author><author><name sortKey="Naora, H" uniqKey="Naora H">H. Naora</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lauchlan, S C" uniqKey="Lauchlan S">S.C. Lauchlan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lauchlan, S C" uniqKey="Lauchlan S">S.C. Lauchlan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lamb, J D" uniqKey="Lamb J">J.D. Lamb</name></author><author><name sortKey="Garcia, R L" uniqKey="Garcia R">R.L. Garcia</name></author><author><name sortKey="Goff, B A" uniqKey="Goff B">B.A. Goff</name></author><author><name sortKey="Paley, P J" uniqKey="Paley P">P.J. Paley</name></author><author><name sortKey="Swisher, E M" uniqKey="Swisher E">E.M. Swisher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Piek, J M" uniqKey="Piek J">J.M. Piek</name></author><author><name sortKey="Van Diest, P J" uniqKey="Van Diest P">P.J. van Diest</name></author><author><name sortKey="Zweemer, R P" uniqKey="Zweemer R">R.P. Zweemer</name></author><author><name sortKey="Jansen, J W" uniqKey="Jansen J">J.W. Jansen</name></author><author><name sortKey="Poort Keesom, R J" uniqKey="Poort Keesom R">R.J. Poort-Keesom</name></author><author><name sortKey="Menko, F H" uniqKey="Menko F">F.H. Menko</name></author><author><name sortKey="Gille, J J" uniqKey="Gille J">J.J. Gille</name></author><author><name sortKey="Jongsma, A P" uniqKey="Jongsma A">A.P. Jongsma</name></author><author><name sortKey="Pals, G" uniqKey="Pals G">G. Pals</name></author><author><name sortKey="Kenemans, P" uniqKey="Kenemans P">P. Kenemans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Finch, A" uniqKey="Finch A">A. Finch</name></author><author><name sortKey="Shaw, P" uniqKey="Shaw P">P. Shaw</name></author><author><name sortKey="Rosen, B" uniqKey="Rosen B">B. Rosen</name></author><author><name sortKey="Murphy, J" uniqKey="Murphy J">J. Murphy</name></author><author><name sortKey="Narod, S A" uniqKey="Narod S">S.A. Narod</name></author><author><name sortKey="Colgan, T J" uniqKey="Colgan T">T.J. Colgan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Callahan, M J" uniqKey="Callahan M">M.J. Callahan</name></author><author><name sortKey="Crum, C P" uniqKey="Crum C">C.P. Crum</name></author><author><name sortKey="Medeiros, F" uniqKey="Medeiros F">F. Medeiros</name></author><author><name sortKey="Kindelberger, D W" uniqKey="Kindelberger D">D.W. Kindelberger</name></author><author><name sortKey="Elvin, J A" uniqKey="Elvin J">J.A. Elvin</name></author><author><name sortKey="Garber, J E" uniqKey="Garber J">J.E. Garber</name></author><author><name sortKey="Feltmate, C M" uniqKey="Feltmate C">C.M. Feltmate</name></author><author><name sortKey="Berkowitz, R S" uniqKey="Berkowitz R">R.S. Berkowitz</name></author><author><name sortKey="Muto, M G" uniqKey="Muto M">M.G. Muto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hermsen, B B" uniqKey="Hermsen B">B.B. Hermsen</name></author><author><name sortKey="Van Diest, P J" uniqKey="Van Diest P">P.J. van Diest</name></author><author><name sortKey="Berkhof, J" uniqKey="Berkhof J">J. Berkhof</name></author><author><name sortKey="Menko, F H" uniqKey="Menko F">F.H. Menko</name></author><author><name sortKey="Gille, J J" uniqKey="Gille J">J.J. Gille</name></author><author><name sortKey="Piek, J M" uniqKey="Piek J">J.M. Piek</name></author><author><name sortKey="Meijer, S" uniqKey="Meijer S">S. Meijer</name></author><author><name sortKey="Winters, H A" uniqKey="Winters H">H.A. Winters</name></author><author><name sortKey="Kenemans, P" uniqKey="Kenemans P">P. Kenemans</name></author><author><name sortKey="Mensdorff Pouilly, S V" uniqKey="Mensdorff Pouilly S">S.V. Mensdorff-Pouilly</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kindelberger, D W" uniqKey="Kindelberger D">D.W. Kindelberger</name></author><author><name sortKey="Lee, Y" uniqKey="Lee Y">Y. Lee</name></author><author><name sortKey="Miron, A" uniqKey="Miron A">A. Miron</name></author><author><name sortKey="Hirsch, M S" uniqKey="Hirsch M">M.S. Hirsch</name></author><author><name sortKey="Feltmate, C" uniqKey="Feltmate C">C. Feltmate</name></author><author><name sortKey="Medeiros, F" uniqKey="Medeiros F">F. Medeiros</name></author><author><name sortKey="Callahan, M J" uniqKey="Callahan M">M.J. Callahan</name></author><author><name sortKey="Garner, E O" uniqKey="Garner E">E.O. Garner</name></author><author><name sortKey="Gordon, R W" uniqKey="Gordon R">R.W. Gordon</name></author><author><name sortKey="Birch, C" uniqKey="Birch C">C. Birch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diaz Padilla, I" uniqKey="Diaz Padilla I">I. Diaz-Padilla</name></author><author><name sortKey="Malpica, A L" uniqKey="Malpica A">A.L. Malpica</name></author><author><name sortKey="Minig, L" uniqKey="Minig L">L. Minig</name></author><author><name sortKey="Chiva, L M" uniqKey="Chiva L">L.M. Chiva</name></author><author><name sortKey="Gershenson, D M" uniqKey="Gershenson D">D.M. Gershenson</name></author><author><name sortKey="Gonzalez Martin, A" uniqKey="Gonzalez Martin A">A. Gonzalez-Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singer, G" uniqKey="Singer G">G. Singer</name></author><author><name sortKey="Oldt, R" uniqKey="Oldt R">R. Oldt</name></author><author><name sortKey="Cohen, Y" uniqKey="Cohen Y">Y. Cohen</name></author><author><name sortKey="Wang, B G" uniqKey="Wang B">B.G. Wang</name></author><author><name sortKey="Sidransky, D" uniqKey="Sidransky D">D. Sidransky</name></author><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, S E" uniqKey="Wang S">S.E. Wang</name></author><author><name sortKey="Narasanna, A" uniqKey="Narasanna A">A. Narasanna</name></author><author><name sortKey="Perez Torres, M" uniqKey="Perez Torres M">M. Perez-Torres</name></author><author><name sortKey="Xiang, B" uniqKey="Xiang B">B. Xiang</name></author><author><name sortKey="Wu, F Y" uniqKey="Wu F">F.Y. Wu</name></author><author><name sortKey="Yang, S" uniqKey="Yang S">S. Yang</name></author><author><name sortKey="Carpenter, G" uniqKey="Carpenter G">G. Carpenter</name></author><author><name sortKey="Gazdar, A F" uniqKey="Gazdar A">A.F. Gazdar</name></author><author><name sortKey="Muthuswamy, S K" uniqKey="Muthuswamy S">S.K. Muthuswamy</name></author><author><name sortKey="Arteaga, C L" uniqKey="Arteaga C">C.L. Arteaga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Campbell, I G" uniqKey="Campbell I">I.G. Campbell</name></author><author><name sortKey="Russell, S E" uniqKey="Russell S">S.E. Russell</name></author><author><name sortKey="Choong, D Y" uniqKey="Choong D">D.Y. Choong</name></author><author><name sortKey="Montgomery, K G" uniqKey="Montgomery K">K.G. Montgomery</name></author><author><name sortKey="Ciavarella, M L" uniqKey="Ciavarella M">M.L. Ciavarella</name></author><author><name sortKey="Hooi, C S" uniqKey="Hooi C">C.S. Hooi</name></author><author><name sortKey="Cristiano, B E" uniqKey="Cristiano B">B.E. Cristiano</name></author><author><name sortKey="Pearson, R B" uniqKey="Pearson R">R.B. Pearson</name></author><author><name sortKey="Phillips, W A" uniqKey="Phillips W">W.A. Phillips</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, S" uniqKey="Jones S">S. Jones</name></author><author><name sortKey="Wang, T L" uniqKey="Wang T">T.L. Wang</name></author><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author><author><name sortKey="Mao, T L" uniqKey="Mao T">T.L. Mao</name></author><author><name sortKey="Nakayama, K" uniqKey="Nakayama K">K. Nakayama</name></author><author><name sortKey="Roden, R" uniqKey="Roden R">R. Roden</name></author><author><name sortKey="Glas, R" uniqKey="Glas R">R. Glas</name></author><author><name sortKey="Slamon, D" uniqKey="Slamon D">D. Slamon</name></author><author><name sortKey="Diaz, L A" uniqKey="Diaz L">L.A. Diaz</name></author><author><name sortKey="Vogelstein, B" uniqKey="Vogelstein B">B. Vogelstein</name></author><author><name sortKey="Papadopoulos, N" uniqKey="Papadopoulos N">N. Papadopoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmed, A A" uniqKey="Ahmed A">A.A. Ahmed</name></author><author><name sortKey="Etemadmoghadam, D" uniqKey="Etemadmoghadam D">D. Etemadmoghadam</name></author><author><name sortKey="Temple, J" uniqKey="Temple J">J. Temple</name></author><author><name sortKey="Lynch, A G" uniqKey="Lynch A">A.G. Lynch</name></author><author><name sortKey="Riad, M" uniqKey="Riad M">M. Riad</name></author><author><name sortKey="Sharma, R" uniqKey="Sharma R">R. Sharma</name></author><author><name sortKey="Stewart, C" uniqKey="Stewart C">C. Stewart</name></author><author><name sortKey="Fereday, S" uniqKey="Fereday S">S. Fereday</name></author><author><name sortKey="Caldas, C" uniqKey="Caldas C">C. Caldas</name></author><author><name sortKey="Defazio, A" uniqKey="Defazio A">A. Defazio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Efeyan, A" uniqKey="Efeyan A">A. Efeyan</name></author><author><name sortKey="Serrano, M" uniqKey="Serrano M">M. Serrano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lane, D P" uniqKey="Lane D">D.P. Lane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuo, K T" uniqKey="Kuo K">K.T. Kuo</name></author><author><name sortKey="Guan, B" uniqKey="Guan B">B. Guan</name></author><author><name sortKey="Feng, Y" uniqKey="Feng Y">Y. Feng</name></author><author><name sortKey="Mao, T L" uniqKey="Mao T">T.L. Mao</name></author><author><name sortKey="Chen, X" uniqKey="Chen X">X. Chen</name></author><author><name sortKey="Jinawath, N" uniqKey="Jinawath N">N. Jinawath</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name></author><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author><author><name sortKey="Wang, T L" uniqKey="Wang T">T.L. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nakayama, K" uniqKey="Nakayama K">K. Nakayama</name></author><author><name sortKey="Nakayama, N" uniqKey="Nakayama N">N. Nakayama</name></author><author><name sortKey="Jinawath, N" uniqKey="Jinawath N">N. Jinawath</name></author><author><name sortKey="Salani, R" uniqKey="Salani R">R. Salani</name></author><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author><author><name sortKey="Shih, I M" uniqKey="Shih I">I.M. Shih</name></author><author><name sortKey="Wang, T L" uniqKey="Wang T">T.L. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perren, T J" uniqKey="Perren T">T.J. Perren</name></author><author><name sortKey="Swart, A M" uniqKey="Swart A">A.M. Swart</name></author><author><name sortKey="Pfisterer, J" uniqKey="Pfisterer J">J. Pfisterer</name></author><author><name sortKey="Ledermann, J A" uniqKey="Ledermann J">J.A. Ledermann</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E. Pujade-Lauraine</name></author><author><name sortKey="Kristensen, G" uniqKey="Kristensen G">G. Kristensen</name></author><author><name sortKey="Carey, M S" uniqKey="Carey M">M.S. Carey</name></author><author><name sortKey="Beale, P" uniqKey="Beale P">P. Beale</name></author><author><name sortKey="Cervantes, A" uniqKey="Cervantes A">A. Cervantes</name></author><author><name sortKey="Kurzeder, C" uniqKey="Kurzeder C">C. Kurzeder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Itamochi, H" uniqKey="Itamochi H">H. Itamochi</name></author><author><name sortKey="Kigawa, J" uniqKey="Kigawa J">J. Kigawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aghajanian, C" uniqKey="Aghajanian C">C. Aghajanian</name></author><author><name sortKey="Blank, S V" uniqKey="Blank S">S.V. Blank</name></author><author><name sortKey="Goff, B A" uniqKey="Goff B">B.A. Goff</name></author><author><name sortKey="Judson, P L" uniqKey="Judson P">P.L. Judson</name></author><author><name sortKey="Teneriello, M G" uniqKey="Teneriello M">M.G. Teneriello</name></author><author><name sortKey="Husain, A" uniqKey="Husain A">A. Husain</name></author><author><name sortKey="Sovak, M A" uniqKey="Sovak M">M.A. Sovak</name></author><author><name sortKey="Yi, J" uniqKey="Yi J">J. Yi</name></author><author><name sortKey="Nycum, L R" uniqKey="Nycum L">L.R. Nycum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hall, A" uniqKey="Hall A">A. Hall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Folkman, J" uniqKey="Folkman J">J. Folkman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weidner, N" uniqKey="Weidner N">N. Weidner</name></author><author><name sortKey="Folkman, J" uniqKey="Folkman J">J. Folkman</name></author><author><name sortKey="Pozza, F" uniqKey="Pozza F">F. Pozza</name></author><author><name sortKey="Bevilacqua, P" uniqKey="Bevilacqua P">P. Bevilacqua</name></author><author><name sortKey="Allred, E N" uniqKey="Allred E">E.N. Allred</name></author><author><name sortKey="Moore, D H" uniqKey="Moore D">D.H. Moore</name></author><author><name sortKey="Meli, S" uniqKey="Meli S">S. Meli</name></author><author><name sortKey="Gasparini, G" uniqKey="Gasparini G">G. Gasparini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith Mccune, K K" uniqKey="Smith Mccune K">K.K. Smith-McCune</name></author><author><name sortKey="Weidner, N" uniqKey="Weidner N">N. Weidner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shibuya, M" uniqKey="Shibuya M">M. Shibuya</name></author><author><name sortKey="Luo, J C" uniqKey="Luo J">J.C. Luo</name></author><author><name sortKey="Toyoda, M" uniqKey="Toyoda M">M. Toyoda</name></author><author><name sortKey="Yamaguchi, S" uniqKey="Yamaguchi S">S. Yamaguchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sherer, D M" uniqKey="Sherer D">D.M. Sherer</name></author><author><name sortKey="Eliakim, R" uniqKey="Eliakim R">R. Eliakim</name></author><author><name sortKey="Abulafia, O" uniqKey="Abulafia O">O. Abulafia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergers, E" uniqKey="Bergers E">E. Bergers</name></author><author><name sortKey="Benjamin, L E" uniqKey="Benjamin L">L.E. Benjamin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergers, G" uniqKey="Bergers G">G. Bergers</name></author><author><name sortKey="Hanahan, D" uniqKey="Hanahan D">D. Hanahan</name></author><author><name sortKey="Coussens, L M" uniqKey="Coussens L">L.M. Coussens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hanahan, D" uniqKey="Hanahan D">D. Hanahan</name></author><author><name sortKey="Folkman, J" uniqKey="Folkman J">J. Folkman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hicklin, D J" uniqKey="Hicklin D">D.J. Hicklin</name></author><author><name sortKey="Ellis, L M" uniqKey="Ellis L">L.M. Ellis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dvorak, H F" uniqKey="Dvorak H">H.F. Dvorak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gasparini, G" uniqKey="Gasparini G">G. Gasparini</name></author><author><name sortKey="Brooks, P C" uniqKey="Brooks P">P.C. Brooks</name></author><author><name sortKey="Biganzoli, E" uniqKey="Biganzoli E">E. Biganzoli</name></author><author><name sortKey="Vermeulen, P B" uniqKey="Vermeulen P">P.B. Vermeulen</name></author><author><name sortKey="Bonoldi, E" uniqKey="Bonoldi E">E. Bonoldi</name></author><author><name sortKey="Dirix, L Y" uniqKey="Dirix L">L.Y. Dirix</name></author><author><name sortKey="Ranieri, G" uniqKey="Ranieri G">G. Ranieri</name></author><author><name sortKey="Miceli, R" uniqKey="Miceli R">R. Miceli</name></author><author><name sortKey="Cheresh, D A" uniqKey="Cheresh D">D.A. Cheresh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Folkman, J" uniqKey="Folkman J">J. Folkman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ranieri, G" uniqKey="Ranieri G">G. Ranieri</name></author><author><name sortKey="Coviello, M" uniqKey="Coviello M">M. Coviello</name></author><author><name sortKey="Chiriatti, A" uniqKey="Chiriatti A">A. Chiriatti</name></author><author><name sortKey="Stea, B" uniqKey="Stea B">B. Stea</name></author><author><name sortKey="Montemuro, S" uniqKey="Montemuro S">S. Montemuro</name></author><author><name sortKey="Quaranta, M" uniqKey="Quaranta M">M. Quaranta</name></author><author><name sortKey="Dittami, R" uniqKey="Dittami R">R. Dittami</name></author><author><name sortKey="Paradiso, A" uniqKey="Paradiso A">A. Paradiso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ranieri, G" uniqKey="Ranieri G">G. Ranieri</name></author><author><name sortKey="Coviello, M" uniqKey="Coviello M">M. Coviello</name></author><author><name sortKey="Patruno, R" uniqKey="Patruno R">R. Patruno</name></author><author><name sortKey="Valerio, P" uniqKey="Valerio P">P. Valerio</name></author><author><name sortKey="Martino, D" uniqKey="Martino D">D. Martino</name></author><author><name sortKey="Milella, P" uniqKey="Milella P">P. Milella</name></author><author><name sortKey="Catalano, V" uniqKey="Catalano V">V. Catalano</name></author><author><name sortKey="Scotto, F" uniqKey="Scotto F">F. Scotto</name></author><author><name sortKey="De Ceglia, A" uniqKey="De Ceglia A">A. De Ceglia</name></author><author><name sortKey="Quaranta, M" uniqKey="Quaranta M">M. Quaranta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jayne, D G" uniqKey="Jayne D">D.G. Jayne</name></author><author><name sortKey="Perry, S L" uniqKey="Perry S">S.L. Perry</name></author><author><name sortKey="Morrison, E" uniqKey="Morrison E">E. Morrison</name></author><author><name sortKey="Farmery, S M" uniqKey="Farmery S">S.M. Farmery</name></author><author><name sortKey="Guillou, P J" uniqKey="Guillou P">P.J. Guillou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sako, A" uniqKey="Sako A">A. Sako</name></author><author><name sortKey="Kitayama, J" uniqKey="Kitayama J">J. Kitayama</name></author><author><name sortKey="Yamaguchi, H" uniqKey="Yamaguchi H">H. Yamaguchi</name></author><author><name sortKey="Kaisaki, S" uniqKey="Kaisaki S">S. Kaisaki</name></author><author><name sortKey="Suzuki, H" uniqKey="Suzuki H">H. Suzuki</name></author><author><name sortKey="Fukatsu, K" uniqKey="Fukatsu K">K. Fukatsu</name></author><author><name sortKey="Fujii, S" uniqKey="Fujii S">S. Fujii</name></author><author><name sortKey="Nagawa, H" uniqKey="Nagawa H">H. Nagawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stadlmann, S" uniqKey="Stadlmann S">S. Stadlmann</name></author><author><name sortKey="Amberger, A" uniqKey="Amberger A">A. Amberger</name></author><author><name sortKey="Pollheimer, J" uniqKey="Pollheimer J">J. Pollheimer</name></author><author><name sortKey="Gastl, G" uniqKey="Gastl G">G. Gastl</name></author><author><name sortKey="Offner, F A" uniqKey="Offner F">F.A. Offner</name></author><author><name sortKey="Margreiter, R" uniqKey="Margreiter R">R. Margreiter</name></author><author><name sortKey="Zeimet, A G" uniqKey="Zeimet A">A.G. Zeimet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gerber, S A" uniqKey="Gerber S">S.A. Gerber</name></author><author><name sortKey="Rybalko, V Y" uniqKey="Rybalko V">V.Y. Rybalko</name></author><author><name sortKey="Bigelow, C E" uniqKey="Bigelow C">C.E. Bigelow</name></author><author><name sortKey="Lugade, A A" uniqKey="Lugade A">A.A. Lugade</name></author><author><name sortKey="Foster, T H" uniqKey="Foster T">T.H. Foster</name></author><author><name sortKey="Frelinger, J G" uniqKey="Frelinger J">J.G. Frelinger</name></author><author><name sortKey="Lord, E M" uniqKey="Lord E">E.M. Lord</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Naora, H" uniqKey="Naora H">H. Naora</name></author><author><name sortKey="Montell, D J" uniqKey="Montell D">D.J. Montell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagy, J A" uniqKey="Nagy J">J.A. Nagy</name></author><author><name sortKey="Masse, E M" uniqKey="Masse E">E.M. Masse</name></author><author><name sortKey="Herzberg, K T" uniqKey="Herzberg K">K.T. Herzberg</name></author><author><name sortKey="Meyers, M S" uniqKey="Meyers M">M.S. Meyers</name></author><author><name sortKey="Yeo, K T" uniqKey="Yeo K">K.T. Yeo</name></author><author><name sortKey="Yeo, T K" uniqKey="Yeo T">T.K. Yeo</name></author><author><name sortKey="Sioussat, T M" uniqKey="Sioussat T">T.M. Sioussat</name></author><author><name sortKey="Dvorak, H F" uniqKey="Dvorak H">H.F. Dvorak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luo, J C" uniqKey="Luo J">J.C. Luo</name></author><author><name sortKey="Yamaguchi, S" uniqKey="Yamaguchi S">S. Yamaguchi</name></author><author><name sortKey="Shinkai, A" uniqKey="Shinkai A">A. Shinkai</name></author><author><name sortKey="Shitara, K" uniqKey="Shitara K">K. Shitara</name></author><author><name sortKey="Shibuya, M" uniqKey="Shibuya M">M. Shibuya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, Y" uniqKey="Liang Y">Y. Liang</name></author><author><name sortKey="Brekken, R A" uniqKey="Brekken R">R.A. Brekken</name></author><author><name sortKey="Hyder, S M" uniqKey="Hyder S">S.M. Hyder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Masood, R" uniqKey="Masood R">R. Masood</name></author><author><name sortKey="Cai, J" uniqKey="Cai J">J. Cai</name></author><author><name sortKey="Zheng, T" uniqKey="Zheng T">T. Zheng</name></author><author><name sortKey="Smith, D L" uniqKey="Smith D">D.L. Smith</name></author><author><name sortKey="Hinton, D R" uniqKey="Hinton D">D.R. Hinton</name></author><author><name sortKey="Gill, P S" uniqKey="Gill P">P.S. Gill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frumovitz, M" uniqKey="Frumovitz M">M. Frumovitz</name></author><author><name sortKey="Sood, A K" uniqKey="Sood A">A.K. Sood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spannuth, W A" uniqKey="Spannuth W">W.A. Spannuth</name></author><author><name sortKey="Sood, A K" uniqKey="Sood A">A.K. Sood</name></author><author><name sortKey="Coleman, R L" uniqKey="Coleman R">R.L. Coleman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Han, E S" uniqKey="Han E">E.S. Han</name></author><author><name sortKey="Wakabayashi, M" uniqKey="Wakabayashi M">M. Wakabayashi</name></author><author><name sortKey="Leong, L" uniqKey="Leong L">L. Leong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duncan, W C" uniqKey="Duncan W">W.C. Duncan</name></author><author><name sortKey="Nio Kobayashi, J" uniqKey="Nio Kobayashi J">J. Nio-Kobayashi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shibuya, M" uniqKey="Shibuya M">M. Shibuya</name></author><author><name sortKey="Claesson Welsh, L" uniqKey="Claesson Welsh L">L. Claesson-Welsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leung, D W" uniqKey="Leung D">D.W. Leung</name></author><author><name sortKey="Cachianes, G" uniqKey="Cachianes G">G. Cachianes</name></author><author><name sortKey="Kuang, W J" uniqKey="Kuang W">W.J. Kuang</name></author><author><name sortKey="Goeddel, D V" uniqKey="Goeddel D">D.V. Goeddel</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author><author><name sortKey="Henzel, W J" uniqKey="Henzel W">W.J. Henzel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roskoski, R" uniqKey="Roskoski R">R. Roskoski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoff, P M" uniqKey="Hoff P">P.M. Hoff</name></author><author><name sortKey="Machado, K K" uniqKey="Machado K">K.K. Machado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taggarshe, D" uniqKey="Taggarshe D">D. Taggarshe</name></author><author><name sortKey="Lobocki, C" uniqKey="Lobocki C">C. Lobocki</name></author><author><name sortKey="Silberberg, B" uniqKey="Silberberg B">B. Silberberg</name></author><author><name sortKey="Mckendrick, A" uniqKey="Mckendrick A">A. McKendrick</name></author><author><name sortKey="Mittal, V K" uniqKey="Mittal V">V.K. Mittal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soffietti, R" uniqKey="Soffietti R">R. Soffietti</name></author><author><name sortKey="Trevisan, E" uniqKey="Trevisan E">E. Trevisan</name></author><author><name sortKey="Bertero, L" uniqKey="Bertero L">L. Bertero</name></author><author><name sortKey="Bosa, C" uniqKey="Bosa C">C. Bosa</name></author><author><name sortKey="Ruda, R" uniqKey="Ruda R">R. Ruda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Vries, C" uniqKey="De Vries C">C. de Vries</name></author><author><name sortKey="Escobedo, J A" uniqKey="Escobedo J">J.A. Escobedo</name></author><author><name sortKey="Ueno, H" uniqKey="Ueno H">H. Ueno</name></author><author><name sortKey="Houck, K" uniqKey="Houck K">K. Houck</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author><author><name sortKey="Williams, L T" uniqKey="Williams L">L.T. Williams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jakeman, L B" uniqKey="Jakeman L">L.B. Jakeman</name></author><author><name sortKey="Winer, J" uniqKey="Winer J">J. Winer</name></author><author><name sortKey="Bennett, G L" uniqKey="Bennett G">G.L. Bennett</name></author><author><name sortKey="Altar, C A" uniqKey="Altar C">C.A. Altar</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ellis, L M" uniqKey="Ellis L">L.M. Ellis</name></author><author><name sortKey="Hicklin, D J" uniqKey="Hicklin D">D.J. Hicklin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joukov, V" uniqKey="Joukov V">V. Joukov</name></author><author><name sortKey="Pajusola, K" uniqKey="Pajusola K">K. Pajusola</name></author><author><name sortKey="Kaipainen, A" uniqKey="Kaipainen A">A. Kaipainen</name></author><author><name sortKey="Chilov, D" uniqKey="Chilov D">D. Chilov</name></author><author><name sortKey="Lahtinen, I" uniqKey="Lahtinen I">I. Lahtinen</name></author><author><name sortKey="Kukk, E" uniqKey="Kukk E">E. Kukk</name></author><author><name sortKey="Saksela, O" uniqKey="Saksela O">O. Saksela</name></author><author><name sortKey="Kalkkinen, N" uniqKey="Kalkkinen N">N. Kalkkinen</name></author><author><name sortKey="Alitalo, K" uniqKey="Alitalo K">K. Alitalo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Rawi, M A" uniqKey="Al Rawi M">M.A. Al-Rawi</name></author><author><name sortKey="Jiang, W G" uniqKey="Jiang W">W.G. Jiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spiliotaki, M" uniqKey="Spiliotaki M">M. Spiliotaki</name></author><author><name sortKey="Markomanolaki, H" uniqKey="Markomanolaki H">H. Markomanolaki</name></author><author><name sortKey="Mela, M" uniqKey="Mela M">M. Mela</name></author><author><name sortKey="Mavroudis, D" uniqKey="Mavroudis D">D. Mavroudis</name></author><author><name sortKey="Georgoulias, V" uniqKey="Georgoulias V">V. Georgoulias</name></author><author><name sortKey="Agelaki, S" uniqKey="Agelaki S">S. Agelaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Salgado, R" uniqKey="Salgado R">R. Salgado</name></author><author><name sortKey="Benoy, I" uniqKey="Benoy I">I. Benoy</name></author><author><name sortKey="Weytjens, R" uniqKey="Weytjens R">R. Weytjens</name></author><author><name sortKey="Van Bockstaele, D" uniqKey="Van Bockstaele D">D. Van Bockstaele</name></author><author><name sortKey="Van Marck, E" uniqKey="Van Marck E">E. Van Marck</name></author><author><name sortKey="Huget, P" uniqKey="Huget P">P. Huget</name></author><author><name sortKey="Hoylaerts, M" uniqKey="Hoylaerts M">M. Hoylaerts</name></author><author><name sortKey="Vermeulen, P" uniqKey="Vermeulen P">P. Vermeulen</name></author><author><name sortKey="Dirix, L Y" uniqKey="Dirix L">L.Y. Dirix</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="White, F C" uniqKey="White F">F.C. White</name></author><author><name sortKey="Benehacene, A" uniqKey="Benehacene A">A. Benehacene</name></author><author><name sortKey="Scheele, J S" uniqKey="Scheele J">J.S. Scheele</name></author><author><name sortKey="Kamps, M" uniqKey="Kamps M">M. Kamps</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, R A" uniqKey="Burger R">R.A. Burger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Millauer, B" uniqKey="Millauer B">B. Millauer</name></author><author><name sortKey="Wizigmann Voos, S" uniqKey="Wizigmann Voos S">S. Wizigmann-Voos</name></author><author><name sortKey="Schnurch, H" uniqKey="Schnurch H">H. Schnurch</name></author><author><name sortKey="Martinez, R" uniqKey="Martinez R">R. Martinez</name></author><author><name sortKey="Moller, N P" uniqKey="Moller N">N.P. Moller</name></author><author><name sortKey="Risau, W" uniqKey="Risau W">W. Risau</name></author><author><name sortKey="Ullrich, A" uniqKey="Ullrich A">A. Ullrich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Youssoufian, H" uniqKey="Youssoufian H">H. Youssoufian</name></author><author><name sortKey="Hicklin, D J" uniqKey="Hicklin D">D.J. Hicklin</name></author><author><name sortKey="Rowinsky, E K" uniqKey="Rowinsky E">E.K. Rowinsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carmeliet, P" uniqKey="Carmeliet P">P. Carmeliet</name></author><author><name sortKey="Moons, L" uniqKey="Moons L">L. Moons</name></author><author><name sortKey="Luttun, A" uniqKey="Luttun A">A. Luttun</name></author><author><name sortKey="Vincenti, V" uniqKey="Vincenti V">V. Vincenti</name></author><author><name sortKey="Compernolle, V" uniqKey="Compernolle V">V. Compernolle</name></author><author><name sortKey="De Mol, M" uniqKey="De Mol M">M. De Mol</name></author><author><name sortKey="Wu, Y" uniqKey="Wu Y">Y. Wu</name></author><author><name sortKey="Bono, F" uniqKey="Bono F">F. Bono</name></author><author><name sortKey="Devy, L" uniqKey="Devy L">L. Devy</name></author><author><name sortKey="Beck, H" uniqKey="Beck H">H. Beck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, S" uniqKey="Yang S">S. Yang</name></author><author><name sortKey="Toy, K" uniqKey="Toy K">K. Toy</name></author><author><name sortKey="Ingle, G" uniqKey="Ingle G">G. Ingle</name></author><author><name sortKey="Ingle, G" uniqKey="Ingle G">G. Ingle</name></author><author><name sortKey="Zlot, C" uniqKey="Zlot C">C. Zlot</name></author><author><name sortKey="Williams, P M" uniqKey="Williams P">P.M. Williams</name></author><author><name sortKey="Fuh, G" uniqKey="Fuh G">G. Fuh</name></author><author><name sortKey="Li, B" uniqKey="Li B">B. Li</name></author><author><name sortKey="De Vos, A" uniqKey="De Vos A">A. de Vos</name></author><author><name sortKey="Gerritsen, M E" uniqKey="Gerritsen M">M.E. Gerritsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kukk, E" uniqKey="Kukk E">E. Kukk</name></author><author><name sortKey="Lymboussaki, A" uniqKey="Lymboussaki A">A. Lymboussaki</name></author><author><name sortKey="Taira, S" uniqKey="Taira S">S. Taira</name></author><author><name sortKey="Kaipainen, A" uniqKey="Kaipainen A">A. Kaipainen</name></author><author><name sortKey="Jeltsch, M" uniqKey="Jeltsch M">M. Jeltsch</name></author><author><name sortKey="Joukov, V" uniqKey="Joukov V">V. Joukov</name></author><author><name sortKey="Alitalo, K" uniqKey="Alitalo K">K. Alitalo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, L" uniqKey="Zhang L">L. Zhang</name></author><author><name sortKey="Zhou, F" uniqKey="Zhou F">F. Zhou</name></author><author><name sortKey="Han, W" uniqKey="Han W">W. Han</name></author><author><name sortKey="Shen, B" uniqKey="Shen B">B. Shen</name></author><author><name sortKey="Luo, J" uniqKey="Luo J">J. Luo</name></author><author><name sortKey="Shibuya, M" uniqKey="Shibuya M">M. Shibuya</name></author><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Banerjee, S" uniqKey="Banerjee S">S. Banerjee</name></author><author><name sortKey="Kaye, S" uniqKey="Kaye S">S. Kaye</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sato, S" uniqKey="Sato S">S. Sato</name></author><author><name sortKey="Itamochi, H" uniqKey="Itamochi H">H. Itamochi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bamberger, E S" uniqKey="Bamberger E">E.S. Bamberger</name></author><author><name sortKey="Perrett, C W" uniqKey="Perrett C">C.W. Perrett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Numnum, T M" uniqKey="Numnum T">T.M. Numnum</name></author><author><name sortKey="Rocconi, R P" uniqKey="Rocconi R">R.P. Rocconi</name></author><author><name sortKey="Whitworth, J" uniqKey="Whitworth J">J. Whitworth</name></author><author><name sortKey="Barnes, M N" uniqKey="Barnes M">M.N. Barnes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Teoh, D" uniqKey="Teoh D">D. Teoh</name></author><author><name sortKey="Secord, A A" uniqKey="Secord A">A.A. Secord</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, R A" uniqKey="Burger R">R.A. Burger</name></author><author><name sortKey="Sill, M W" uniqKey="Sill M">M.W. Sill</name></author><author><name sortKey="Monk, B J" uniqKey="Monk B">B.J. Monk</name></author><author><name sortKey="Greer, B E" uniqKey="Greer B">B.E. Greer</name></author><author><name sortKey="Sorosky, J I" uniqKey="Sorosky J">J.I. Sorosky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, L" uniqKey="Zhang L">L. Zhang</name></author><author><name sortKey="Yang, N" uniqKey="Yang N">N. Yang</name></author><author><name sortKey="Katsaros, D" uniqKey="Katsaros D">D. Katsaros</name></author><author><name sortKey="Huang, W" uniqKey="Huang W">W. Huang</name></author><author><name sortKey="Park, J W" uniqKey="Park J">J.W. Park</name></author><author><name sortKey="Fracchioli, S" uniqKey="Fracchioli S">S. Fracchioli</name></author><author><name sortKey="Vezzani, C" uniqKey="Vezzani C">C. Vezzani</name></author><author><name sortKey="De La Longrais, I A R" uniqKey="De La Longrais I">I.A.R. de la Longrais</name></author><author><name sortKey="Yao, W" uniqKey="Yao W">W. Yao</name></author><author><name sortKey="Rubin, S C" uniqKey="Rubin S">S.C. Rubin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, L" uniqKey="Xu L">L. Xu</name></author><author><name sortKey="Pathak, P S" uniqKey="Pathak P">P.S. Pathak</name></author><author><name sortKey="Fukumura, D" uniqKey="Fukumura D">D. Fukumura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author><author><name sortKey="Ye, D" uniqKey="Ye D">D. Ye</name></author><author><name sortKey="Xie, X" uniqKey="Xie X">X. Xie</name></author><author><name sortKey="Chen, B" uniqKey="Chen B">B. Chen</name></author><author><name sortKey="Lu, W" uniqKey="Lu W">W. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bermudez, Y" uniqKey="Bermudez Y">Y. Bermudez</name></author><author><name sortKey="Yang, H" uniqKey="Yang H">H. Yang</name></author><author><name sortKey="Saunders, B O" uniqKey="Saunders B">B.O. Saunders</name></author><author><name sortKey="Cheng, J Q" uniqKey="Cheng J">J.Q. Cheng</name></author><author><name sortKey="Nicosia, S V" uniqKey="Nicosia S">S.V. Nicosia</name></author><author><name sortKey="Kruk, P A" uniqKey="Kruk P">P.A. Kruk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weis, S" uniqKey="Weis S">S. Weis</name></author><author><name sortKey="Cui, J" uniqKey="Cui J">J. Cui</name></author><author><name sortKey="Barnes, L" uniqKey="Barnes L">L. Barnes</name></author><author><name sortKey="Cheresh, D" uniqKey="Cheresh D">D. Cheresh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mukhopadhyay, D" uniqKey="Mukhopadhyay D">D. Mukhopadhyay</name></author><author><name sortKey="Nagy, J A" uniqKey="Nagy J">J.A. Nagy</name></author><author><name sortKey="Manseau, E J" uniqKey="Manseau E">E.J. Manseau</name></author><author><name sortKey="Dvorak, H F" uniqKey="Dvorak H">H.F. Dvorak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oikawa, T" uniqKey="Oikawa T">T. Oikawa</name></author><author><name sortKey="Onozawa, C" uniqKey="Onozawa C">C. Onozawa</name></author><author><name sortKey="Sakaguchi, M" uniqKey="Sakaguchi M">M. Sakaguchi</name></author><author><name sortKey="Morita, I" uniqKey="Morita I">I. Morita</name></author><author><name sortKey="Murota, S" uniqKey="Murota S">S. Murota</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, C" uniqKey="Lu C">C. Lu</name></author><author><name sortKey="Thaker, P H" uniqKey="Thaker P">P.H. Thaker</name></author><author><name sortKey="Lin, Y G" uniqKey="Lin Y">Y.G. Lin</name></author><author><name sortKey="Spannuth, W" uniqKey="Spannuth W">W. Spannuth</name></author><author><name sortKey="Landen, C N" uniqKey="Landen C">C.N. Landen</name></author><author><name sortKey="Merritt, W M" uniqKey="Merritt W">W.M. Merritt</name></author><author><name sortKey="Jennings, N B" uniqKey="Jennings N">N.B. Jennings</name></author><author><name sortKey="Langley, R R" uniqKey="Langley R">R.R. Langley</name></author><author><name sortKey="Gershenson, D M" uniqKey="Gershenson D">D.M. Gershenson</name></author><author><name sortKey="Yancopoulos, G D" uniqKey="Yancopoulos G">G.D. Yancopoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Erber, R" uniqKey="Erber R">R. Erber</name></author><author><name sortKey="Thurner, A" uniqKey="Thurner A">A. Thurner</name></author><author><name sortKey="Katsen, A D" uniqKey="Katsen A">A.D. Katsen</name></author><author><name sortKey="Groth, G" uniqKey="Groth G">G. Groth</name></author><author><name sortKey="Kerger, H" uniqKey="Kerger H">H. Kerger</name></author><author><name sortKey="Hammes, H P" uniqKey="Hammes H">H.P. Hammes</name></author><author><name sortKey="Menger, M D" uniqKey="Menger M">M.D. Menger</name></author><author><name sortKey="Ullrich, A" uniqKey="Ullrich A">A. Ullrich</name></author><author><name sortKey="Vajkoczy, P" uniqKey="Vajkoczy P">P. Vajkoczy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lassus, H" uniqKey="Lassus H">H. Lassus</name></author><author><name sortKey="Sihto, H" uniqKey="Sihto H">H. Sihto</name></author><author><name sortKey="Leminen, A" uniqKey="Leminen A">A. Leminen</name></author><author><name sortKey="Nordling, S" uniqKey="Nordling S">S. Nordling</name></author><author><name sortKey="Joensuu, H" uniqKey="Joensuu H">H. Joensuu</name></author><author><name sortKey="Nupponen, N N" uniqKey="Nupponen N">N.N. Nupponen</name></author><author><name sortKey="Butzow, R" uniqKey="Butzow R">R. Butzow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fredriksson, L" uniqKey="Fredriksson L">L. Fredriksson</name></author><author><name sortKey="Li, H" uniqKey="Li H">H. Li</name></author><author><name sortKey="Fieber, C" uniqKey="Fieber C">C. Fieber</name></author><author><name sortKey="Li, X" uniqKey="Li X">X. Li</name></author><author><name sortKey="Eriksson, U" uniqKey="Eriksson U">U. Eriksson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kazlauskas, A" uniqKey="Kazlauskas A">A. Kazlauskas</name></author><author><name sortKey="Cooper, J A" uniqKey="Cooper J">J.A. Cooper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Andrae, J" uniqKey="Andrae J">J. Andrae</name></author><author><name sortKey="Gallini, R" uniqKey="Gallini R">R. Gallini</name></author><author><name sortKey="Betsholtz, C" uniqKey="Betsholtz C">C. Betsholtz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Board, R" uniqKey="Board R">R. Board</name></author><author><name sortKey="Jayson, G C" uniqKey="Jayson G">G.C. Jayson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Valius, M" uniqKey="Valius M">M. Valius</name></author><author><name sortKey="Kazlauskas, A" uniqKey="Kazlauskas A">A. Kazlauskas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coughlin, S R" uniqKey="Coughlin S">S.R. Coughlin</name></author><author><name sortKey="Escobedo, J A" uniqKey="Escobedo J">J.A. Escobedo</name></author><author><name sortKey="Williams, L T" uniqKey="Williams L">L.T. Williams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heldin, C H" uniqKey="Heldin C">C.H. Heldin</name></author><author><name sortKey="Ostman, A" uniqKey="Ostman A">A. Ostman</name></author><author><name sortKey="Ronnstrand, L" uniqKey="Ronnstrand L">L. Ronnstrand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Apte, S M" uniqKey="Apte S">S.M. Apte</name></author><author><name sortKey="Bucana, C D" uniqKey="Bucana C">C.D. Bucana</name></author><author><name sortKey="Killion, J J" uniqKey="Killion J">J.J. Killion</name></author><author><name sortKey="Gershenson, D" uniqKey="Gershenson D">D. Gershenson</name></author><author><name sortKey="Fidler, I J" uniqKey="Fidler I">I.J. Fidler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matei, D" uniqKey="Matei D">D. Matei</name></author><author><name sortKey="Graeber, T G" uniqKey="Graeber T">T.G. Graeber</name></author><author><name sortKey="Baldwin, R L" uniqKey="Baldwin R">R.L. Baldwin</name></author><author><name sortKey="Karlan, B Y" uniqKey="Karlan B">B.Y. Karlan</name></author><author><name sortKey="Rao, J" uniqKey="Rao J">J. Rao</name></author><author><name sortKey="Chang, D D" uniqKey="Chang D">D.D. Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Apte, S M" uniqKey="Apte S">S.M. Apte</name></author><author><name sortKey="Fan, D" uniqKey="Fan D">D. Fan</name></author><author><name sortKey="Killion, J J" uniqKey="Killion J">J.J. Killion</name></author><author><name sortKey="Fidler, I J" uniqKey="Fidler I">I.J. Fidler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matei, D" uniqKey="Matei D">D. Matei</name></author><author><name sortKey="Emerson, R E" uniqKey="Emerson R">R.E. Emerson</name></author><author><name sortKey="Lai, Y C" uniqKey="Lai Y">Y.C. Lai</name></author><author><name sortKey="Baldridge, L A" uniqKey="Baldridge L">L.A. Baldridge</name></author><author><name sortKey="Rao, J" uniqKey="Rao J">J. Rao</name></author><author><name sortKey="Yiannoutsos, C" uniqKey="Yiannoutsos C">C. Yiannoutsos</name></author><author><name sortKey="Donner, D D" uniqKey="Donner D">D.D. Donner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pietras, K" uniqKey="Pietras K">K. Pietras</name></author><author><name sortKey="Pahler, J" uniqKey="Pahler J">J. Pahler</name></author><author><name sortKey="Bergers, G" uniqKey="Bergers G">G. Bergers</name></author><author><name sortKey="Hanahan, D" uniqKey="Hanahan D">D. Hanahan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Uren, A" uniqKey="Uren A">A. Uren</name></author><author><name sortKey="Yu, J C" uniqKey="Yu J">J.C. Yu</name></author><author><name sortKey="Gholami, N S" uniqKey="Gholami N">N.S. Gholami</name></author><author><name sortKey="Pierce, J H" uniqKey="Pierce J">J.H. Pierce</name></author><author><name sortKey="Heidaran, M A" uniqKey="Heidaran M">M.A. Heidaran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pietras, K" uniqKey="Pietras K">K. Pietras</name></author><author><name sortKey="Sjoblom, T" uniqKey="Sjoblom T">T. Sjöblom</name></author><author><name sortKey="Rubin, K" uniqKey="Rubin K">K. Rubin</name></author><author><name sortKey="Heldin, C H" uniqKey="Heldin C">C.H. Heldin</name></author><author><name sortKey="Ostman, A" uniqKey="Ostman A">A. Ostman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colvin, J S" uniqKey="Colvin J">J.S. Colvin</name></author><author><name sortKey="Bohne, B A" uniqKey="Bohne B">B.A. Bohne</name></author><author><name sortKey="Harding, G W" uniqKey="Harding G">G.W. Harding</name></author><author><name sortKey="Mcewen, D G" uniqKey="Mcewen D">D.G. McEwen</name></author><author><name sortKey="Ornitz, D M" uniqKey="Ornitz D">D.M. Ornitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaffer, C L" uniqKey="Chaffer C">C.L. Chaffer</name></author><author><name sortKey="Dopheide, B" uniqKey="Dopheide B">B. Dopheide</name></author><author><name sortKey="Savagner, P" uniqKey="Savagner P">P. Savagner</name></author><author><name sortKey="Thompson, E W" uniqKey="Thompson E">E.W. Thompson</name></author><author><name sortKey="Williams, E D" uniqKey="Williams E">E.D. Williams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alshenawy, H A" uniqKey="Alshenawy H">H.A. Alshenawy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Itoh, N" uniqKey="Itoh N">N. Itoh</name></author><author><name sortKey="Ornitz, D M" uniqKey="Ornitz D">D.M. Ornitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Turner, N" uniqKey="Turner N">N. Turner</name></author><author><name sortKey="Grose, R" uniqKey="Grose R">R. Grose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Korc, M" uniqKey="Korc M">M. Korc</name></author><author><name sortKey="Friesel, R E" uniqKey="Friesel R">R.E. Friesel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lappi, D A" uniqKey="Lappi D">D.A. Lappi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Gorry, M C" uniqKey="Gorry M">M.C. Gorry</name></author><author><name sortKey="Post, J C" uniqKey="Post J">J.C. Post</name></author><author><name sortKey="Ehrlich, G D" uniqKey="Ehrlich G">G.D. Ehrlich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Byron, S A" uniqKey="Byron S">S.A. Byron</name></author><author><name sortKey="Gartside, M G" uniqKey="Gartside M">M.G. Gartside</name></author><author><name sortKey="Wellens, C L" uniqKey="Wellens C">C.L. Wellens</name></author><author><name sortKey="Goodfellow, P J" uniqKey="Goodfellow P">P.J. Goodfellow</name></author><author><name sortKey="Birrer, M J" uniqKey="Birrer M">M.J. Birrer</name></author><author><name sortKey="Campbell, I G" uniqKey="Campbell I">I.G. Campbell</name></author><author><name sortKey="Pollock, P M" uniqKey="Pollock P">P.M. Pollock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carstens, R P" uniqKey="Carstens R">R.P. Carstens</name></author><author><name sortKey="Mckeehan, W L" uniqKey="Mckeehan W">W.L. McKeehan</name></author><author><name sortKey="Garcia Blanco, M A" uniqKey="Garcia Blanco M">M.A. Garcia-Blanco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steele, I A" uniqKey="Steele I">I.A. Steele</name></author><author><name sortKey="Edmondson, R J" uniqKey="Edmondson R">R.J. Edmondson</name></author><author><name sortKey="Bulmer, J N" uniqKey="Bulmer J">J.N. Bulmer</name></author><author><name sortKey="Bolger, B S" uniqKey="Bolger B">B.S. Bolger</name></author><author><name sortKey="Leung, H Y" uniqKey="Leung H">H.Y. Leung</name></author><author><name sortKey="Davies, B R" uniqKey="Davies B">B.R. Davies</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoneda, J" uniqKey="Yoneda J">J. Yoneda</name></author><author><name sortKey="Kuniyasu, H" uniqKey="Kuniyasu H">H. Kuniyasu</name></author><author><name sortKey="Crispens, M A" uniqKey="Crispens M">M.A. Crispens</name></author><author><name sortKey="Price, J E" uniqKey="Price J">J.E. Price</name></author><author><name sortKey="Bucana, C D" uniqKey="Bucana C">C.D. Bucana</name></author><author><name sortKey="Fidler, I J" uniqKey="Fidler I">I.J. Fidler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barton, D P" uniqKey="Barton D">D.P. Barton</name></author><author><name sortKey="Cai, A" uniqKey="Cai A">A. Cai</name></author><author><name sortKey="Wendt, K" uniqKey="Wendt K">K. Wendt</name></author><author><name sortKey="Young, M" uniqKey="Young M">M. Young</name></author><author><name sortKey="Gamero, A" uniqKey="Gamero A">A. Gamero</name></author><author><name sortKey="De Cesare, S" uniqKey="De Cesare S">S. de Cesare</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Madsen, C V" uniqKey="Madsen C">C.V. Madsen</name></author><author><name sortKey="Steffensen, K D" uniqKey="Steffensen K">K.D. Steffensen</name></author><author><name sortKey="Olsen, D A" uniqKey="Olsen D">D.A. Olsen</name></author><author><name sortKey="Waldstr M, M" uniqKey="Waldstr M M">M. Waldstrøm</name></author><author><name sortKey="S Gaard, C H" uniqKey="S Gaard C">C.H. Søgaard</name></author><author><name sortKey="Brandslund, I" uniqKey="Brandslund I">I. Brandslund</name></author><author><name sortKey="Jakobsen, A" uniqKey="Jakobsen A">A. Jakobsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steele, I A" uniqKey="Steele I">I.A. Steele</name></author><author><name sortKey="Edmondson, R J" uniqKey="Edmondson R">R.J. Edmondson</name></author><author><name sortKey="Leung, H Y" uniqKey="Leung H">H.Y. Leung</name></author><author><name sortKey="Davies, B R" uniqKey="Davies B">B.R. Davies</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tebben, P J" uniqKey="Tebben P">P.J. Tebben</name></author><author><name sortKey="Kalli, K R" uniqKey="Kalli K">K.R. Kalli</name></author><author><name sortKey="Cliby, W A" uniqKey="Cliby W">W.A. Cliby</name></author><author><name sortKey="Hartmann, L C" uniqKey="Hartmann L">L.C. Hartmann</name></author><author><name sortKey="Grande, J P" uniqKey="Grande J">J.P. Grande</name></author><author><name sortKey="Singh, R J" uniqKey="Singh R">R.J. Singh</name></author><author><name sortKey="Kumar, R" uniqKey="Kumar R">R. Kumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jouanneau, J" uniqKey="Jouanneau J">J. Jouanneau</name></author><author><name sortKey="Moens, G" uniqKey="Moens G">G. Moens</name></author><author><name sortKey="Montesano, R" uniqKey="Montesano R">R. Montesano</name></author><author><name sortKey="Thiery, J P" uniqKey="Thiery J">J.P. Thiery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seghezzi, G" uniqKey="Seghezzi G">G. Seghezzi</name></author><author><name sortKey="Patel, S" uniqKey="Patel S">S. Patel</name></author><author><name sortKey="Ren, C J" uniqKey="Ren C">C.J. Ren</name></author><author><name sortKey="Gualandris, A" uniqKey="Gualandris A">A. Gualandris</name></author><author><name sortKey="Pintucci, C" uniqKey="Pintucci C">C. Pintucci</name></author><author><name sortKey="Robbins, E S" uniqKey="Robbins E">E.S. Robbins</name></author><author><name sortKey="Shapiro, R L" uniqKey="Shapiro R">R.L. Shapiro</name></author><author><name sortKey="Galloway, A C" uniqKey="Galloway A">A.C. Galloway</name></author><author><name sortKey="Rifkin, D B" uniqKey="Rifkin D">D.B. Rifkin</name></author><author><name sortKey="Mignatti, P" uniqKey="Mignatti P">P. Mignatti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Katoh, M" uniqKey="Katoh M">M. Katoh</name></author><author><name sortKey="Katoh, M" uniqKey="Katoh M">M. Katoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akai, J" uniqKey="Akai J">J. Akai</name></author><author><name sortKey="Halley, P A" uniqKey="Halley P">P.A. Halley</name></author><author><name sortKey="Storey, K G" uniqKey="Storey K">K.G. Storey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reiss, Y" uniqKey="Reiss Y">Y. Reiss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falcon, B L" uniqKey="Falcon B">B.L. Falcon</name></author><author><name sortKey="Hashizume, H" uniqKey="Hashizume H">H. Hashizume</name></author><author><name sortKey="Koumoutsakos, P" uniqKey="Koumoutsakos P">P. Koumoutsakos</name></author><author><name sortKey="Chou, J" uniqKey="Chou J">J. Chou</name></author><author><name sortKey="Bready, J V" uniqKey="Bready J">J.V. Bready</name></author><author><name sortKey="Coxon, A" uniqKey="Coxon A">A. Coxon</name></author><author><name sortKey="Oliner, J D" uniqKey="Oliner J">J.D. Oliner</name></author><author><name sortKey="Mcdonald, D M" uniqKey="Mcdonald D">D.M. McDonald</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Papapetropoulos, A" uniqKey="Papapetropoulos A">A. Papapetropoulos</name></author><author><name sortKey="Fulton, D" uniqKey="Fulton D">D. Fulton</name></author><author><name sortKey="Mahboubi, K" uniqKey="Mahboubi K">K. Mahboubi</name></author><author><name sortKey="Kalb, R G" uniqKey="Kalb R">R.G. Kalb</name></author><author><name sortKey="O Onnor, D S" uniqKey="O Onnor D">D.S. O’Connor</name></author><author><name sortKey="Li, F" uniqKey="Li F">F. Li</name></author><author><name sortKey="Altieri, D C" uniqKey="Altieri D">D.C. Altieri</name></author><author><name sortKey="Sessa, W C" uniqKey="Sessa W">W.C. Sessa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petrillo, M" uniqKey="Petrillo M">M. Petrillo</name></author><author><name sortKey="Scambia, G" uniqKey="Scambia G">G. Scambia</name></author><author><name sortKey="Ferrandina, G" uniqKey="Ferrandina G">G. Ferrandina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yuan, H T" uniqKey="Yuan H">H.T. Yuan</name></author><author><name sortKey="Khankin, E V" uniqKey="Khankin E">E.V. Khankin</name></author><author><name sortKey="Karumanchi, S A" uniqKey="Karumanchi S">S.A. Karumanchi</name></author><author><name sortKey="Parikh, S M" uniqKey="Parikh S">S.M. Parikh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, L" uniqKey="Zhang L">L. Zhang</name></author><author><name sortKey="Yang, N" uniqKey="Yang N">N. Yang</name></author><author><name sortKey="Park, J W" uniqKey="Park J">J.W. Park</name></author><author><name sortKey="Katsaros, D" uniqKey="Katsaros D">D. Katsaros</name></author><author><name sortKey="Fracchioli, S" uniqKey="Fracchioli S">S. Fracchioli</name></author><author><name sortKey="Cao, G" uniqKey="Cao G">G. Cao</name></author><author><name sortKey="O Rien Jenkins, A" uniqKey="O Rien Jenkins A">A. O’Brien-Jenkins</name></author><author><name sortKey="Randall, T C" uniqKey="Randall T">T.C. Randall</name></author><author><name sortKey="Rubin, S C" uniqKey="Rubin S">S.C. Rubin</name></author><author><name sortKey="Coukos, G" uniqKey="Coukos G">G. Coukos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oliner, J" uniqKey="Oliner J">J. Oliner</name></author><author><name sortKey="Min, H" uniqKey="Min H">H. Min</name></author><author><name sortKey="Leal, J" uniqKey="Leal J">J. Leal</name></author><author><name sortKey="Yu, D" uniqKey="Yu D">D. Yu</name></author><author><name sortKey="Rao, S" uniqKey="Rao S">S. Rao</name></author><author><name sortKey="You, E" uniqKey="You E">E. You</name></author><author><name sortKey="Tang, X" uniqKey="Tang X">X. Tang</name></author><author><name sortKey="Kim, H" uniqKey="Kim H">H. Kim</name></author><author><name sortKey="Meyer, S" uniqKey="Meyer S">S. Meyer</name></author><author><name sortKey="Han, S J" uniqKey="Han S">S.J. Han</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thomas, M" uniqKey="Thomas M">M. Thomas</name></author><author><name sortKey="Felcht, M" uniqKey="Felcht M">M. Felcht</name></author><author><name sortKey="Kruse, K" uniqKey="Kruse K">K. Kruse</name></author><author><name sortKey="Kretschmer, S" uniqKey="Kretschmer S">S. Kretschmer</name></author><author><name sortKey="Deppermann, C" uniqKey="Deppermann C">C. Deppermann</name></author><author><name sortKey="Biesdorf, A" uniqKey="Biesdorf A">A. Biesdorf</name></author><author><name sortKey="Rohr, K" uniqKey="Rohr K">K. Rohr</name></author><author><name sortKey="Benest, A V" uniqKey="Benest A">A.V. Benest</name></author><author><name sortKey="Fiedler, U" uniqKey="Fiedler U">U. Fiedler</name></author><author><name sortKey="Augustin, H G" uniqKey="Augustin H">H.G. Augustin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanchez Mu Oz, A" uniqKey="Sanchez Mu Oz A">A. Sánchez-Muñoz</name></author><author><name sortKey="Mendiola, C" uniqKey="Mendiola C">C. Mendiola</name></author><author><name sortKey="Perez Ruiz, E" uniqKey="Perez Ruiz E">E. Pérez-Ruiz</name></author><author><name sortKey="Rodriguez Sanchez, C A" uniqKey="Rodriguez Sanchez C">C.A. Rodríguez-Sánchez</name></author><author><name sortKey="Jurado, J M" uniqKey="Jurado J">J.M. Jurado</name></author><author><name sortKey="Alonso Carri N, L" uniqKey="Alonso Carri N L">L. Alonso-Carrión</name></author><author><name sortKey="Ghanem, I" uniqKey="Ghanem I">I. Ghanem</name></author><author><name sortKey="De Velasco, G" uniqKey="De Velasco G">G. de Velasco</name></author><author><name sortKey="Quero Blanco, C" uniqKey="Quero Blanco C">C. Quero-Blanco</name></author><author><name sortKey="Alba, E" uniqKey="Alba E">E. Alba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcgonigle, K F" uniqKey="Mcgonigle K">K.F. McGonigle</name></author><author><name sortKey="Muntz, H G" uniqKey="Muntz H">H.G. Muntz</name></author><author><name sortKey="Vuky, J" uniqKey="Vuky J">J. Vuky</name></author><author><name sortKey="Paley, P J" uniqKey="Paley P">P.J. Paley</name></author><author><name sortKey="Veljovich, D S" uniqKey="Veljovich D">D.S. Veljovich</name></author><author><name sortKey="Greer, B E" uniqKey="Greer B">B.E. Greer</name></author><author><name sortKey="Goff, B A" uniqKey="Goff B">B.A. Goff</name></author><author><name sortKey="Gray, H J" uniqKey="Gray H">H.J. Gray</name></author><author><name sortKey="Malpass, T W" uniqKey="Malpass T">T.W. Malpass</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kudoh, K" uniqKey="Kudoh K">K. Kudoh</name></author><author><name sortKey="Takano, M" uniqKey="Takano M">M. Takano</name></author><author><name sortKey="Kouta, H" uniqKey="Kouta H">H. Kouta</name></author><author><name sortKey="Kikuchi, R" uniqKey="Kikuchi R">R. Kikuchi</name></author><author><name sortKey="Kita, T" uniqKey="Kita T">T. Kita</name></author><author><name sortKey="Miyamoto, M" uniqKey="Miyamoto M">M. Miyamoto</name></author><author><name sortKey="Watanabe, A" uniqKey="Watanabe A">A. Watanabe</name></author><author><name sortKey="Kato, M" uniqKey="Kato M">M. Kato</name></author><author><name sortKey="Goto, T" uniqKey="Goto T">T. Goto</name></author><author><name sortKey="Kikuchi, Y" uniqKey="Kikuchi Y">Y. Kikuchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorbe, B" uniqKey="Sorbe B">B. Sorbe</name></author><author><name sortKey="Graflund, M" uniqKey="Graflund M">M. Graflund</name></author><author><name sortKey="Horvath, G" uniqKey="Horvath G">G. Horvath</name></author><author><name sortKey="Swahn, M" uniqKey="Swahn M">M. Swahn</name></author><author><name sortKey="Boman, K" uniqKey="Boman K">K. Boman</name></author><author><name sortKey="Bangshoj, R" uniqKey="Bangshoj R">R. Bangshöj</name></author><author><name sortKey="Lood, M" uniqKey="Lood M">M. Lood</name></author><author><name sortKey="Malmstrom, H" uniqKey="Malmstrom H">H. Malmström</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agheli, A" uniqKey="Agheli A">A. Agheli</name></author><author><name sortKey="Park, S C" uniqKey="Park S">S.C. Park</name></author><author><name sortKey="Huang, C J" uniqKey="Huang C">C.J. Huang</name></author><author><name sortKey="Wang, J C" uniqKey="Wang J">J.C. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mesiano, S" uniqKey="Mesiano S">S. Mesiano</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author><author><name sortKey="Jaffe, R B" uniqKey="Jaffe R">R.B. Jaffe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hu, L" uniqKey="Hu L">L. Hu</name></author><author><name sortKey="Hofmann, J" uniqKey="Hofmann J">J. Hofmann</name></author><author><name sortKey="Zaloudek, C" uniqKey="Zaloudek C">C. Zaloudek</name></author><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N. Ferrara</name></author><author><name sortKey="Hamilton, T" uniqKey="Hamilton T">T. Hamilton</name></author><author><name sortKey="Jaffe, R B" uniqKey="Jaffe R">R.B. Jaffe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mabuchi, S" uniqKey="Mabuchi S">S. Mabuchi</name></author><author><name sortKey="Terai, Y" uniqKey="Terai Y">Y. Terai</name></author><author><name sortKey="Morishige, K" uniqKey="Morishige K">K. Morishige</name></author><author><name sortKey="Tanabe Kimura, A" uniqKey="Tanabe Kimura A">A. Tanabe-Kimura</name></author><author><name sortKey="Sasaki, H" uniqKey="Sasaki H">H. Sasaki</name></author><author><name sortKey="Kanemura, M" uniqKey="Kanemura M">M. Kanemura</name></author><author><name sortKey="Tsunetoh, S" uniqKey="Tsunetoh S">S. Tsunetoh</name></author><author><name sortKey="Tanaka, Y" uniqKey="Tanaka Y">Y. Tanaka</name></author><author><name sortKey="Sakata, M" uniqKey="Sakata M">M. Sakata</name></author><author><name sortKey="Burger, R A" uniqKey="Burger R">R.A. Burger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, R A" uniqKey="Burger R">R.A. Burger</name></author><author><name sortKey="Brady, M F" uniqKey="Brady M">M.F. Brady</name></author><author><name sortKey="Bookman, M A" uniqKey="Bookman M">M.A. Bookman</name></author><author><name sortKey="Fleming, G F" uniqKey="Fleming G">G.F. Fleming</name></author><author><name sortKey="Monk, B J" uniqKey="Monk B">B.J. Monk</name></author><author><name sortKey="Huang, H" uniqKey="Huang H">H. Huang</name></author><author><name sortKey="Mannel, R S" uniqKey="Mannel R">R.S. Mannel</name></author><author><name sortKey="Homesley, H D" uniqKey="Homesley H">H.D. Homesley</name></author><author><name sortKey="Fowler, J" uniqKey="Fowler J">J. Fowler</name></author><author><name sortKey="Greer, B E" uniqKey="Greer B">B.E. Greer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poveda, A M" uniqKey="Poveda A">A.M. Poveda</name></author><author><name sortKey="Selle, F" uniqKey="Selle F">F. Selle</name></author><author><name sortKey="Hilpert, F" uniqKey="Hilpert F">F. Hilpert</name></author><author><name sortKey="Reuss, A" uniqKey="Reuss A">A. Reuss</name></author><author><name sortKey="Pasic, A" uniqKey="Pasic A">A. Pasic</name></author><author><name sortKey="Savarese, A" uniqKey="Savarese A">A. Savarese</name></author><author><name sortKey="Vergote, I B" uniqKey="Vergote I">I.B. Vergote</name></author><author><name sortKey="Witteveen, P" uniqKey="Witteveen P">P. Witteveen</name></author><author><name sortKey="Bamias, A" uniqKey="Bamias A">A. Bamias</name></author><author><name sortKey="Bollag, D" uniqKey="Bollag D">D. Bollag</name></author><author><name sortKey="Pujade Lauraine, E" uniqKey="Pujade Lauraine E">E. Pujade-Lauraine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, T" uniqKey="Sharma T">T. Sharma</name></author><author><name sortKey="Dhingra, R" uniqKey="Dhingra R">R. Dhingra</name></author><author><name sortKey="Singh, S" uniqKey="Singh S">S. Singh</name></author><author><name sortKey="Sharma, S" uniqKey="Sharma S">S. Sharma</name></author><author><name sortKey="Tomar, P" uniqKey="Tomar P">P. Tomar</name></author><author><name sortKey="Malhotra, M" uniqKey="Malhotra M">M. Malhotra</name></author><author><name sortKey="Bhardwaj, T R" uniqKey="Bhardwaj T">T.R. Bhardwaj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Troiani, T" uniqKey="Troiani T">T. Troiani</name></author><author><name sortKey="Martinelli, E" uniqKey="Martinelli E">E. Martinelli</name></author><author><name sortKey="Orditura, M" uniqKey="Orditura M">M. Orditura</name></author><author><name sortKey="De Vita, F" uniqKey="De Vita F">F. De Vita</name></author><author><name sortKey="Ciardiello, F" uniqKey="Ciardiello F">F. Ciardiello</name></author><author><name sortKey="Morgillo, F" uniqKey="Morgillo F">F. Morgillo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Byrne, A T" uniqKey="Byrne A">A.T. Byrne</name></author><author><name sortKey="Ross, L" uniqKey="Ross L">L. Ross</name></author><author><name sortKey="Holash, J" uniqKey="Holash J">J. Holash</name></author><author><name sortKey="Nakanishi, M" uniqKey="Nakanishi M">M. Nakanishi</name></author><author><name sortKey="Hu, L" uniqKey="Hu L">L. Hu</name></author><author><name sortKey="Hofmann, J I" uniqKey="Hofmann J">J.I. Hofmann</name></author><author><name sortKey="Yancopoulos, G D" uniqKey="Yancopoulos G">G.D. Yancopoulos</name></author><author><name sortKey="Jaffe, R B" uniqKey="Jaffe R">R.B. Jaffe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baffert, F" uniqKey="Baffert F">F. Baffert</name></author><author><name sortKey="Le, T" uniqKey="Le T">T. Le</name></author><author><name sortKey="Sennino, B" uniqKey="Sennino B">B. Sennino</name></author><author><name sortKey="Thurston, G" uniqKey="Thurston G">G. Thurston</name></author><author><name sortKey="Kuo, C J" uniqKey="Kuo C">C.J. Kuo</name></author><author><name sortKey="Hu Lowe, D" uniqKey="Hu Lowe D">D. Hu-Lowe</name></author><author><name sortKey="Mcdonald, D M" uniqKey="Mcdonald D">D.M. McDonald</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freyer, G" uniqKey="Freyer G">G. Freyer</name></author><author><name sortKey="Isambert, N" uniqKey="Isambert N">N. Isambert</name></author><author><name sortKey="You, B" uniqKey="You B">B. You</name></author><author><name sortKey="Zanetta, S" uniqKey="Zanetta S">S. Zanetta</name></author><author><name sortKey="Falandry, C" uniqKey="Falandry C">C. Falandry</name></author><author><name sortKey="Favier, L" uniqKey="Favier L">L. Favier</name></author><author><name sortKey="Trillet Lenoir, V" uniqKey="Trillet Lenoir V">V. Trillet-Lenoir</name></author><author><name sortKey="Assadourian, S" uniqKey="Assadourian S">S. Assadourian</name></author><author><name sortKey="Soussan Lazard, K" uniqKey="Soussan Lazard K">K. Soussan-Lazard</name></author><author><name sortKey="Ziti Ljajic, S" uniqKey="Ziti Ljajic S">S. Ziti-Ljajic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coleman, R L" uniqKey="Coleman R">R.L. Coleman</name></author><author><name sortKey="Duska, L R" uniqKey="Duska L">L.R. Duska</name></author><author><name sortKey="Ramirez, P T" uniqKey="Ramirez P">P.T. Ramirez</name></author><author><name sortKey="Heymach, J V" uniqKey="Heymach J">J.V. Heymach</name></author><author><name sortKey="Kamat, A A" uniqKey="Kamat A">A.A. Kamat</name></author><author><name sortKey="Modesitt, S C" uniqKey="Modesitt S">S.C. Modesitt</name></author><author><name sortKey="Schmeler, K M" uniqKey="Schmeler K">K.M. Schmeler</name></author><author><name sortKey="Iyer, R B" uniqKey="Iyer R">R.B. Iyer</name></author><author><name sortKey="Garcia, M E" uniqKey="Garcia M">M.E. Garcia</name></author><author><name sortKey="Miller, D L" uniqKey="Miller D">D.L. Miller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roth, G J" uniqKey="Roth G">G.J. Roth</name></author><author><name sortKey="Heckel, A" uniqKey="Heckel A">A. Heckel</name></author><author><name sortKey="Colbatzky, F" uniqKey="Colbatzky F">F. Colbatzky</name></author><author><name sortKey="Handschuh, S" uniqKey="Handschuh S">S. Handschuh</name></author><author><name sortKey="Kley, J" uniqKey="Kley J">J. Kley</name></author><author><name sortKey="Lehmann Lintz, T" uniqKey="Lehmann Lintz T">T. Lehmann-Lintz</name></author><author><name sortKey="Lotz, R" uniqKey="Lotz R">R. Lotz</name></author><author><name sortKey="Tontsch Grunt, U" uniqKey="Tontsch Grunt U">U. Tontsch-Grunt</name></author><author><name sortKey="Walter, R" uniqKey="Walter R">R. Walter</name></author><author><name sortKey="Hilberg, F" uniqKey="Hilberg F">F. Hilberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hilberg, F" uniqKey="Hilberg F">F. Hilberg</name></author><author><name sortKey="Roth, G J" uniqKey="Roth G">G.J. Roth</name></author><author><name sortKey="Krssak, M" uniqKey="Krssak M">M. Krssak</name></author><author><name sortKey="Kautschitsch, S" uniqKey="Kautschitsch S">S. Kautschitsch</name></author><author><name sortKey="Sommergruber, W" uniqKey="Sommergruber W">W. Sommergruber</name></author><author><name sortKey="Tontsch Grunt, U" uniqKey="Tontsch Grunt U">U. Tontsch-Grunt</name></author><author><name sortKey="Garin Chesa, P" uniqKey="Garin Chesa P">P. Garin-Chesa</name></author><author><name sortKey="Bader, G" uniqKey="Bader G">G. Bader</name></author><author><name sortKey="Zoephel, A" uniqKey="Zoephel A">A. Zoephel</name></author><author><name sortKey="Quant, J" uniqKey="Quant J">J. Quant</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du Bois, A" uniqKey="Du Bois A">A. Du Bois</name></author><author><name sortKey="Huober, J" uniqKey="Huober J">J. Huober</name></author><author><name sortKey="Stopfer, P" uniqKey="Stopfer P">P. Stopfer</name></author><author><name sortKey="Pfisterer, J" uniqKey="Pfisterer J">J. Pfisterer</name></author><author><name sortKey="Wimberger, P" uniqKey="Wimberger P">P. Wimberger</name></author><author><name sortKey="Loibl, S" uniqKey="Loibl S">S. Loibl</name></author><author><name sortKey="Reichardt, V L" uniqKey="Reichardt V">V.L. Reichardt</name></author><author><name sortKey="Harter, P" uniqKey="Harter P">P. Harter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friedlander, M" uniqKey="Friedlander M">M. Friedlander</name></author><author><name sortKey="Hancock, K C" uniqKey="Hancock K">K.C. Hancock</name></author><author><name sortKey="Rischin, D" uniqKey="Rischin D">D. Rischin</name></author><author><name sortKey="Messing, M J" uniqKey="Messing M">M.J. Messing</name></author><author><name sortKey="Stringer, C A" uniqKey="Stringer C">C.A. Stringer</name></author><author><name sortKey="Matthys, G M" uniqKey="Matthys G">G.M. Matthys</name></author><author><name sortKey="Ma, B" uniqKey="Ma B">B. Ma</name></author><author><name sortKey="Hodge, J P" uniqKey="Hodge J">J.P. Hodge</name></author><author><name sortKey="Lager, J J" uniqKey="Lager J">J.J. Lager</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamberg, P" uniqKey="Hamberg P">P. Hamberg</name></author><author><name sortKey="Verweij, J" uniqKey="Verweij J">J. Verweij</name></author><author><name sortKey="Sleijfer, S" uniqKey="Sleijfer S">S. Sleijfer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matulonis, U A" uniqKey="Matulonis U">U.A. Matulonis</name></author><author><name sortKey="Berlin, S" uniqKey="Berlin S">S. Berlin</name></author><author><name sortKey="Ivy, P" uniqKey="Ivy P">P. Ivy</name></author><author><name sortKey="Tyburski, K" uniqKey="Tyburski K">K. Tyburski</name></author><author><name sortKey="Krasner, C" uniqKey="Krasner C">C. Krasner</name></author><author><name sortKey="Zarwan, C" uniqKey="Zarwan C">C. Zarwan</name></author><author><name sortKey="Berkenblit, A" uniqKey="Berkenblit A">A. Berkenblit</name></author><author><name sortKey="Campos, S" uniqKey="Campos S">S. Campos</name></author><author><name sortKey="Horowitz, N" uniqKey="Horowitz N">N. Horowitz</name></author><author><name sortKey="Cannistra, S A" uniqKey="Cannistra S">S.A. Cannistra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sahade, M" uniqKey="Sahade M">M. Sahade</name></author><author><name sortKey="Caparelli, F" uniqKey="Caparelli F">F. Caparelli</name></author><author><name sortKey="Hoff, P M" uniqKey="Hoff P">P.M. Hoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wedge, S R" uniqKey="Wedge S">S.R. Wedge</name></author><author><name sortKey="Kendrew, J" uniqKey="Kendrew J">J. Kendrew</name></author><author><name sortKey="Hennequin, L F" uniqKey="Hennequin L">L.F. Hennequin</name></author><author><name sortKey="Valentine, P J" uniqKey="Valentine P">P.J. Valentine</name></author><author><name sortKey="Barry, S T" uniqKey="Barry S">S.T. Barry</name></author><author><name sortKey="Brave, S R" uniqKey="Brave S">S.R. Brave</name></author><author><name sortKey="Smith, N R" uniqKey="Smith N">N.R. Smith</name></author><author><name sortKey="James, N H" uniqKey="James N">N.H. James</name></author><author><name sortKey="Dukes, M" uniqKey="Dukes M">M. Dukes</name></author><author><name sortKey="Curwen, J O" uniqKey="Curwen J">J.O. Curwen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matei, D" uniqKey="Matei D">D. Matei</name></author><author><name sortKey="Sill, M W" uniqKey="Sill M">M.W. Sill</name></author><author><name sortKey="Lankes, H A" uniqKey="Lankes H">H.A. Lankes</name></author><author><name sortKey="Degeest, K" uniqKey="Degeest K">K. DeGeest</name></author><author><name sortKey="Bristow, R E" uniqKey="Bristow R">R.E. Bristow</name></author><author><name sortKey="Mutch, D" uniqKey="Mutch D">D. Mutch</name></author><author><name sortKey="Yamada, S D" uniqKey="Yamada S">S.D. Yamada</name></author><author><name sortKey="Cohn, D" uniqKey="Cohn D">D. Cohn</name></author><author><name sortKey="Calvert, V" uniqKey="Calvert V">V. Calvert</name></author><author><name sortKey="Farley, J" uniqKey="Farley J">J. Farley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matsumura, N" uniqKey="Matsumura N">N. Matsumura</name></author><author><name sortKey="Mandai, M" uniqKey="Mandai M">M. Mandai</name></author><author><name sortKey="Okamoto, T" uniqKey="Okamoto T">T. Okamoto</name></author><author><name sortKey="Yamaguchi, K" uniqKey="Yamaguchi K">K. Yamaguchi</name></author><author><name sortKey="Yamamura, S" uniqKey="Yamamura S">S. Yamamura</name></author><author><name sortKey="Oura, T" uniqKey="Oura T">T. Oura</name></author><author><name sortKey="Baba, T" uniqKey="Baba T">T. Baba</name></author><author><name sortKey="Hamanishi, J" uniqKey="Hamanishi J">J. Hamanishi</name></author><author><name sortKey="Kang, H S" uniqKey="Kang H">H.S. Kang</name></author><author><name sortKey="Matsui, S" uniqKey="Matsui S">S. Matsui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bauerschlag, D O" uniqKey="Bauerschlag D">D.O. Bauerschlag</name></author><author><name sortKey="Schem, C" uniqKey="Schem C">C. Schem</name></author><author><name sortKey="Tiwari, S" uniqKey="Tiwari S">S. Tiwari</name></author><author><name sortKey="Egberts, J H" uniqKey="Egberts J">J.H. Egberts</name></author><author><name sortKey="Weigel, M T" uniqKey="Weigel M">M.T. Weigel</name></author><author><name sortKey="Kalthoff, H" uniqKey="Kalthoff H">H. Kalthoff</name></author><author><name sortKey="Jonat, W" uniqKey="Jonat W">W. Jonat</name></author><author><name sortKey="Maass, N" uniqKey="Maass N">N. Maass</name></author><author><name sortKey="Meinhold Heerlein, I" uniqKey="Meinhold Heerlein I">I. Meinhold-Heerlein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Campos, S M" uniqKey="Campos S">S.M. Campos</name></author><author><name sortKey="Penson, R T" uniqKey="Penson R">R.T. Penson</name></author><author><name sortKey="Matulonis, U" uniqKey="Matulonis U">U. Matulonis</name></author><author><name sortKey="Horowitz, N S" uniqKey="Horowitz N">N.S. Horowitz</name></author><author><name sortKey="Whalen, C" uniqKey="Whalen C">C. Whalen</name></author><author><name sortKey="Pereira, L" uniqKey="Pereira L">L. Pereira</name></author><author><name sortKey="Tyburski, K" uniqKey="Tyburski K">K. Tyburski</name></author><author><name sortKey="Roche, M" uniqKey="Roche M">M. Roche</name></author><author><name sortKey="Szymonifka, J" uniqKey="Szymonifka J">J. Szymonifka</name></author><author><name sortKey="Berlin, S" uniqKey="Berlin S">S. Berlin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karlan, B Y" uniqKey="Karlan B">B.Y. Karlan</name></author><author><name sortKey="Oza, A M" uniqKey="Oza A">A.M. Oza</name></author><author><name sortKey="Richardson, G E" uniqKey="Richardson G">G.E. Richardson</name></author><author><name sortKey="Provencher, D M" uniqKey="Provencher D">D.M. Provencher</name></author><author><name sortKey="Hansen, V L" uniqKey="Hansen V">V.L. Hansen</name></author><author><name sortKey="Buck, M" uniqKey="Buck M">M. Buck</name></author><author><name sortKey="Chambers, S K" uniqKey="Chambers S">S.K. Chambers</name></author><author><name sortKey="Ghatage, P" uniqKey="Ghatage P">P. Ghatage</name></author><author><name sortKey="Pippitt, C H" uniqKey="Pippitt C">C.H. Pippitt</name></author><author><name sortKey="Brown, J V" uniqKey="Brown J">J.V. Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Polverino, A" uniqKey="Polverino A">A. Polverino</name></author><author><name sortKey="Coxon, A" uniqKey="Coxon A">A. Coxon</name></author><author><name sortKey="Starnes, C" uniqKey="Starnes C">C. Starnes</name></author><author><name sortKey="Diaz, Z" uniqKey="Diaz Z">Z. Diaz</name></author><author><name sortKey="Demelfi, T" uniqKey="Demelfi T">T. DeMelfi</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L. Wang</name></author><author><name sortKey="Bready, J" uniqKey="Bready J">J. Bready</name></author><author><name sortKey="Estrada, J" uniqKey="Estrada J">J. Estrada</name></author><author><name sortKey="Cattley, R" uniqKey="Cattley R">R. Cattley</name></author><author><name sortKey="Kaufman, S" uniqKey="Kaufman S">S. Kaufman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Teoh, D" uniqKey="Teoh D">D. Teoh</name></author><author><name sortKey="Secord, A A" uniqKey="Secord A">A.A. Secord</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pasquier, E" uniqKey="Pasquier E">E. Pasquier</name></author><author><name sortKey="Carre, M" uniqKey="Carre M">M. Carré</name></author><author><name sortKey="Pourroy, B" uniqKey="Pourroy B">B. Pourroy</name></author><author><name sortKey="Camoin, L" uniqKey="Camoin L">L. Camoin</name></author><author><name sortKey="Rebai, O" uniqKey="Rebai O">O. Rebaï</name></author><author><name sortKey="Briand, C" uniqKey="Briand C">C. Briand</name></author><author><name sortKey="Braguer, D" uniqKey="Braguer D">D. Braguer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merchan, J R" uniqKey="Merchan J">J.R. Merchan</name></author><author><name sortKey="Jayaram, D R" uniqKey="Jayaram D">D.R. Jayaram</name></author><author><name sortKey="Supko, J G" uniqKey="Supko J">J.G. Supko</name></author><author><name sortKey="He, X" uniqKey="He X">X. He</name></author><author><name sortKey="Bubley, G J" uniqKey="Bubley G">G.J. Bubley</name></author><author><name sortKey="Sukhatme, V P" uniqKey="Sukhatme V">V.P. Sukhatme</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jubb, A M" uniqKey="Jubb A">A.M. Jubb</name></author><author><name sortKey="Hurwitz, H I" uniqKey="Hurwitz H">H.I. Hurwitz</name></author><author><name sortKey="Bai, W" uniqKey="Bai W">W. Bai</name></author><author><name sortKey="Holmgren, E B" uniqKey="Holmgren E">E.B. Holmgren</name></author><author><name sortKey="Tobin, P" uniqKey="Tobin P">P. Tobin</name></author><author><name sortKey="Guerrero, A S" uniqKey="Guerrero A">A.S. Guerrero</name></author><author><name sortKey="Kabbinavar, F" uniqKey="Kabbinavar F">F. Kabbinavar</name></author><author><name sortKey="Holden, S N" uniqKey="Holden S">S.N. Holden</name></author><author><name sortKey="Novotny, W F" uniqKey="Novotny W">W.F. Novotny</name></author><author><name sortKey="Frantz, G D" uniqKey="Frantz G">G.D. Frantz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dowlati, A" uniqKey="Dowlati A">A. Dowlati</name></author><author><name sortKey="Gray, R" uniqKey="Gray R">R. Gray</name></author><author><name sortKey="Johnson, D H" uniqKey="Johnson D">D.H. Johnson</name></author><author><name sortKey="Schiller, J H" uniqKey="Schiller J">J.H. Schiller</name></author><author><name sortKey="Brahmer, J" uniqKey="Brahmer J">J. Brahmer</name></author><author><name sortKey="Sandler, A B" uniqKey="Sandler A">A.B. Sandler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horowitz, N S" uniqKey="Horowitz N">N.S. Horowitz</name></author><author><name sortKey="Penson, R T" uniqKey="Penson R">R.T. Penson</name></author><author><name sortKey="Duda, D G" uniqKey="Duda D">D.G. Duda</name></author><author><name sortKey="Di Tomaso, E" uniqKey="Di Tomaso E">E. di Tomaso</name></author><author><name sortKey="Boucher, Y" uniqKey="Boucher Y">Y. Boucher</name></author><author><name sortKey="Ancukiewicz, M" uniqKey="Ancukiewicz M">M. Ancukiewicz</name></author><author><name sortKey="Cohen, K S" uniqKey="Cohen K">K.S. Cohen</name></author><author><name sortKey="Berlin, S" uniqKey="Berlin S">S. Berlin</name></author><author><name sortKey="Krasner, C N" uniqKey="Krasner C">C.N. Krasner</name></author><author><name sortKey="Moses, M A" uniqKey="Moses M">M.A. Moses</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duda, D G" uniqKey="Duda D">D.G. Duda</name></author><author><name sortKey="Willett, C G" uniqKey="Willett C">C.G. Willett</name></author><author><name sortKey="Ancukiewicz, M" uniqKey="Ancukiewicz M">M. Ancukiewicz</name></author><author><name sortKey="Di Tomaso, E" uniqKey="Di Tomaso E">E. di Tomaso</name></author><author><name sortKey="Shah, M" uniqKey="Shah M">M. Shah</name></author><author><name sortKey="Czito, B G" uniqKey="Czito B">B.G. Czito</name></author><author><name sortKey="Bentley, R" uniqKey="Bentley R">R. Bentley</name></author><author><name sortKey="Poleski, M" uniqKey="Poleski M">M. Poleski</name></author><author><name sortKey="Lauwers, G Y" uniqKey="Lauwers G">G.Y. Lauwers</name></author><author><name sortKey="Carroll, M" uniqKey="Carroll M">M. Carroll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorensen, A G" uniqKey="Sorensen A">A.G. Sorensen</name></author><author><name sortKey="Batchelor, T T" uniqKey="Batchelor T">T.T. Batchelor</name></author><author><name sortKey="Zhang, W T" uniqKey="Zhang W">W.T. Zhang</name></author><author><name sortKey="Chen, P J" uniqKey="Chen P">P.J. Chen</name></author><author><name sortKey="Yeo, P" uniqKey="Yeo P">P. Yeo</name></author><author><name sortKey="Wang, M" uniqKey="Wang M">M. Wang</name></author><author><name sortKey="Jennings, D" uniqKey="Jennings D">D. Jennings</name></author><author><name sortKey="Wen, P Y" uniqKey="Wen P">P.Y. Wen</name></author><author><name sortKey="Lahdenranta, J" uniqKey="Lahdenranta J">J. Lahdenranta</name></author><author><name sortKey="Ancukiewicz, M" uniqKey="Ancukiewicz M">M. Ancukiewicz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, A X" uniqKey="Zhu A">A.X. Zhu</name></author><author><name sortKey="Sahani, D V" uniqKey="Sahani D">D.V. Sahani</name></author><author><name sortKey="Duda, D G" uniqKey="Duda D">D.G. Duda</name></author><author><name sortKey="Di Tomaso, E" uniqKey="Di Tomaso E">E. di Tomaso</name></author><author><name sortKey="Ancukiewicz, M" uniqKey="Ancukiewicz M">M. Ancukiewicz</name></author><author><name sortKey="Catalano, O A" uniqKey="Catalano O">O.A. Catalano</name></author><author><name sortKey="Sindhwani, V" uniqKey="Sindhwani V">V. Sindhwani</name></author><author><name sortKey="Blaszkowsky, L S" uniqKey="Blaszkowsky L">L.S. Blaszkowsky</name></author><author><name sortKey="Yoon, S S" uniqKey="Yoon S">S.S. Yoon</name></author><author><name sortKey="Lahdenranta, J" uniqKey="Lahdenranta J">J. Lahdenranta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Motzer, R J" uniqKey="Motzer R">R.J. Motzer</name></author><author><name sortKey="Bukowski, R M" uniqKey="Bukowski R">R.M. Bukowski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grepin, R" uniqKey="Grepin R">R. Grepin</name></author><author><name sortKey="Guyot, M" uniqKey="Guyot M">M. Guyot</name></author><author><name sortKey="Jacquin, M" uniqKey="Jacquin M">M. Jacquin</name></author><author><name sortKey="Durivault, J" uniqKey="Durivault J">J. Durivault</name></author><author><name sortKey="Chamorey, E" uniqKey="Chamorey E">E. Chamorey</name></author><author><name sortKey="Sudaka, A" uniqKey="Sudaka A">A. Sudaka</name></author><author><name sortKey="Serdjebi, C" uniqKey="Serdjebi C">C. Serdjebi</name></author><author><name sortKey="Lacarelle, B" uniqKey="Lacarelle B">B. Lacarelle</name></author><author><name sortKey="Scoazec, J Y" uniqKey="Scoazec J">J.Y. Scoazec</name></author><author><name sortKey="Negrier, S" uniqKey="Negrier S">S. Negrier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ebos, J M" uniqKey="Ebos J">J.M. Ebos</name></author><author><name sortKey="Lee, C R" uniqKey="Lee C">C.R. Lee</name></author><author><name sortKey="Cruz Munoz, W" uniqKey="Cruz Munoz W">W. Cruz-Munoz</name></author><author><name sortKey="Bjarnason, G A" uniqKey="Bjarnason G">G.A. Bjarnason</name></author><author><name sortKey="Christensen, J G" uniqKey="Christensen J">J.G. Christensen</name></author><author><name sortKey="Kerbel, R S" uniqKey="Kerbel R">R.S. Kerbel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grunewald, M" uniqKey="Grunewald M">M. Grunewald</name></author><author><name sortKey="Avraham, I" uniqKey="Avraham I">I. Avraham</name></author><author><name sortKey="Dor, Y" uniqKey="Dor Y">Y. Dor</name></author><author><name sortKey="Bachar Lustig, E" uniqKey="Bachar Lustig E">E. Bachar-Lustig</name></author><author><name sortKey="Itin, A" uniqKey="Itin A">A. Itin</name></author><author><name sortKey="Jung, S" uniqKey="Jung S">S. Jung</name></author><author><name sortKey="Chimenti, S" uniqKey="Chimenti S">S. Chimenti</name></author><author><name sortKey="Landsman, L" uniqKey="Landsman L">L. Landsman</name></author><author><name sortKey="Abramovitch, R" uniqKey="Abramovitch R">R. Abramovitch</name></author><author><name sortKey="Keshet, E" uniqKey="Keshet E">E. Keshet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Favaro, E" uniqKey="Favaro E">E. Favaro</name></author><author><name sortKey="Amadori, A" uniqKey="Amadori A">A. Amadori</name></author><author><name sortKey="Indraccolo, S" uniqKey="Indraccolo S">S. Indraccolo</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23903048</article-id><article-id pub-id-type="pmc">3759892</article-id><article-id pub-id-type="doi">10.3390/ijms140815885</article-id><article-id pub-id-type="publisher-id">ijms-14-15885</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gavalas</surname><given-names>Nikos G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Liontos</surname><given-names>Michalis</given-names></name></contrib><contrib contrib-type="author"><name><surname>Trachana</surname><given-names>Sofia-Paraskevi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bagratuni</surname><given-names>Tina</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arapinis</surname><given-names>Calliope</given-names></name></contrib><contrib contrib-type="author"><name><surname>Liacos</surname><given-names>Christine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dimopoulos</surname><given-names>Meletios A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bamias</surname><given-names>Aristotle</given-names></name><xref rid="c1-ijms-14-15885" ref-type="corresp">*</xref></contrib><aff id="af1-ijms-14-15885">Department of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vas. Sofias Avenue, Athens 115 28, Greece; E-Mails:<email>ngavalas@med.uoa.gr</email> (N.G.G.);<email>mliontos@gmail.com</email> (L.M.);<email>sp.voula@yahoo.com</email> (S.-P.T.);<email>tbagratuni@hotmail.co.uk</email> (T.B.);<email>karapini@gmail.com</email> (C.A.);<email>liakou@med.uoa.gr</email> (C.L.);<email>mdimop@med.uoa.gr</email> (M.A.G.)</aff></contrib-group><author-notes><corresp id="c1-ijms-14-15885"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>abamias@med.uoa.gr</email>; Tel.: +30-210-3381-580; Fax: +30-210-3381-511.</corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>7</month><year>2013</year></pub-date><volume>14</volume><issue>8</issue><fpage>15885</fpage><lpage>15909</lpage><history><date date-type="received"><day>20</day><month>5</month><year>2013</year></date><date date-type="rev-recd"><day>13</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 by the authors; licensee MDPI, Basel, Switzerland</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><pmc-comment>CREATIVE COMMONS</pmc-comment>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Ovarian Cancer represents the most fatal type of gynecological malignancies. A number of processes are involved in the pathogenesis of ovarian cancer, especially within the tumor microenvironment. Angiogenesis represents a hallmark phenomenon in cancer, and it is responsible for tumor spread and metastasis in ovarian cancer, among other tumor types, as it leads to new blood vessel formation. In recent years angiogenesis has been given considerable attention in order to identify targets for developing effective anti-tumor therapies. Growth factors have been identified to play key roles in driving angiogenesis and, thus, the formation of new blood vessels that assist in “feeding” cancer. Such molecules include the vascular endothelial growth factor (VEGF), the platelet derived growth factor (PDGF), the fibroblast growth factor (FGF), and the angiopoietin/Tie2 receptor complex. These proteins are key players in complex molecular pathways within the tumor cell and they have been in the spotlight of the development of anti-angiogenic molecules that may act as stand-alone therapeutics, or in concert with standard treatment regimes such as chemotherapy. The pathways involved in angiogenesis and molecules that have been developed in order to combat angiogenesis are described in this paper.</p></abstract><kwd-group><kwd>ovarian</kwd><kwd>cancer</kwd><kwd>angiogenesis</kwd><kwd>pathway</kwd><kwd>VEGF</kwd><kwd>PDGF</kwd><kwd>FGF</kwd><kwd>Ang</kwd><kwd>Tie2</kwd></kwd-group></article-meta></front><body><sec><title>1. Ovarian Cancer: Pathogenesis and Clinical Aspects</title><p>Cancer is a major public health problem and it constitutes one of the most frequent causes of death in the Western world. A total of 1,638,910 new cancer cases, and 577,190 deaths from cancer, were estimated to occur in the United States in 2012 [<xref rid="b1-ijms-14-15885" ref-type="bibr">1</xref>]. The economic burden of cancer is associated with expenditures including aspects such as prevention, screening and treatment services, and the lost productivity due to cancer-related death [<xref rid="b2-ijms-14-15885" ref-type="bibr">2</xref>]. The five-year net burden for the American Health System has reached almost $21 billion, whereas later findings calculate the total cost of cancer reaching up to $1 trillion in 2009.</p><p>Ovarian cancer is the most fatal among gynecologic cancers. In terms of pathology, epithelial ovarian cancers are classified into five main types including High-Grade Serous Carcinomas (HGSC), Endometroid Carcinomas (EC), Clear Cell Carcinomas (CCC), Mucinous Carcinomas (MC), and Low-Grade Serous Carcinomas (LGSC) [<xref rid="b3-ijms-14-15885" ref-type="bibr">3</xref>]. These distinct histological subtypes share few molecular similarities and many of them arise from non-ovarian tissues [<xref rid="b4-ijms-14-15885" ref-type="bibr">4</xref>]. Interestingly, contemporary therapeutic approaches are common for all subtypes of epithelial ovarian carcinomas, while the effectiveness of the cytotoxic drugs used has reached a plateau, as indicated by the unaltered five-year survival of ovarian cancer patients the last 15 years [<xref rid="b5-ijms-14-15885" ref-type="bibr">5</xref>]. Ovarian carcinomas have been considered to arise from the epithelium that lines the ovarian surface. The latter is composed from a layer of flat to cuboidal epithelial cells that derive from the embryonic coleomic epithelium [<xref rid="b6-ijms-14-15885" ref-type="bibr">6</xref>].</p><p>Invagination of the ovarian surface epithelium during ovulatory cycles forms inclusion cysts. The exposure of invaginated epithelium to hormonal stimulation accounts for its metaplasia and promotes its malignant transformation [<xref rid="b7-ijms-14-15885" ref-type="bibr">7</xref>]. The normal ovary, though, lacks constituents that resemble the major histological subtypes of ovarian carcinoma. Furthermore, ovaries develop embryologically from mesodermal epithelium on the urogenital ridge, separate from the müllerian ducts, and although inclusion cysts are frequently encountered in ovaries, there is no histological evidence that these structures could constitute the precursors of high-grade serous carcinomas.</p><p>An alternative theory proposed by Lauchlan [<xref rid="b8-ijms-14-15885" ref-type="bibr">8</xref>,<xref rid="b9-ijms-14-15885" ref-type="bibr">9</xref>] suggests that tumors with a müllerian phenotype arise from müllerian-type tissue, outside from the primary Müllerian system, that is collectively referred as the “secondary Müllerian system”. This includes the Müllerian type epithelium encountered in ovarian inclusion cysts. As these tumors enlarge, they obliterate ovarian tissue resulting in an adnexal tumor that appears to have arisen from the ovary. This theory explains the pathogenesis of some tumors, identical to ovarian carcinomas that develop, despite the ovaries or the ovaries along with the fallopian tubes and the uterus having been previously removed. However, the value of this theory is limited since rarely, if ever, have [<xref rid="b10-ijms-14-15885" ref-type="bibr">10</xref>] premalignant lesions resembling ovarian carcinomas in paratubal or paraovarian cysts been recognized [<xref rid="b4-ijms-14-15885" ref-type="bibr">4</xref>].</p><p>During the last decade, the interest in the pathogenesis of ovarian cancer, and especially High Grade Serous Carcinomas, has been transferred to the fallopian tube. More specifically, in 2001 Pick <italic>et al.</italic> described dysplastic lesions in the fallopian tube of women, with germline BRCA1 mutation, that were subjected to prophylactic salpingoophorectomy [<xref rid="b11-ijms-14-15885" ref-type="bibr">11</xref>]. These lesions, later characterized as Serous Tubular Intraepithelial Carcinomas (STICs), were also described in a number of subsequent studies [<xref rid="b10-ijms-14-15885" ref-type="bibr">10</xref>,<xref rid="b12-ijms-14-15885" ref-type="bibr">12</xref>–<xref rid="b14-ijms-14-15885" ref-type="bibr">14</xref>]. Based on this observation, Kindelberger <italic>et al.</italic> not only recognized STICs after careful examination of the fimbria in a series of serous ovarian carcinomas, but also identified identical <italic>TP53</italic> mutations among STICs and the corresponding invasive carcinomas [<xref rid="b15-ijms-14-15885" ref-type="bibr">15</xref>], thus providing the etiological link between these two entities.</p><p>The heterogenous group of epithelial ovarian carcinomas is reflected, not only in histopathology, but also in genetic lesions. Based on morphological and genetic analysis, Shih and Kurman have proposed the dualistic model for ovarian carcinogenesis [<xref rid="b16-ijms-14-15885" ref-type="bibr">16</xref>]. They have classified epithelial ovarian carcinomas, based on the genetic alterations implicated in their carcinogenesis, into two types.</p><p>Type I tumors include low-grade serous carcinomas, mucinous carcinomas, clear cell carcinomas, endometroid carcinomas, and malignant Brenner tumors [<xref rid="b16-ijms-14-15885" ref-type="bibr">16</xref>]. They are slow growing tumors and are usually detected at a low FIGO stage, with most of these tumors confined in the ovary [<xref rid="b17-ijms-14-15885" ref-type="bibr">17</xref>]. Their development proceeds in a stepwise fashion from well-recognized precursor lesions and are genetically stable [<xref rid="b16-ijms-14-15885" ref-type="bibr">16</xref>]. Mutations of genes such as <italic>KRAS</italic> and <italic>ERBB2</italic> that deregulate MAPK signaling pathway drive carcinogenesis in approximately 70% of LSGC [<xref rid="b18-ijms-14-15885" ref-type="bibr">18</xref>,<xref rid="b19-ijms-14-15885" ref-type="bibr">19</xref>]. In Low Grade Endometroid and Clear Cell Carcinomas similar genetic alterations are detected, such as those that affect the PI3K signaling pathway. These include activating mulation of the <italic>PIK3CA</italic> in approximately 50% of cases [<xref rid="b20-ijms-14-15885" ref-type="bibr">20</xref>]. Genome-wide mutation analysis in these tumors has also highlighted the implication of tumor suppressor genes in their pathogenesis [<xref rid="b21-ijms-14-15885" ref-type="bibr">21</xref>].</p><p>In sharp contrast to type I ovarian tumors, the predominant genetic alteration that drives carcinogenesis in type II tumors are <italic>TP53</italic> mutations. High Grade Serous Carcinomas harbor <italic>TP53</italic> mutations in >95% of cases [<xref rid="b22-ijms-14-15885" ref-type="bibr">22</xref>], and analogous is the percentage in High-Grade Endometroid Carcinomas, an entity that is often morphologically indistinguishable from serous counterparts. As anticipated, mutations in the “guardian of the genome” <italic>TP53</italic> gene, results in increased genomic instability detected in HGSCs [<xref rid="b23-ijms-14-15885" ref-type="bibr">23</xref>,<xref rid="b24-ijms-14-15885" ref-type="bibr">24</xref>]. DNA copy number gains or losses have been frequently detected in genes such as <italic>PIK3CA</italic> [<xref rid="b25-ijms-14-15885" ref-type="bibr">25</xref>,<xref rid="b26-ijms-14-15885" ref-type="bibr">26</xref>]. Mutations in <italic>BRCA1/2</italic> genes that characterize cases of familiar ovarian carcinomas are rarely encountered in sporadic cases.</p><p>Even newly approved molecular therapies for ovarian carcinomas [<xref rid="b27-ijms-14-15885" ref-type="bibr">27</xref>–<xref rid="b29-ijms-14-15885" ref-type="bibr">29</xref>], despite being promising, lack well defined biomarkers that could improve their effective use. The above, underscore the need to improve our understanding of ovarian cancer at the molecular and cellular level by recognizing the cell of origin, identifying precancerous lesions, and delineating the pathogenesis of the disease.</p><p>One of the main targets for future drug developments is angiogenesis.</p></sec><sec><title>2. Angiogenesis in Cancer Pathogenesis</title><p>Angiogenesis refers to the process of the formation of new vessels, and it constitutes a hallmark process of cancer progression and metastasis. The angiogenetic process is rather complex and involves a large number of cytokines and associated receptors. It occurs during the menstrual cycle, and also wound healing in the ovaries and the endometrium, in adult life. The angiogenesis term was founded over a century ago [<xref rid="b30-ijms-14-15885" ref-type="bibr">30</xref>], but its meaning was not fully elucidated until the 1960s decade when Judah Folkman discovered that tiny tumors grew to about 1–2 mm in size and also stopped expanding in the absence of the vascularization process [<xref rid="b31-ijms-14-15885" ref-type="bibr">31</xref>].</p><p>Angiogenesis has been shown to be a necessary process for oncogenesis, as well as subsequent tumor growth and dissemination through metastases.</p><p>Microvessel density related quantitative analysis in a number of different cancer types in patients revealed that the angiogenic switch and the initiation of angiogenesis also occur during the growth of human cancers [<xref rid="b32-ijms-14-15885" ref-type="bibr">32</xref>,<xref rid="b33-ijms-14-15885" ref-type="bibr">33</xref>]. In ovarian cancer, angiogenesis has also been associated with the formation of malignant ascites [<xref rid="b34-ijms-14-15885" ref-type="bibr">34</xref>,<xref rid="b35-ijms-14-15885" ref-type="bibr">35</xref>].</p><p>During oncogenesis, tumor endothelial cells, which line blood vessels, may divide up to 50 times faster than normal endothelial cells, providing them with a significant growth advantage over their normal counterparts. Continuous neovascularisation allows tumor cells to grow beyond a diffusion-limited size, therefore rendering angiogenesis an important process in the pathogenesis of cancer. The architecture of the tumor blood vessels exhibits differences to the architecture of normal blood vessels, more specifically, abnormalities. Tumor vessels exhibit high vascular permeability, poor blood flow, and a rather irregular shape when compared to normal ones [<xref rid="b36-ijms-14-15885" ref-type="bibr">36</xref>]. The elimination of the angiogenic process may result in the inability of the tumor to grow further although cell proliferation occurs, counter balanced by apoptosis, as observed in tumor dormant areas, and it allows metastasis to occur [<xref rid="b37-ijms-14-15885" ref-type="bibr">37</xref>].</p><p>The mechanism by which angiogenesis occurs is quite complex and it is yet to be elucidated although advances in this field of research are quite intensive. Cancer cells release pro-angiogenic factors, such as the Vascular Endothelial Growth Factor (VEGF) and the platelet derived growth factor (PDGF) [<xref rid="b38-ijms-14-15885" ref-type="bibr">38</xref>–<xref rid="b40-ijms-14-15885" ref-type="bibr">40</xref>]. These factors act by activating endothelial cells, thus leading to new blood vessel formation, in order to initiate angiogenesis. The angiogenic process itself in the tumor microenvironment involves the interplay of angiogenic growth factors with their corresponding receptors, leading to endothelial cell activation, and also vascular remodeling.</p><p>Pro-angiogenic factors’ action is counterbalanced by anti-angiogenic action by numerous other factors such as thrombospondin and angiostatin [<xref rid="b40-ijms-14-15885" ref-type="bibr">40</xref>], and this balance has been termed the angiogenic switch [<xref rid="b38-ijms-14-15885" ref-type="bibr">38</xref>]. In the case of normal tissues, the angiogenic switch is turned off, thus the vasculature remains quiescent as a result of the balance between pro- and anti-angiogenic factors [<xref rid="b38-ijms-14-15885" ref-type="bibr">38</xref>,<xref rid="b40-ijms-14-15885" ref-type="bibr">40</xref>]. In tumor tissues though, the exact opposite happens; balance is leaning towards the greater expression of pro-angiogenic factors and angiogenesis occurs [<xref rid="b38-ijms-14-15885" ref-type="bibr">38</xref>]. These pro-angiogenic factors diffuse out of the tumor cells, during the course of tumor development, then bind onto adjacent endothelial cells in the case of mature blood vessels, thus triggering a process called vessel sprouting [<xref rid="b41-ijms-14-15885" ref-type="bibr">41</xref>]. Sprouting seems to play a pivotal role in the angiogenesis process. When switching to the angiogenic phenotype according to the angiogenic switch process described earlier, the formation of new blood vessels occurs from pre-existing vasculature [<xref rid="b42-ijms-14-15885" ref-type="bibr">42</xref>–<xref rid="b45-ijms-14-15885" ref-type="bibr">45</xref>]. The newly formed vessels infiltrate the tumor mass in the local tumor microenvironment and promote tumor mass expansion, and subsequent hematogenous metastatic spread, therefore contributing to the pathogenesis of cancer. An overview of the angiogenic process is shown in <xref rid="f1-ijms-14-15885" ref-type="fig">Figure 1</xref>.</p><p>It may also be of importance to briefly mention that angiogenesis is involved in the metastasis of the tumor to the peritoneal cavity. At the time of metastasis, tumor cells from their organ of origin are secreted and move over to the peritoneum where they eventually reach the innermost layer of the peritoneum, the mesothelium. The mesothelium forms a cellular monolayer supported by a basement membrane. Tumor cells then adhere to the mesothelium, followed by penetration of the mesothelium so that tumor cells gain access to the submesothelial connective tissue. Invasion of the connective tissue provides the scaffold for further tumor proliferation, thereby establishing a metastatic deposit. The final step in this process is the induction of angiogenesis for sustainability of the tumor proliferation potential and also the achievement of further metastatic growth.</p><p>Peritoneal mesothelial cells have been shown to secrete angiogenic factors such as VEGF and Fibroblast Growth Factor (FGF) [<xref rid="b46-ijms-14-15885" ref-type="bibr">46</xref>,<xref rid="b47-ijms-14-15885" ref-type="bibr">47</xref>]. An increase in the secretion of such factors has been observed upon the stimulation with IL-1β and TNF-α, whereas factors such as IL-2 inhibited secretion of such pro-angiogenic proteins [<xref rid="b46-ijms-14-15885" ref-type="bibr">46</xref>]. Such action for IL-1β has been shown to be possible in ovarian cancer as well, as a recent study has shown [<xref rid="b48-ijms-14-15885" ref-type="bibr">48</xref>]. Gerber <italic>et al.</italic> have shown that the omentum was a major site of metastases growth for intraperitoneal tumors [<xref rid="b49-ijms-14-15885" ref-type="bibr">49</xref>]. A subset of mesothelial cells located in the omentum was found to be hypoxic and also secrete VEGF. In addition, the presence of CD105+ vessels and localized sprouting indicated that active angiogenesis was occurring in the peritoneum.</p><p>In the case of ovarian cancer the seeding of the peritoneum and the resultant cancer development seem to be significant processes in the development of ovarian cancer and especially for the production of ascites [<xref rid="b50-ijms-14-15885" ref-type="bibr">50</xref>]. The role of VEGF is quite important in this process. Experiments using animal models with peritoneal cancer spread have shown that VEGF overexpression may lead to tumor increase and also to peritoneal related neovasculogenesis and also increased vascular permeability in the peritoneum [<xref rid="b51-ijms-14-15885" ref-type="bibr">51</xref>,<xref rid="b52-ijms-14-15885" ref-type="bibr">52</xref>]. Therefore, there is a strong indication that angiogenesis may play a role in cancer metastasis in the peritoneum with mesothelial cells playing significant role in the process.</p><p>Angiogenic growth factors may also influence the growth of cancer cells <italic>per se</italic>. This has been shown by the direct effect of VEGF on to tumor cells [<xref rid="b53-ijms-14-15885" ref-type="bibr">53</xref>]. It has also been shown that the autocrine VEGF/VEGFR loop, when both of these molecules are expressed in tumor cells, may be responsible for the growth enhancement of tumor cells <italic>per se</italic> [<xref rid="b54-ijms-14-15885" ref-type="bibr">54</xref>]. The fact that VEGF plays a tumor cell proliferative role has also been shown in the case of ovarian tumor cells as well [<xref rid="b55-ijms-14-15885" ref-type="bibr">55</xref>].</p><p>Angiogenesis plays an important role in all types of cancer, including gynecological [<xref rid="b56-ijms-14-15885" ref-type="bibr">56</xref>–<xref rid="b58-ijms-14-15885" ref-type="bibr">58</xref>], thereby a role for angiogenesis in the pathophysiology of all gynecological cancers including ovarian cancer has now been established. We hereby describe the important molecular pathways that are involved in this process in the pathogenesis and expansion of ovarian cancer.</p></sec><sec><title>3. Vascular Endothelial Growth Factor (VEGF) Related Pathways</title><p>VEGF plays an exceptional role in angiogenesis. It is involved in this process by mainly regulating new blood vessel growth [<xref rid="b59-ijms-14-15885" ref-type="bibr">59</xref>]. It also promotes survival of immature vasculature before it turns into its mature form. VEGF was first discovered by Ferrara and colleagues [<xref rid="b60-ijms-14-15885" ref-type="bibr">60</xref>] and was previously known as the vascular permeability factor due to its capacity of increasing vascular permeability [<xref rid="b61-ijms-14-15885" ref-type="bibr">61</xref>]. There are seven member molecules that fall into this family of proteins, including VEGF A–E, and also the placental growth factor 1 and 2 (PIGF-1 and PIGF-2) [<xref rid="b62-ijms-14-15885" ref-type="bibr">62</xref>,<xref rid="b63-ijms-14-15885" ref-type="bibr">63</xref>]. VEGF-A multiple isoforms may be formed due to alternative mRNA splicing, with VEGF<sub>165</sub> being the most prevalent VEGF isoform in a number of tumors [<xref rid="b64-ijms-14-15885" ref-type="bibr">64</xref>–<xref rid="b66-ijms-14-15885" ref-type="bibr">66</xref>].</p><p>Molecules of this family exert their effect via signaling through their tyrosine kinase receptor counterparts that are expressed normally on the surface of endothelial cells [<xref rid="b62-ijms-14-15885" ref-type="bibr">62</xref>,<xref rid="b64-ijms-14-15885" ref-type="bibr">64</xref>] and are termed vascular endothelial growth factor receptors (VEGFR). There are three isoforms of this type of receptors namely VEGFR1-3 [<xref rid="b67-ijms-14-15885" ref-type="bibr">67</xref>–<xref rid="b69-ijms-14-15885" ref-type="bibr">69</xref>]. VEGF-A binds preferentially to VEGFR1 and 2, VEGFB and PIGF-1 and PIGF-2 bind to VEGFR1, whereas VEGF-C and D bind preferentially to VEGFR3 [<xref rid="b70-ijms-14-15885" ref-type="bibr">70</xref>,<xref rid="b71-ijms-14-15885" ref-type="bibr">71</xref>]. The binding of the ligand onto the receptor induces a receptor dimerization that leads to intracellular signaling initiation.</p><p>VEGF expression has been shown to be upregulated by factors such as IGF-1 and IL-6 [<xref rid="b72-ijms-14-15885" ref-type="bibr">72</xref>,<xref rid="b73-ijms-14-15885" ref-type="bibr">73</xref>]. The expression of VEGF may also be regulated by mutations in genes such as <italic>p53</italic>, <italic>ras</italic>, <italic>src</italic>, and <italic>vhl</italic> [<xref rid="b74-ijms-14-15885" ref-type="bibr">74</xref>,<xref rid="b75-ijms-14-15885" ref-type="bibr">75</xref>] Function-wise, VEGFR2 is the main receptor isoform through which VEGF, mainly VEGF-A, mediates its effects that are directly related to angiogenesis [<xref rid="b76-ijms-14-15885" ref-type="bibr">76</xref>,<xref rid="b77-ijms-14-15885" ref-type="bibr">77</xref>]. VEGFR-1 has a less defined role, although recent studies have shown that both VEGF and PIGF may bind onto the receptor, in pathological conditions such as tumors, and enhance angiogenesis effects [<xref rid="b78-ijms-14-15885" ref-type="bibr">78</xref>]. Moreover, soluble VEGFR1 may even play a role in controlling VEGFR2 signaling as it can act as a decoy receptor molecule [<xref rid="b79-ijms-14-15885" ref-type="bibr">79</xref>]. In turn, VEGFR3 plays a lesser role in angiogenesis, but it has been documented to play an important role in lymphangiogenesis upon binding of VEGF-C and VEGF-D [<xref rid="b59-ijms-14-15885" ref-type="bibr">59</xref>,<xref rid="b80-ijms-14-15885" ref-type="bibr">80</xref>,<xref rid="b81-ijms-14-15885" ref-type="bibr">81</xref>]. The main VEGF isoform being important in angiogenesis is VEGF-A and it will be referred as VEGF from this point onwards.</p><p>VEGF is produced by cancer cells and relates to the metastatic potential of a number of different types of tumors, including ovarian cancer [<xref rid="b82-ijms-14-15885" ref-type="bibr">82</xref>,<xref rid="b83-ijms-14-15885" ref-type="bibr">83</xref>]. It is detected by immunostaining in most ovarian cancerous tissues and it is also an important facilitator of the creation of ascites in the latter stages of the disease [<xref rid="b84-ijms-14-15885" ref-type="bibr">84</xref>,<xref rid="b85-ijms-14-15885" ref-type="bibr">85</xref>]. VEGF alongside its receptors constitute the dominant pathway that regulates angiogenesis in ovarian cancer [<xref rid="b39-ijms-14-15885" ref-type="bibr">39</xref>,<xref rid="b86-ijms-14-15885" ref-type="bibr">86</xref>]. The role of the VEGF/VEGFR axis in ovarian cancer has been well documented due to pharmacological studies of agents that reduce the burden of women with the disease [<xref rid="b83-ijms-14-15885" ref-type="bibr">83</xref>,<xref rid="b87-ijms-14-15885" ref-type="bibr">87</xref>].</p><p>Intracellular signaling related to VEGF in ovarian cancer includes the elaboration of molecules such as JAK and STAT pathway components, PI-3 kinases, and MAP kinases [<xref rid="b82-ijms-14-15885" ref-type="bibr">82</xref>]. More specifically, PI-3K has been shown to play an important role in angiogenesis with its expression correlating with VEGF upregulation [<xref rid="b88-ijms-14-15885" ref-type="bibr">88</xref>], and an upregulation of the PI3K/Akt pathway is observed [<xref rid="b89-ijms-14-15885" ref-type="bibr">89</xref>]. The activation of the JAK-STAT pathway has been correlated with upregulation of VEGF and intracellular signaling in angiogenesis, especially the upregulation of STAT3 and STAT5 [<xref rid="b90-ijms-14-15885" ref-type="bibr">90</xref>]. MAP kinases are also involved in an interplay with VEGF levels [<xref rid="b91-ijms-14-15885" ref-type="bibr">91</xref>]. For the initiation of signaling, an autocrine loop of VEGF/VEGFR has been indicated to be responsible [<xref rid="b36-ijms-14-15885" ref-type="bibr">36</xref>,<xref rid="b40-ijms-14-15885" ref-type="bibr">40</xref>].</p><p>Lately, there are other protein molecules that have been studied and shown to be involved in a signaling interplay with the VEGF/VEGFR complex, mainly VEGF/VEGFR2. These include the Src kinases, which increase vascular permeability [<xref rid="b92-ijms-14-15885" ref-type="bibr">92</xref>], and phospholipase C that may interact with Erk/MAPK molecules enhancing the VEGF effect on vascular permeability and vessel formation [<xref rid="b93-ijms-14-15885" ref-type="bibr">93</xref>]. Some elements of the VEGF pathway are shown in <xref rid="f2-ijms-14-15885" ref-type="fig">Figure 2</xref>.</p></sec><sec><title>4. The Platelet Derived Growth Factor (PDGF) Pathway</title><p>PDGF is an essential protein to pericyte recruitment, which is a critical aspect of blood vessel maturation. It has been shown that the activation of the PDGF Receptor (PDGFR) leads to upregulation of angiogenic events [<xref rid="b94-ijms-14-15885" ref-type="bibr">94</xref>,<xref rid="b95-ijms-14-15885" ref-type="bibr">95</xref>]. PDGF also interacts with VEGF and they either converge their signaling cascades or the PDGF pathway may be activated in response to resistance to VEGF inhibition [<xref rid="b95-ijms-14-15885" ref-type="bibr">95</xref>,<xref rid="b96-ijms-14-15885" ref-type="bibr">96</xref>]. The importance of PDGF in angiogenesis and in tumor progress is highlighted by the correlation of its expression with ovarian cancer patients’ prognosis [<xref rid="b97-ijms-14-15885" ref-type="bibr">97</xref>].</p><p>Four isoforms of the PDGF molecule have been identified namely PDGF A-D [<xref rid="b98-ijms-14-15885" ref-type="bibr">98</xref>,<xref rid="b99-ijms-14-15885" ref-type="bibr">99</xref>]. As in the case of VEGF, there is specificity on which isoforms of PDGF bind specific corresponding receptor isoforms either PDGFR-α or PDGFR-β in order to exert their effects. In this case, PDGF A–C bind onto PDGFR-α, whereas PDGF-B and PDGF-D bind onto PDGFR-β [<xref rid="b100-ijms-14-15885" ref-type="bibr">100</xref>]. As in the case of VEGF/VEGFR, an autocrine signaling mechanism, may be responsible for PDGF promoting angiogenesis and tumor growth [<xref rid="b101-ijms-14-15885" ref-type="bibr">101</xref>].</p><p>Upon activation of the PDGF pathway, signaling occurs via the use of the PI3K/Akt complex pathway but there are also MAPK molecules involved alongside proteins of the Src family and Phospholipase C-γ [<xref rid="b102-ijms-14-15885" ref-type="bibr">102</xref>]. Other molecules related to the PDGF signaling include the Ras protein [<xref rid="b103-ijms-14-15885" ref-type="bibr">103</xref>], STAT proteins, and guanine-5′-triphosphate (GTP-ase) activating protein [<xref rid="b104-ijms-14-15885" ref-type="bibr">104</xref>].</p><p>In the case of ovarian cancer, PDGF has been recorded in a large number of samples and a five to six-fold increase in the level of PDGF has been measured in ovarian cancer tumor cells when compared to cells of the normal ovarian epithelium [<xref rid="b105-ijms-14-15885" ref-type="bibr">105</xref>–<xref rid="b107-ijms-14-15885" ref-type="bibr">107</xref>]. PDGFR is expressed in ovarian carcinomas and it is also present in malignant ascites [<xref rid="b108-ijms-14-15885" ref-type="bibr">108</xref>].</p><p>PDGF has been shown to interfere with the stroma formation and also act as a substrate for angiogenesis [<xref rid="b109-ijms-14-15885" ref-type="bibr">109</xref>]. It has also been shown to act in concert with VEGF in order to promote new vessel formation and stabilize newly synthesized vessels [<xref rid="b75-ijms-14-15885" ref-type="bibr">75</xref>,<xref rid="b110-ijms-14-15885" ref-type="bibr">110</xref>,<xref rid="b111-ijms-14-15885" ref-type="bibr">111</xref>], so PDGF molecules are key regulatory molecules in oncogenesis and angiogenesis, important in ovarian cancer. Some elements of the PDGF signaling pathways are shown in <xref rid="f3-ijms-14-15885" ref-type="fig">Figure 3</xref>.</p></sec><sec><title>5. The Fibroblast Growth Factor (FGF) Pathway</title><p>FGF signaling mechanism has originally been studied as a significant embryogenesis pathway [<xref rid="b112-ijms-14-15885" ref-type="bibr">112</xref>] and it has since become an important research target when it comes to angiogenesis research in cancer [<xref rid="b113-ijms-14-15885" ref-type="bibr">113</xref>,<xref rid="b114-ijms-14-15885" ref-type="bibr">114</xref>]. There are over 20 FGF isoforms identified, namely 23, and five receptor molecules (FGFR) have also been described [<xref rid="b115-ijms-14-15885" ref-type="bibr">115</xref>]. The receptor molecules pose great similarity in structure, including an extracellular immunoglobulin (Ig)-like domain and an intracellular tyrosine kinase domain [<xref rid="b116-ijms-14-15885" ref-type="bibr">116</xref>,<xref rid="b117-ijms-14-15885" ref-type="bibr">117</xref>]. These domains are conserved between the first four isoforms of the receptor but the fifth isoform (FGFR-5) lacks the intracellular tyrosine kinase domain [<xref rid="b118-ijms-14-15885" ref-type="bibr">118</xref>,<xref rid="b119-ijms-14-15885" ref-type="bibr">119</xref>].</p><p>Upon binding of the ligand onto the receptor, the receptor molecules dimerise, a process that leads to the initiation of the intracellular signaling cascade. In ovarian cancer, disruptions to the appropriate signaling cascade have been reported, such as alternative splicing events differentiating the ability of the receptor to bind ligands effectively, while mutation events have not been considered significant in altering the receptor’s function [<xref rid="b119-ijms-14-15885" ref-type="bibr">119</xref>–<xref rid="b121-ijms-14-15885" ref-type="bibr">121</xref>].</p><p>In ovarian cancer, differences in alternative splicing may confer sensitivity to the ligand [<xref rid="b122-ijms-14-15885" ref-type="bibr">122</xref>]. Moreover, in the case of ovarian cancer, FGF may be secreted into malignant ascites alongside VEGF, therefore, it may be contributing to cancer progression and angiogenesis [<xref rid="b123-ijms-14-15885" ref-type="bibr">123</xref>,<xref rid="b124-ijms-14-15885" ref-type="bibr">124</xref>]. The expression of FGF may be associated with prognosis [<xref rid="b125-ijms-14-15885" ref-type="bibr">125</xref>].</p><p>It has been shown that FGF may play a direct role in tumor cell proliferation in ovarian cancer [<xref rid="b126-ijms-14-15885" ref-type="bibr">126</xref>,<xref rid="b127-ijms-14-15885" ref-type="bibr">127</xref>], but may also play a role in angiogenesis acting alongside other pro-angiogenic factors such as VEGF [<xref rid="b128-ijms-14-15885" ref-type="bibr">128</xref>,<xref rid="b129-ijms-14-15885" ref-type="bibr">129</xref>].</p><p>The FGF signaling pathway involves the employment of downstream proteins such as MAPK proteins and proteins of the PI3K/Akt cascade [<xref rid="b130-ijms-14-15885" ref-type="bibr">130</xref>]. Phospsholipase-c and IP3 cascades are also involved in the downstream signaling of FGF, whereas the FGF pathway may crosstalk with other pathways such as the Notch pathway [<xref rid="b131-ijms-14-15885" ref-type="bibr">131</xref>]. A schematic overview of some elements of the FGF related pathways are shown in <xref rid="f4-ijms-14-15885" ref-type="fig">Figure 4</xref>.</p></sec><sec><title>6. The Angiopoietin Pathway and the Tie2 Receptor</title><p>There are two forms of the angiopoietin (Ang) protein, namely angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), and both these proteins may interact with the Tie2 receptor [<xref rid="b132-ijms-14-15885" ref-type="bibr">132</xref>]. Ang-1 and 2 may interact with Tie2 and enhance new vessel production [<xref rid="b133-ijms-14-15885" ref-type="bibr">133</xref>], whereas Ang-1 acts via the use of the Akt/survivin pathway in order to stabilize newly produced vessels [<xref rid="b134-ijms-14-15885" ref-type="bibr">134</xref>]. Ang-2 may act alone or in synergy with other pro-angiogenic factors, such as VEGF, in order to establish and enhance vasculature and it acts in promoting endothelial cell migration by blocking the vessel stabilizing action of angiopoietin 1 [<xref rid="b135-ijms-14-15885" ref-type="bibr">135</xref>]. It has to be mentioned, though, that late studies show that Ang-2 may be acting in an agonist manner to Ang-1 when the latter is lacking or alternatively in a dose dependent manner when Ang-1 is actually present [<xref rid="b136-ijms-14-15885" ref-type="bibr">136</xref>]. Although in the normal ovary, Tie2 localization may indicate communication between the extracellular matrix and the endothelial cells, in mouse ovarian tumor models Ang-2 is mainly expressed in endothelial cells and the tumor stroma and its expression levels correlate with those of VEGF, therefore proposing a synergistic effect of the two molecules in ovarian cancer angiogenesis [<xref rid="b137-ijms-14-15885" ref-type="bibr">137</xref>].</p><p>Other molecules involved in the downstream signaling pathway of the Ang/Tie2 receptor include the PI3K protein, involved in the PI3K/Akt pathway, and also proteins such as Protein Kinase B, MAPK/Erk molecules, and also molecules of the Ras pathway [<xref rid="b135-ijms-14-15885" ref-type="bibr">135</xref>,<xref rid="b138-ijms-14-15885" ref-type="bibr">138</xref>], and these molecules may possibly, also, be involved in the downstream signaling of the Tie2 receptor in ovarian cancer. Finally, recent studies show that Ang-2 may be exerting its signaling effects via the employment of integrin molecules [<xref rid="b139-ijms-14-15885" ref-type="bibr">139</xref>]. The possible effects of Ang in angiogenesis can be further exhibited by the blocking of the binding of Ang onto the Tie2 receptor that leads to decreased sprouting and reduction of the number of tumor vessels [<xref rid="b138-ijms-14-15885" ref-type="bibr">138</xref>]. <xref rid="f5-ijms-14-15885" ref-type="fig">Figure 5</xref> depicts some of the signaling elements of the Ang related pathways.</p></sec><sec><title>7. Targeting the Angiogenesis Related Pathways for Ovarian Cancer Treatment</title><p>Since angiogenesis poses an important process for ovarian cancer dissemination it is of significance to attempt to devise therapeutic strategies that target angiogenesis pathways. So far strategies that target molecules such as VEGF and PDGF have been developed that act alone or in combination with chemotherapy in order to achieve a more effective treatment [<xref rid="b75-ijms-14-15885" ref-type="bibr">75</xref>,<xref rid="b82-ijms-14-15885" ref-type="bibr">82</xref>].</p><p>Anti-angiogenic agents include bevacizumab, an anti-VEGF monoclonal antibody that has exhibited satisfactory action as a single-phase treatment agent in phase II trials in recurrent epithelial ovarian cancer [<xref rid="b75-ijms-14-15885" ref-type="bibr">75</xref>,<xref rid="b87-ijms-14-15885" ref-type="bibr">87</xref>]. Bevacizumab is a humanized monoclonal antibody that binds onto VEGF (mainly VEGF-A) with high affinity, thus neutralizing the VEGF activity. Bevacizumab has also been used in combination with other therapeutic agents such as platinum compounds e.g. carboplatin, and also paclitaxel, nab-paclitaxel, topotecan, doxorubicin, and docetaxel [<xref rid="b140-ijms-14-15885" ref-type="bibr">140</xref>–<xref rid="b144-ijms-14-15885" ref-type="bibr">144</xref>]. In terms of pre-clinical studies Mesiano <italic>et al.</italic> tested Bevacizumab;s activity in immunodeficient mice and showed that the drug inhibited subcutaneous tumor growth, partially inhibited the tumor’s intraperitoneal growth, and completely inhibited ascites formation [<xref rid="b145-ijms-14-15885" ref-type="bibr">145</xref>]. In another study the synergistic effect of bevacizumab with paclitaxel has been described reducing tumor growth and ascites formation [<xref rid="b146-ijms-14-15885" ref-type="bibr">146</xref>]. Mabuchi <italic>et al.</italic> also showed that the continuous administration of bevacizumab could significantly prolong survival <italic>in vivo</italic> [<xref rid="b147-ijms-14-15885" ref-type="bibr">147</xref>]. Recent results established the role of Bevacizumab in ovarian cancer, showing that it increases the efficacy of chemotherapy in the initial management of the disease [<xref rid="b27-ijms-14-15885" ref-type="bibr">27</xref>,<xref rid="b148-ijms-14-15885" ref-type="bibr">148</xref>] but also in relapsed platinum-sensitive [<xref rid="b29-ijms-14-15885" ref-type="bibr">29</xref>] and platinum-resistant [<xref rid="b149-ijms-14-15885" ref-type="bibr">149</xref>] disease.</p><p>Another anti-angiogenic agent is aflibercept or VEGF-Trap as it is commonly called, which is a fusion protein combined from the domain 2 of VEGFR1 with domain 3 from VEGFR2, attached to the hinge region Fc of a human IgG1 [<xref rid="b150-ijms-14-15885" ref-type="bibr">150</xref>]. VEGF-Trap binds all isoforms of VEGF and confers a neutralizing effect [<xref rid="b150-ijms-14-15885" ref-type="bibr">150</xref>,<xref rid="b151-ijms-14-15885" ref-type="bibr">151</xref>]. Research is ongoing concerning the efficacy of the agent. Pre-clinical data on aflibercept has shown that it is able to inhibit the angiogenic effect including narrowing of vessels, endothelial cell apoptosis, and stop of blood flow and also reduction of tumor burden and ascite formation [<xref rid="b152-ijms-14-15885" ref-type="bibr">152</xref>,<xref rid="b153-ijms-14-15885" ref-type="bibr">153</xref>]. VEGF-Trap has also been used in combination with other therapeuting agents such as docetaxel and cisplatin [<xref rid="b154-ijms-14-15885" ref-type="bibr">154</xref>,<xref rid="b155-ijms-14-15885" ref-type="bibr">155</xref>]. Preliminary results from a phase 1/phase 2 trial of aflibercept in combination with docetaxel in patients with recurrent gynecologic malignancies, including ovarian cancer, reported promising preliminary findings [<xref rid="b155-ijms-14-15885" ref-type="bibr">155</xref>].</p><p>Except the anti-VEGF inhibitor molecules, multiple anti-VEGFR inhibitor molecules, termed anti-angiogenic tyrosine kinase inhibitors are currently undergoing investigation. BIBF 1120 (Intedanib) is an agent that blocks the activity of VEGFR 1–3, PDGFRa and PDGFRb, and FGFRs [<xref rid="b156-ijms-14-15885" ref-type="bibr">156</xref>]. Pre-clinical data show that BIBF 1120 exhibits high activity in decreasing vessel density and reducing tumor growth in mouse models [<xref rid="b157-ijms-14-15885" ref-type="bibr">157</xref>]. BIBF 1120 has been used as a single agent, but also in combination with the combination of carboplatin/paclitaxel has also been used in epithelial ovarian cancer patients [<xref rid="b158-ijms-14-15885" ref-type="bibr">158</xref>].</p><p>Pazopanib is another tyrosine kinase inhibitor that inhibits the activity of VEGFR 1–3 and also PDGFRa and PDGFRb, and FGFR-1 and FGFR-3 [<xref rid="b159-ijms-14-15885" ref-type="bibr">159</xref>]. Pre-clinical data showed that Pazopanib may inhibit VEGF and FGF induced angiogenesis in mouse models, although the effect was higher related to VEGF stimulation [<xref rid="b160-ijms-14-15885" ref-type="bibr">160</xref>]. Studies using Pazopanib as a single agent are currently undergoing [<xref rid="b159-ijms-14-15885" ref-type="bibr">159</xref>]. Cediranib consists another multiple tyrosine kinase inhibitor, thus neutralizing the effect of molecules such as VEGFR 1–3, FGFR-1, and PDGFRa and PDGFRb [<xref rid="b161-ijms-14-15885" ref-type="bibr">161</xref>,<xref rid="b162-ijms-14-15885" ref-type="bibr">162</xref>]. In the case of cediranib pre-clinical data has shown that the drug inhibits angiogenesis in ovarian cancer in a dose dependent manner [<xref rid="b163-ijms-14-15885" ref-type="bibr">163</xref>]. Clinical trials in phase II are currently underway and there is also a necessity for trials including a therapeutic combination of cediranib and platinum therapeutic agents.</p><p>Sorafenib is a tyrosine kinase inhibitor that neutralizes the effect of VEGFR-2, VEGFR-3, and PDGFRb [<xref rid="b164-ijms-14-15885" ref-type="bibr">164</xref>]. Studies are ongoing and results for some of them are currently in process [<xref rid="b164-ijms-14-15885" ref-type="bibr">164</xref>]. Pre-clinical data have shown the drug to inhibit tumor growth in nude mice and reduce tumor growth at a significant level [<xref rid="b165-ijms-14-15885" ref-type="bibr">165</xref>]. Sunitinib inhibits VEGFR-2 and PDGFRB among other molecules. Sunitinib related pre-clinical data have shown also that it can inhibit tumor growth and reduce microvessel density count [<xref rid="b166-ijms-14-15885" ref-type="bibr">166</xref>]. Some studies exhibit modest efficacy results [<xref rid="b167-ijms-14-15885" ref-type="bibr">167</xref>] but other studies are still ongoing.</p><p>Finally, AMG-386, is a fusion protein that inhibits the binding of both Ang-1 and Ang-2, and Tie2 receptors [<xref rid="b168-ijms-14-15885" ref-type="bibr">168</xref>]. Pre-clinical data shows that AMG-386 is directly involved with intracellular signaling as studies in mouse models have exhibited [<xref rid="b169-ijms-14-15885" ref-type="bibr">169</xref>]. Results from studies using AMG-386 as a single agent or in combination with other agents, such as bevacizumab, are awaited [<xref rid="b170-ijms-14-15885" ref-type="bibr">170</xref>].</p><p>Separate reference should be made to the hypothesized antioangiogenic effect of paclitaxel. Paclitaxel is used alone, or in combination with other anti-angiogenic agents such as Bevacizumab. The actual mechanism of its anti-angiogenic effect is not clear yet. A few hypotheses on that matter have accounted for that effect, including the inhibition of endothelial cell morphogenesis <italic>in vitro</italic> [<xref rid="b171-ijms-14-15885" ref-type="bibr">171</xref>]. In another study paclitaxel seems to have an antiangiogenic effect due to a possible increased uptake by endothelial cells [<xref rid="b172-ijms-14-15885" ref-type="bibr">172</xref>]. We should also note here that paclitaxel has been shown to increase <italic>Cox-2</italic> mRNA expression, which is a pro-angiogenesis molecule, and thus a combined treatment of paclitaxel alongside a <italic>Cox-2</italic> inhibitor molecule may be desirable in some cases [<xref rid="b172-ijms-14-15885" ref-type="bibr">172</xref>].</p><p>A number of studies have also attempted to shed more light in predicting the effect of anti-angiogenic drugs, mainly via the usage of potential biomarkers that may be used for this purpose. Such examples include the possible use of VEGF as a biomarker when attempting to predict the effect of bevacizumab [<xref rid="b173-ijms-14-15885" ref-type="bibr">173</xref>,<xref rid="b174-ijms-14-15885" ref-type="bibr">174</xref>], with different isoforms varying in their reliability as predictive factors of the function of the drug. PIGF is another angiogenesis related molecule that may act as a biomarker for predicting the effect of anti-angiogenic drugs as its levels have been shown to be elevated upon usage of almost all anti-VEGF drugs [<xref rid="b175-ijms-14-15885" ref-type="bibr">175</xref>]. In the same way, soluble fragments of VEGF receptors may play such roles for predicting the effects of cancer anti-angiogenic agents. Examples include the soluble form of VEGFR-1 (sVEGFR1), where the high plasma concentrations of the molecule in blood circulation may predict a poor outcome for patients treated with agents such as bevacizumab and sunitinib [<xref rid="b176-ijms-14-15885" ref-type="bibr">176</xref>].</p><p>Finally, other molecules that may play a role in assisting prediction of the effect of anti-angiogenic drugs include collagen IV in the case of using a number of angiogenic agents [<xref rid="b177-ijms-14-15885" ref-type="bibr">177</xref>], and IL-8 in the case of using sunitinib [<xref rid="b178-ijms-14-15885" ref-type="bibr">178</xref>].</p><p>Antioangiogenic therapy, though, has not been so far able, though, to completely cure the disease due to the fact that resistance develops during this type of tumor treatment. Postulated mechanisms for overcoming anti-angiogenic therapy include the use of an alternative pathway when one is blocked [<xref rid="b179-ijms-14-15885" ref-type="bibr">179</xref>], hypoxia by accounting for the selection of more aggressive cells [<xref rid="b180-ijms-14-15885" ref-type="bibr">180</xref>], and also by assisting the survival of cancer stem-like cells [<xref rid="b181-ijms-14-15885" ref-type="bibr">181</xref>]. Other causes for resistance include the recruitment of vascular progenitors and modulators such as the pericyte progenitor cells [<xref rid="b182-ijms-14-15885" ref-type="bibr">182</xref>], and tumor cell dormancy that tumor cells enter upon the effect of different types of cell stress [<xref rid="b183-ijms-14-15885" ref-type="bibr">183</xref>].</p></sec><sec><title>8. Conclusions</title><p>Angiogenesis represents a hallmark process that leads to cancer dissemination. Pathways that are related to angiogenesis consist of biochemical processes that occur downstream of the binding of molecules such as VEGF, PDGF, FGF, and Ang with their cognate receptors. Through studying these pathways, molecular targets for developing therapeutic strategies have emerged. Anti-angiogenic molecules have been developed and many clinical trials are underway. It is of importance for angiogenesis research in ovarian cancer to continue, since this is a promising area for devising more effective treatments against gynecological cancer.</p></sec></body><back><notes><title>Conflict of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="b1-ijms-14-15885"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Naishadham</surname><given-names>D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer Statistics, 2012</article-title><source>CA Cancer J. Clin</source><year>2012</year><volume>62</volume><fpage>10</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22237781</pub-id></element-citation></ref><ref id="b2-ijms-14-15885"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yabroff</surname><given-names>K.R.</given-names></name><name><surname>Lamont</surname><given-names>E.B.</given-names></name><name><surname>Mariotto</surname><given-names>A.</given-names></name><name><surname>Warren</surname><given-names>J.L.</given-names></name><name><surname>Topor</surname><given-names>M.</given-names></name><name><surname>Meekins</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>M.L.</given-names></name></person-group><article-title>Cost of care for elderly cancer patients in the United States</article-title><source>J. Natl. Cancer Inst</source><year>2008</year><volume>100</volume><fpage>630</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">18445825</pub-id></element-citation></ref><ref id="b3-ijms-14-15885"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilks</surname><given-names>C.B.</given-names></name><name><surname>Prat</surname><given-names>J.</given-names></name></person-group><article-title>Ovarian carcinoma pathology and genetics: Recent advances</article-title><source>Hum. Pathol</source><year>2009</year><volume>40</volume><fpage>1213</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">19552940</pub-id></element-citation></ref><ref id="b4-ijms-14-15885"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name></person-group><article-title>The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory</article-title><source>Am. J. Surg. Pathol</source><year>2010</year><volume>34</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">20154587</pub-id></element-citation></ref><ref id="b5-ijms-14-15885"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>S.</given-names></name><name><surname>Coward</surname><given-names>J.I.</given-names></name><name><surname>Bast</surname><given-names>R.C.</given-names><suffix>Jr</suffix></name><name><surname>Berchuck</surname><given-names>A.</given-names></name><name><surname>Berek</surname><given-names>J.S.</given-names></name><name><surname>Brenton</surname><given-names>J.D.</given-names></name><name><surname>Coukos</surname><given-names>G.</given-names></name><name><surname>Crum</surname><given-names>C.C.</given-names></name><name><surname>Drapkin</surname><given-names>R.</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D.</given-names></name><etal></etal></person-group><article-title>Rethinking ovarian cancer: Recommendations for improving outcomes</article-title><source>Nat. Rev. Cancer</source><year>2011</year><volume>11</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">21941283</pub-id></element-citation></ref><ref id="b6-ijms-14-15885"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liliac</surname><given-names>L.</given-names></name><name><surname>Amalinei</surname><given-names>C.</given-names></name><name><surname>Balan</surname><given-names>R.</given-names></name><name><surname>Grigoras</surname><given-names>A.</given-names></name><name><surname>Caruntu</surname><given-names>I.D.</given-names></name></person-group><article-title>Ovarian cancer: Insights into genetics and pathogeny</article-title><source>Histol. Histopathol</source><year>2012</year><volume>27</volume><fpage>707</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">22473692</pub-id></element-citation></ref><ref id="b7-ijms-14-15885"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Rosen</surname><given-names>D.</given-names></name><name><surname>Naora</surname><given-names>H.</given-names></name></person-group><article-title>Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract</article-title><source>Nat. Med</source><year>2005</year><volume>11</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">15821746</pub-id></element-citation></ref><ref id="b8-ijms-14-15885"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauchlan</surname><given-names>S.C.</given-names></name></person-group><article-title>The secondary Müllerian system</article-title><source>Obstet. Gynecol. Surv</source><year>1972</year><volume>27</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">4614139</pub-id></element-citation></ref><ref id="b9-ijms-14-15885"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauchlan</surname><given-names>S.C.</given-names></name></person-group><article-title>The secondary müllerian system revisited</article-title><source>Int. J. Gynecol. Pathol</source><year>1994</year><volume>13</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">8112958</pub-id></element-citation></ref><ref id="b10-ijms-14-15885"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J.D.</given-names></name><name><surname>Garcia</surname><given-names>R.L.</given-names></name><name><surname>Goff</surname><given-names>B.A.</given-names></name><name><surname>Paley</surname><given-names>P.J.</given-names></name><name><surname>Swisher</surname><given-names>E.M.</given-names></name></person-group><article-title>Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy</article-title><source>Am. J. Obstet. Gynecol</source><year>2006</year><volume>194</volume><fpage>1702</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">16731090</pub-id></element-citation></ref><ref id="b11-ijms-14-15885"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piek</surname><given-names>J.M.</given-names></name><name><surname>van Diest</surname><given-names>P.J.</given-names></name><name><surname>Zweemer</surname><given-names>R.P.</given-names></name><name><surname>Jansen</surname><given-names>J.W.</given-names></name><name><surname>Poort-Keesom</surname><given-names>R.J.</given-names></name><name><surname>Menko</surname><given-names>F.H.</given-names></name><name><surname>Gille</surname><given-names>J.J.</given-names></name><name><surname>Jongsma</surname><given-names>A.P.</given-names></name><name><surname>Pals</surname><given-names>G.</given-names></name><name><surname>Kenemans</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer</article-title><source>J. Pathol</source><year>2001</year><volume>195</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">11745677</pub-id></element-citation></ref><ref id="b12-ijms-14-15885"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>A.</given-names></name><name><surname>Shaw</surname><given-names>P.</given-names></name><name><surname>Rosen</surname><given-names>B.</given-names></name><name><surname>Murphy</surname><given-names>J.</given-names></name><name><surname>Narod</surname><given-names>S.A.</given-names></name><name><surname>Colgan</surname><given-names>T.J.</given-names></name></person-group><article-title>Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers</article-title><source>Gynecol. Oncol</source><year>2006</year><volume>100</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">16137750</pub-id></element-citation></ref><ref id="b13-ijms-14-15885"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>M.J.</given-names></name><name><surname>Crum</surname><given-names>C.P.</given-names></name><name><surname>Medeiros</surname><given-names>F.</given-names></name><name><surname>Kindelberger</surname><given-names>D.W.</given-names></name><name><surname>Elvin</surname><given-names>J.A.</given-names></name><name><surname>Garber</surname><given-names>J.E.</given-names></name><name><surname>Feltmate</surname><given-names>C.M.</given-names></name><name><surname>Berkowitz</surname><given-names>R.S.</given-names></name><name><surname>Muto</surname><given-names>M.G.</given-names></name></person-group><article-title>Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction</article-title><source>J. Clin. Oncol</source><year>2007</year><volume>25</volume><fpage>3985</fpage><lpage>3990</lpage><pub-id pub-id-type="pmid">17761984</pub-id></element-citation></ref><ref id="b14-ijms-14-15885"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermsen</surname><given-names>B.B.</given-names></name><name><surname>van Diest</surname><given-names>P.J.</given-names></name><name><surname>Berkhof</surname><given-names>J.</given-names></name><name><surname>Menko</surname><given-names>F.H.</given-names></name><name><surname>Gille</surname><given-names>J.J.</given-names></name><name><surname>Piek</surname><given-names>J.M.</given-names></name><name><surname>Meijer</surname><given-names>S.</given-names></name><name><surname>Winters</surname><given-names>H.A.</given-names></name><name><surname>Kenemans</surname><given-names>P.</given-names></name><name><surname>Mensdorff-Pouilly</surname><given-names>S.V.</given-names></name><etal></etal></person-group><article-title>Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer</article-title><source>Int. J. Cancer</source><year>2006</year><volume>119</volume><fpage>1412</fpage><lpage>1418</lpage><pub-id pub-id-type="pmid">16615107</pub-id></element-citation></ref><ref id="b15-ijms-14-15885"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindelberger</surname><given-names>D.W.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Miron</surname><given-names>A.</given-names></name><name><surname>Hirsch</surname><given-names>M.S.</given-names></name><name><surname>Feltmate</surname><given-names>C.</given-names></name><name><surname>Medeiros</surname><given-names>F.</given-names></name><name><surname>Callahan</surname><given-names>M.J.</given-names></name><name><surname>Garner</surname><given-names>E.O.</given-names></name><name><surname>Gordon</surname><given-names>R.W.</given-names></name><name><surname>Birch</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship</article-title><source>Am. J. Surg. Pathol</source><year>2007</year><volume>31</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">17255760</pub-id></element-citation></ref><ref id="b16-ijms-14-15885"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>I.M.</given-names></name><name><surname>Kurman</surname><given-names>R.J.</given-names></name></person-group><article-title>Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis</article-title><source>Am. J. Pathol</source><year>2004</year><volume>164</volume><fpage>1511</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">15111296</pub-id></element-citation></ref><ref id="b17-ijms-14-15885"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Padilla</surname><given-names>I.</given-names></name><name><surname>Malpica</surname><given-names>A.L.</given-names></name><name><surname>Minig</surname><given-names>L.</given-names></name><name><surname>Chiva</surname><given-names>L.M.</given-names></name><name><surname>Gershenson</surname><given-names>D.M.</given-names></name><name><surname>Gonzalez-Martin</surname><given-names>A.</given-names></name></person-group><article-title>Ovarian low-grade serous carcinoma: A comprehensive update</article-title><source>Gynecol. Oncol</source><year>2012</year><volume>126</volume><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">22555104</pub-id></element-citation></ref><ref id="b18-ijms-14-15885"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>G.</given-names></name><name><surname>Oldt</surname><given-names>R.</given-names><suffix>III</suffix></name><name><surname>Cohen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>B.G.</given-names></name><name><surname>Sidransky</surname><given-names>D.</given-names></name><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name></person-group><article-title>Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma</article-title><source>J. Natl. Cancer Inst.</source><year>2003</year><volume>95</volume><fpage>484</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">12644542</pub-id></element-citation></ref><ref id="b19-ijms-14-15885"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.E.</given-names></name><name><surname>Narasanna</surname><given-names>A.</given-names></name><name><surname>Perez-Torres</surname><given-names>M.</given-names></name><name><surname>Xiang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>F.Y.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Carpenter</surname><given-names>G.</given-names></name><name><surname>Gazdar</surname><given-names>A.F.</given-names></name><name><surname>Muthuswamy</surname><given-names>S.K.</given-names></name><name><surname>Arteaga</surname><given-names>C.L.</given-names></name></person-group><article-title>HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16843263</pub-id></element-citation></ref><ref id="b20-ijms-14-15885"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>I.G.</given-names></name><name><surname>Russell</surname><given-names>S.E.</given-names></name><name><surname>Choong</surname><given-names>D.Y.</given-names></name><name><surname>Montgomery</surname><given-names>K.G.</given-names></name><name><surname>Ciavarella</surname><given-names>M.L.</given-names></name><name><surname>Hooi</surname><given-names>C.S.</given-names></name><name><surname>Cristiano</surname><given-names>B.E.</given-names></name><name><surname>Pearson</surname><given-names>R.B.</given-names></name><name><surname>Phillips</surname><given-names>W.A.</given-names></name></person-group><article-title>Mutation of the PIK3CA gene in ovarian and breast cancer</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7678</fpage><lpage>7681</lpage><pub-id pub-id-type="pmid">15520168</pub-id></element-citation></ref><ref id="b21-ijms-14-15885"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>T.L.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name><name><surname>Mao</surname><given-names>T.L.</given-names></name><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Roden</surname><given-names>R.</given-names></name><name><surname>Glas</surname><given-names>R.</given-names></name><name><surname>Slamon</surname><given-names>D.</given-names></name><name><surname>Diaz</surname><given-names>L.A.</given-names><suffix>Jr</suffix></name><name><surname>Vogelstein</surname><given-names>B.</given-names></name><name><surname>Papadopoulos</surname><given-names>N.</given-names></name><etal></etal></person-group><article-title>Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">20826764</pub-id></element-citation></ref><ref id="b22-ijms-14-15885"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>A.A.</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D.</given-names></name><name><surname>Temple</surname><given-names>J.</given-names></name><name><surname>Lynch</surname><given-names>A.G.</given-names></name><name><surname>Riad</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Stewart</surname><given-names>C.</given-names></name><name><surname>Fereday</surname><given-names>S.</given-names></name><name><surname>Caldas</surname><given-names>C.</given-names></name><name><surname>Defazio</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary</article-title><source>J. Pathol</source><year>2010</year><volume>221</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">20229506</pub-id></element-citation></ref><ref id="b23-ijms-14-15885"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efeyan</surname><given-names>A.</given-names></name><name><surname>Serrano</surname><given-names>M.</given-names></name></person-group><article-title>p53: Guardian of the genome and policeman of the oncogenes</article-title><source>Cell Cycle</source><year>2007</year><volume>6</volume><fpage>1006</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">17457049</pub-id></element-citation></ref><ref id="b24-ijms-14-15885"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>D.P.</given-names></name></person-group><article-title>Cancer. p53, guardian of the genome</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">1614522</pub-id></element-citation></ref><ref id="b25-ijms-14-15885"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>K.T.</given-names></name><name><surname>Guan</surname><given-names>B.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Mao</surname><given-names>T.L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Jinawath</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name><name><surname>Wang</surname><given-names>T.L.</given-names></name></person-group><article-title>Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>4036</fpage><lpage>4042</lpage><pub-id pub-id-type="pmid">19383911</pub-id></element-citation></ref><ref id="b26-ijms-14-15885"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Nakayama</surname><given-names>N.</given-names></name><name><surname>Jinawath</surname><given-names>N.</given-names></name><name><surname>Salani</surname><given-names>R.</given-names></name><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Shih</surname><given-names>I.M.</given-names></name><name><surname>Wang</surname><given-names>T.L.</given-names></name></person-group><article-title>Amplicon profiles in ovarian serous carcinomas</article-title><source>Int. J. Cancer</source><year>2007</year><volume>120</volume><fpage>2613</fpage><lpage>2617</lpage><pub-id pub-id-type="pmid">17351921</pub-id></element-citation></ref><ref id="b27-ijms-14-15885"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perren</surname><given-names>T.J.</given-names></name><name><surname>Swart</surname><given-names>A.M.</given-names></name><name><surname>Pfisterer</surname><given-names>J.</given-names></name><name><surname>Ledermann</surname><given-names>J.A.</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name><name><surname>Kristensen</surname><given-names>G.</given-names></name><name><surname>Carey</surname><given-names>M.S.</given-names></name><name><surname>Beale</surname><given-names>P.</given-names></name><name><surname>Cervantes</surname><given-names>A.</given-names></name><name><surname>Kurzeder</surname><given-names>C.</given-names></name><etal></etal></person-group><article-title>ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer</article-title><source>N. Engl. J. Med</source><year>2011</year><volume>365</volume><fpage>2484</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">22204725</pub-id></element-citation></ref><ref id="b28-ijms-14-15885"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itamochi</surname><given-names>H.</given-names></name><name><surname>Kigawa</surname><given-names>J.</given-names></name></person-group><article-title>Clinical trials and future potential of targeted therapy for ovarian cancer</article-title><source>Int. J. Clin. Oncol</source><year>2012</year><volume>17</volume><fpage>430</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">22926640</pub-id></element-citation></ref><ref id="b29-ijms-14-15885"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>C.</given-names></name><name><surname>Blank</surname><given-names>S.V.</given-names></name><name><surname>Goff</surname><given-names>B.A.</given-names></name><name><surname>Judson</surname><given-names>P.L.</given-names></name><name><surname>Teneriello</surname><given-names>M.G.</given-names></name><name><surname>Husain</surname><given-names>A.</given-names></name><name><surname>Sovak</surname><given-names>M.A.</given-names></name><name><surname>Yi</surname><given-names>J.</given-names></name><name><surname>Nycum</surname><given-names>L.R.</given-names></name></person-group><article-title>OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer</article-title><source>J. Clin. Oncol</source><year>2012</year><volume>30</volume><fpage>2039</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">22529265</pub-id></element-citation></ref><ref id="b30-ijms-14-15885"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>A.</given-names></name></person-group><article-title>The role of angiogenesis in cancer</article-title><source>Comp. Clin. Path</source><year>2005</year><volume>13</volume><fpage>95</fpage><lpage>99</lpage></element-citation></ref><ref id="b31-ijms-14-15885"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Tumor angiogenesis: Therapeutic implications</article-title><source>N. Engl. J. Med</source><year>1971</year><volume>285</volume><fpage>1182</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">4938153</pub-id></element-citation></ref><ref id="b32-ijms-14-15885"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>N.</given-names></name><name><surname>Folkman</surname><given-names>J.</given-names></name><name><surname>Pozza</surname><given-names>F.</given-names></name><name><surname>Bevilacqua</surname><given-names>P.</given-names></name><name><surname>Allred</surname><given-names>E.N.</given-names></name><name><surname>Moore</surname><given-names>D.H.</given-names></name><name><surname>Meli</surname><given-names>S.</given-names></name><name><surname>Gasparini</surname><given-names>G.</given-names></name></person-group><article-title>Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma</article-title><source>J. Natl. Cancer Inst</source><year>1992</year><volume>84</volume><fpage>1875</fpage><lpage>1887</lpage><pub-id pub-id-type="pmid">1281237</pub-id></element-citation></ref><ref id="b33-ijms-14-15885"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-McCune</surname><given-names>K.K.</given-names></name><name><surname>Weidner</surname><given-names>N.</given-names></name></person-group><article-title>Demonstration and characterization of the angiogenic properties of cervical dysplasia</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>800</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">7508337</pub-id></element-citation></ref><ref id="b34-ijms-14-15885"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>J.C.</given-names></name><name><surname>Toyoda</surname><given-names>M.</given-names></name><name><surname>Yamaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Involvement of VEGF and its receptors in ascites tumor formation</article-title><source>Cancer Chemother. Pharmacol</source><year>1999</year><volume>43</volume><fpage>72</fpage><lpage>77</lpage></element-citation></ref><ref id="b35-ijms-14-15885"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>D.M.</given-names></name><name><surname>Eliakim</surname><given-names>R.</given-names></name><name><surname>Abulafia</surname><given-names>O.</given-names></name></person-group><article-title>The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female</article-title><source>Gynecol. Obstet. Invest</source><year>2000</year><volume>50</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">11093042</pub-id></element-citation></ref><ref id="b36-ijms-14-15885"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergers</surname><given-names>E.</given-names></name><name><surname>Benjamin</surname><given-names>L.E.</given-names></name></person-group><article-title>Tumorigenesis and the angiogenic switch</article-title><source>Nat. Rev. Cancer</source><year>2003</year><volume>3</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">12778130</pub-id></element-citation></ref><ref id="b37-ijms-14-15885"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergers</surname><given-names>G.</given-names></name><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Coussens</surname><given-names>L.M.</given-names></name></person-group><article-title>Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis</article-title><source>Int. J. Dev. Biol</source><year>1998</year><volume>42</volume><fpage>995</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">9853830</pub-id></element-citation></ref><ref id="b38-ijms-14-15885"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</article-title><source>Cell</source><year>1996</year><volume>86</volume><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">8756718</pub-id></element-citation></ref><ref id="b39-ijms-14-15885"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>VEGF and the quest for tumour angiogenesis factors</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">12360282</pub-id></element-citation></ref><ref id="b40-ijms-14-15885"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicklin</surname><given-names>D.J.</given-names></name><name><surname>Ellis</surname><given-names>L.M.</given-names></name></person-group><article-title>Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis</article-title><source>J. Clin. Oncol</source><year>2005</year><volume>23</volume><fpage>1011</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">15585754</pub-id></element-citation></ref><ref id="b41-ijms-14-15885"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>H.F.</given-names></name></person-group><article-title>Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy</article-title><source>J. Clin. Oncol</source><year>2002</year><volume>20</volume><fpage>4368</fpage><lpage>4380</lpage><pub-id pub-id-type="pmid">12409337</pub-id></element-citation></ref><ref id="b42-ijms-14-15885"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>G.</given-names></name><name><surname>Brooks</surname><given-names>P.C.</given-names></name><name><surname>Biganzoli</surname><given-names>E.</given-names></name><name><surname>Vermeulen</surname><given-names>P.B.</given-names></name><name><surname>Bonoldi</surname><given-names>E.</given-names></name><name><surname>Dirix</surname><given-names>L.Y.</given-names></name><name><surname>Ranieri</surname><given-names>G.</given-names></name><name><surname>Miceli</surname><given-names>R.</given-names></name><name><surname>Cheresh</surname><given-names>D.A.</given-names></name></person-group><article-title>Vascular integrin alpha(v)beta: A new prognostic indicator in breast cancer</article-title><source>Clin. Cancer Res</source><year>1998</year><volume>4</volume><fpage>2625</fpage><lpage>2634</lpage><pub-id pub-id-type="pmid">9829725</pub-id></element-citation></ref><ref id="b43-ijms-14-15885"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Role of angiogenesis in tumor growth and metastasis</article-title><source>Semin. Oncol</source><year>2002</year><volume>29</volume><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12516034</pub-id></element-citation></ref><ref id="b44-ijms-14-15885"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>G.</given-names></name><name><surname>Coviello</surname><given-names>M.</given-names></name><name><surname>Chiriatti</surname><given-names>A.</given-names></name><name><surname>Stea</surname><given-names>B.</given-names></name><name><surname>Montemuro</surname><given-names>S.</given-names></name><name><surname>Quaranta</surname><given-names>M.</given-names></name><name><surname>Dittami</surname><given-names>R.</given-names></name><name><surname>Paradiso</surname><given-names>A.</given-names></name></person-group><article-title>Vascular endothelial growth factor concentrations in gastrointestinal cancer patients and healthy controls</article-title><source>Oncol. Rep</source><year>2004</year><volume>11</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">14719080</pub-id></element-citation></ref><ref id="b45-ijms-14-15885"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>G.</given-names></name><name><surname>Coviello</surname><given-names>M.</given-names></name><name><surname>Patruno</surname><given-names>R.</given-names></name><name><surname>Valerio</surname><given-names>P.</given-names></name><name><surname>Martino</surname><given-names>D.</given-names></name><name><surname>Milella</surname><given-names>P.</given-names></name><name><surname>Catalano</surname><given-names>V.</given-names></name><name><surname>Scotto</surname><given-names>F.</given-names></name><name><surname>De Ceglia</surname><given-names>A.</given-names></name><name><surname>Quaranta</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-ARP) of healthy controls and colorectal cancer patients</article-title><source>Oncol. Rep</source><year>2004</year><volume>12</volume><fpage>817</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">15375505</pub-id></element-citation></ref><ref id="b46-ijms-14-15885"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>D.G.</given-names></name><name><surname>Perry</surname><given-names>S.L.</given-names></name><name><surname>Morrison</surname><given-names>E.</given-names></name><name><surname>Farmery</surname><given-names>S.M.</given-names></name><name><surname>Guillou</surname><given-names>P.J.</given-names></name></person-group><article-title>Activated mesothelial cells produce heparin-binding growth factors: Implications for tumour metastases</article-title><source>Br. J. Cancer</source><year>2000</year><volume>82</volume><fpage>1233</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">10735511</pub-id></element-citation></ref><ref id="b47-ijms-14-15885"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sako</surname><given-names>A.</given-names></name><name><surname>Kitayama</surname><given-names>J.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Kaisaki</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Fukatsu</surname><given-names>K.</given-names></name><name><surname>Fujii</surname><given-names>S.</given-names></name><name><surname>Nagawa</surname><given-names>H.</given-names></name></person-group><article-title>Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis</article-title><source>J. Surg. Res</source><year>2003</year><volume>115</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">14572781</pub-id></element-citation></ref><ref id="b48-ijms-14-15885"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadlmann</surname><given-names>S.</given-names></name><name><surname>Amberger</surname><given-names>A.</given-names></name><name><surname>Pollheimer</surname><given-names>J.</given-names></name><name><surname>Gastl</surname><given-names>G.</given-names></name><name><surname>Offner</surname><given-names>F.A.</given-names></name><name><surname>Margreiter</surname><given-names>R.</given-names></name><name><surname>Zeimet</surname><given-names>A.G.</given-names></name></person-group><article-title>Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions</article-title><source>Gynecol. Oncol</source><year>2005</year><volume>97</volume><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">15943987</pub-id></element-citation></ref><ref id="b49-ijms-14-15885"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>S.A.</given-names></name><name><surname>Rybalko</surname><given-names>V.Y.</given-names></name><name><surname>Bigelow</surname><given-names>C.E.</given-names></name><name><surname>Lugade</surname><given-names>A.A.</given-names></name><name><surname>Foster</surname><given-names>T.H.</given-names></name><name><surname>Frelinger</surname><given-names>J.G.</given-names></name><name><surname>Lord</surname><given-names>E.M.</given-names></name></person-group><article-title>Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth</article-title><source>Am. J. Pathol</source><year>2006</year><volume>169</volume><fpage>1739</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">17071597</pub-id></element-citation></ref><ref id="b50-ijms-14-15885"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naora</surname><given-names>H.</given-names></name><name><surname>Montell</surname><given-names>D.J.</given-names></name></person-group><article-title>Ovarian cancer metastasis: Integrating insights from disparate model organisms</article-title><source>Nat. Rev. Cancer</source><year>2005</year><volume>5</volume><fpage>355</fpage><lpage> 366</lpage><pub-id pub-id-type="pmid">15864277</pub-id></element-citation></ref><ref id="b51-ijms-14-15885"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>J.A.</given-names></name><name><surname>Masse</surname><given-names>E.M.</given-names></name><name><surname>Herzberg</surname><given-names>K.T.</given-names></name><name><surname>Meyers</surname><given-names>M.S.</given-names></name><name><surname>Yeo</surname><given-names>K.T.</given-names></name><name><surname>Yeo</surname><given-names>T.K.</given-names></name><name><surname>Sioussat</surname><given-names>T.M.</given-names></name><name><surname>Dvorak</surname><given-names>H.F.</given-names></name></person-group><article-title>Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">7812969</pub-id></element-citation></ref><ref id="b52-ijms-14-15885"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.C.</given-names></name><name><surname>Yamaguchi</surname><given-names>S.</given-names></name><name><surname>Shinkai</surname><given-names>A.</given-names></name><name><surname>Shitara</surname><given-names>K.</given-names></name><name><surname>Shibuya</surname><given-names>M.</given-names></name></person-group><article-title>Significant expression of vascular endothelial growth Factor/vascular permeability factor in mouse ascites tumors</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>2652</fpage><lpage>2660</lpage><pub-id pub-id-type="pmid">9635593</pub-id></element-citation></ref><ref id="b53-ijms-14-15885"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Brekken</surname><given-names>R.A.</given-names></name><name><surname>Hyder</surname><given-names>S.M.</given-names></name></person-group><article-title>Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones</article-title><source>Endocr. Relat. Cancer</source><year>2006</year><volume>13</volume><fpage>905</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">16954439</pub-id></element-citation></ref><ref id="b54-ijms-14-15885"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masood</surname><given-names>R.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>T.</given-names></name><name><surname>Smith</surname><given-names>D.L.</given-names></name><name><surname>Hinton</surname><given-names>D.R.</given-names></name><name><surname>Gill</surname><given-names>P.S.</given-names></name></person-group><article-title>Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">11535528</pub-id></element-citation></ref><ref id="b55-ijms-14-15885"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frumovitz</surname><given-names>M.</given-names></name><name><surname>Sood</surname><given-names>A.K.</given-names></name></person-group><article-title>Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies</article-title><source>Gynecol. Oncol</source><year>2007</year><volume>104</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">17306693</pub-id></element-citation></ref><ref id="b56-ijms-14-15885"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spannuth</surname><given-names>W.A.</given-names></name><name><surname>Sood</surname><given-names>A.K.</given-names></name><name><surname>Coleman</surname><given-names>R.L.</given-names></name></person-group><article-title>Angiogenesis as a strategic target for ovarian cancer therapy</article-title><source>Nat. Clin. Pract</source><year>2008</year><volume>4</volume><fpage>194</fpage><lpage>204</lpage></element-citation></ref><ref id="b57-ijms-14-15885"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>E.S.</given-names></name><name><surname>Wakabayashi</surname><given-names>M.</given-names></name><name><surname>Leong</surname><given-names>L.</given-names></name></person-group><article-title>Angiogenesis inhibitors in the treatment of epithelial ovarian cancer</article-title><source>Curr. Treat. Options Oncol</source><year>2013</year><volume>14</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23288484</pub-id></element-citation></ref><ref id="b58-ijms-14-15885"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>W.C.</given-names></name><name><surname>Nio-Kobayashi</surname><given-names>J.</given-names></name></person-group><article-title>Targeting angiogenesis in the pathological ovary</article-title><source>Reprod. Fertil. Dev</source><year>2013</year><volume>25</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">22951108</pub-id></element-citation></ref><ref id="b59-ijms-14-15885"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>M.</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L.</given-names></name></person-group><article-title>Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis</article-title><source>Exp. Cell Res</source><year>2006</year><volume>312</volume><fpage>549</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">16336962</pub-id></element-citation></ref><ref id="b60-ijms-14-15885"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>D.W.</given-names></name><name><surname>Cachianes</surname><given-names>G.</given-names></name><name><surname>Kuang</surname><given-names>W.J.</given-names></name><name><surname>Goeddel</surname><given-names>D.V.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>Vascular endothelial growth factor is a secreted angiogenic mitogen</article-title><source>Science</source><year>1989</year><volume>246</volume><fpage>1306</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">2479986</pub-id></element-citation></ref><ref id="b61-ijms-14-15885"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Henzel</surname><given-names>W.J.</given-names></name></person-group><article-title>Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells</article-title><source>Biochem. Biophys. Res. Commun</source><year>1989</year><volume>161</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">2735925</pub-id></element-citation></ref><ref id="b62-ijms-14-15885"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roskoski</surname><given-names>R.</given-names><suffix>Jr</suffix></name></person-group><article-title>Vascular endothelial growth factor (VEGF) signaling in tumor progression</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2007</year><volume>62</volume><fpage>179</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">17324579</pub-id></element-citation></ref><ref id="b63-ijms-14-15885"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoff</surname><given-names>P.M.</given-names></name><name><surname>Machado</surname><given-names>K.K.</given-names></name></person-group><article-title>Role of angiogenesis in the pathogenesis of cancer</article-title><source>Cancer Treat Rev</source><year>2012</year><volume>38</volume><fpage>825</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">22677191</pub-id></element-citation></ref><ref id="b64-ijms-14-15885"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>Vascular endothelial growth factor</article-title><source>Eur. J. Cancer</source><year>1996</year><volume>32A</volume><fpage>2413</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">9059329</pub-id></element-citation></ref><ref id="b65-ijms-14-15885"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taggarshe</surname><given-names>D.</given-names></name><name><surname>Lobocki</surname><given-names>C.</given-names></name><name><surname>Silberberg</surname><given-names>B.</given-names></name><name><surname>McKendrick</surname><given-names>A.</given-names></name><name><surname>Mittal</surname><given-names>V.K.</given-names></name></person-group><article-title>Clinicopathological significance of the expression of estrogen receptor-beta and vascular endothelial growth factor-A in colorectal cancer</article-title><source>Am. Surg</source><year>2012</year><volume>78</volume><fpage>1376</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">23265127</pub-id></element-citation></ref><ref id="b66-ijms-14-15885"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soffietti</surname><given-names>R.</given-names></name><name><surname>Trevisan</surname><given-names>E.</given-names></name><name><surname>Bertero</surname><given-names>L.</given-names></name><name><surname>Bosa</surname><given-names>C.</given-names></name><name><surname>Ruda</surname><given-names>R.</given-names></name></person-group><article-title>Anti-angiogenic approaches to malignant gliomas</article-title><source>Curr. Cancer Drug Targets</source><year>2012</year><volume>12</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">22229250</pub-id></element-citation></ref><ref id="b67-ijms-14-15885"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>C.</given-names></name><name><surname>Escobedo</surname><given-names>J.A.</given-names></name><name><surname>Ueno</surname><given-names>H.</given-names></name><name><surname>Houck</surname><given-names>K.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Williams</surname><given-names>L.T.</given-names></name></person-group><article-title>The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor</article-title><source>Science</source><year>1992</year><volume>255</volume><fpage>989</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">1312256</pub-id></element-citation></ref><ref id="b68-ijms-14-15885"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakeman</surname><given-names>L.B.</given-names></name><name><surname>Winer</surname><given-names>J.</given-names></name><name><surname>Bennett</surname><given-names>G.L.</given-names></name><name><surname>Altar</surname><given-names>C.A.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues</article-title><source>J. Clin. Invest</source><year>1992</year><volume>89</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">1729274</pub-id></element-citation></ref><ref id="b69-ijms-14-15885"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>L.M.</given-names></name><name><surname>Hicklin</surname><given-names>D.J.</given-names></name></person-group><article-title>VEGF-targeted therapy: Mechanisms of anti-tumour activity</article-title><source>Nat. Rev. Cancer</source><year>2008</year><volume>8</volume><fpage>579</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">18596824</pub-id></element-citation></ref><ref id="b70-ijms-14-15885"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joukov</surname><given-names>V.</given-names></name><name><surname>Pajusola</surname><given-names>K.</given-names></name><name><surname>Kaipainen</surname><given-names>A.</given-names></name><name><surname>Chilov</surname><given-names>D.</given-names></name><name><surname>Lahtinen</surname><given-names>I.</given-names></name><name><surname>Kukk</surname><given-names>E.</given-names></name><name><surname>Saksela</surname><given-names>O.</given-names></name><name><surname>Kalkkinen</surname><given-names>N.</given-names></name><name><surname>Alitalo</surname><given-names>K.</given-names></name></person-group><article-title>A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases</article-title><source>EMBO J</source><year>1996</year><volume>15</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">8617204</pub-id></element-citation></ref><ref id="b71-ijms-14-15885"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Rawi</surname><given-names>M.A.</given-names></name><name><surname>Jiang</surname><given-names>W.G.</given-names></name></person-group><article-title>Lymphangiogenesis and cancer metastasis</article-title><source>Front. Biosci</source><year>2011</year><volume>16</volume><fpage>723</fpage><lpage>739</lpage></element-citation></ref><ref id="b72-ijms-14-15885"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiliotaki</surname><given-names>M.</given-names></name><name><surname>Markomanolaki</surname><given-names>H.</given-names></name><name><surname>Mela</surname><given-names>M.</given-names></name><name><surname>Mavroudis</surname><given-names>D.</given-names></name><name><surname>Georgoulias</surname><given-names>V.</given-names></name><name><surname>Agelaki</surname><given-names>S.</given-names></name></person-group><article-title>Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect</article-title><source>Lung Cancer</source><year>2011</year><volume>73</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">21190751</pub-id></element-citation></ref><ref id="b73-ijms-14-15885"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname><given-names>R.</given-names></name><name><surname>Benoy</surname><given-names>I.</given-names></name><name><surname>Weytjens</surname><given-names>R.</given-names></name><name><surname>Van Bockstaele</surname><given-names>D.</given-names></name><name><surname>Van Marck</surname><given-names>E.</given-names></name><name><surname>Huget</surname><given-names>P.</given-names></name><name><surname>Hoylaerts</surname><given-names>M.</given-names></name><name><surname>Vermeulen</surname><given-names>P.</given-names></name><name><surname>Dirix</surname><given-names>L.Y.</given-names></name></person-group><article-title>Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer</article-title><source>Br. J. Cancer</source><year>2002</year><volume>87</volume><fpage>1437</fpage><lpage>1444</lpage><pub-id pub-id-type="pmid">12454774</pub-id></element-citation></ref><ref id="b74-ijms-14-15885"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>F.C.</given-names></name><name><surname>Benehacene</surname><given-names>A.</given-names></name><name><surname>Scheele</surname><given-names>J.S.</given-names></name><name><surname>Kamps</surname><given-names>M.</given-names></name></person-group><article-title>VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation—Evidence for divergent stabilization pathways</article-title><source>Growth Factors</source><year>1997</year><volume>14</volume><fpage>199</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">9255609</pub-id></element-citation></ref><ref id="b75-ijms-14-15885"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>R.A.</given-names></name></person-group><article-title>Overview of anti-angiogenic agents in development for ovarian cancer</article-title><source>Gynecol. Oncol</source><year>2011</year><volume>121</volume><fpage>230</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">21215996</pub-id></element-citation></ref><ref id="b76-ijms-14-15885"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millauer</surname><given-names>B.</given-names></name><name><surname>Wizigmann-Voos</surname><given-names>S.</given-names></name><name><surname>Schnurch</surname><given-names>H.</given-names></name><name><surname>Martinez</surname><given-names>R.</given-names></name><name><surname>Moller</surname><given-names>N.P.</given-names></name><name><surname>Risau</surname><given-names>W.</given-names></name><name><surname>Ullrich</surname><given-names>A.</given-names></name></person-group><article-title>High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis</article-title><source>Cell</source><year>1993</year><volume>72</volume><fpage>835</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">7681362</pub-id></element-citation></ref><ref id="b77-ijms-14-15885"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youssoufian</surname><given-names>H.</given-names></name><name><surname>Hicklin</surname><given-names>D.J.</given-names></name><name><surname>Rowinsky</surname><given-names>E.K.</given-names></name></person-group><article-title>Review: Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy</article-title><source>Clin. Cancer Res</source><year>2007</year><volume>13</volume><fpage>5544</fpage><lpage>5548</lpage></element-citation></ref><ref id="b78-ijms-14-15885"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P.</given-names></name><name><surname>Moons</surname><given-names>L.</given-names></name><name><surname>Luttun</surname><given-names>A.</given-names></name><name><surname>Vincenti</surname><given-names>V.</given-names></name><name><surname>Compernolle</surname><given-names>V.</given-names></name><name><surname>De Mol</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Bono</surname><given-names>F.</given-names></name><name><surname>Devy</surname><given-names>L.</given-names></name><name><surname>Beck</surname><given-names>H.</given-names></name><etal></etal></person-group><article-title>Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</article-title><source>Nat. Med</source><year>2001</year><volume>7</volume><fpage>575</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">11329059</pub-id></element-citation></ref><ref id="b79-ijms-14-15885"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Toy</surname><given-names>K.</given-names></name><name><surname>Ingle</surname><given-names>G.</given-names></name><name><surname>Ingle</surname><given-names>G.</given-names></name><name><surname>Zlot</surname><given-names>C.</given-names></name><name><surname>Williams</surname><given-names>P.M.</given-names></name><name><surname>Fuh</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>de Vos</surname><given-names>A.</given-names></name><name><surname>Gerritsen</surname><given-names>M.E.</given-names></name></person-group><article-title>Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: Relative roles of KDR and Flt-1 receptors</article-title><source>Arterioscler. Thromb. Vasc. Biol</source><year>2002</year><volume>22</volume><fpage>1797</fpage><lpage>1803</lpage><pub-id pub-id-type="pmid">12426207</pub-id></element-citation></ref><ref id="b80-ijms-14-15885"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukk</surname><given-names>E.</given-names></name><name><surname>Lymboussaki</surname><given-names>A.</given-names></name><name><surname>Taira</surname><given-names>S.</given-names></name><name><surname>Kaipainen</surname><given-names>A.</given-names></name><name><surname>Jeltsch</surname><given-names>M.</given-names></name><name><surname>Joukov</surname><given-names>V.</given-names></name><name><surname>Alitalo</surname><given-names>K.</given-names></name></person-group><article-title>VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development</article-title><source>Development</source><year>1996</year><volume>122</volume><fpage>3829</fpage><lpage>3837</lpage><pub-id pub-id-type="pmid">9012504</pub-id></element-citation></ref><ref id="b81-ijms-14-15885"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Shibuya</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name></person-group><article-title>VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis</article-title><source>Cell Res</source><year>2010</year><volume>20</volume><fpage>1319</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">20697430</pub-id></element-citation></ref><ref id="b82-ijms-14-15885"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Kaye</surname><given-names>S.</given-names></name></person-group><article-title>The role of targeted therapy in ovarian cancer</article-title><source>Eur. J. Cancer</source><year>2011</year><volume>47</volume><fpage>116</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">20691583</pub-id></element-citation></ref><ref id="b83-ijms-14-15885"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S.</given-names></name><name><surname>Itamochi</surname><given-names>H.</given-names></name></person-group><article-title>Bevacizumab and ovarian cancer</article-title><source>Curr. Opin. Obstet. Gynecol</source><year>2012</year><volume>24</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22123222</pub-id></element-citation></ref><ref id="b84-ijms-14-15885"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamberger</surname><given-names>E.S.</given-names></name><name><surname>Perrett</surname><given-names>C.W.</given-names></name></person-group><article-title>Angiogenesis in epithelian ovarian cancer</article-title><source>Mol. Pathol</source><year>2002</year><volume>55</volume><fpage>348</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">12456770</pub-id></element-citation></ref><ref id="b85-ijms-14-15885"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numnum</surname><given-names>T.M.</given-names></name><name><surname>Rocconi</surname><given-names>R.P.</given-names></name><name><surname>Whitworth</surname><given-names>J.</given-names></name><name><surname>Barnes</surname><given-names>M.N.</given-names></name></person-group><article-title>The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma</article-title><source>Gynecol. Oncol</source><year>2006</year><volume>102</volume><fpage>425</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">16797681</pub-id></element-citation></ref><ref id="b86-ijms-14-15885"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>D.</given-names></name><name><surname>Secord</surname><given-names>A.A.</given-names></name></person-group><article-title>Antiangiogenic therapies in epithelial ovarian cancer</article-title><source>Cancer Control</source><year>2011</year><volume>18</volume><fpage>31</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21273978</pub-id></element-citation></ref><ref id="b87-ijms-14-15885"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>R.A.</given-names></name><name><surname>Sill</surname><given-names>M.W.</given-names></name><name><surname>Monk</surname><given-names>B.J.</given-names></name><name><surname>Greer</surname><given-names>B.E.</given-names></name><name><surname>Sorosky</surname><given-names>J.I.</given-names></name></person-group><article-title>Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study</article-title><source>J. Clin. Oncol</source><year>2007</year><volume>25</volume><fpage>5165</fpage><lpage>5171</lpage><pub-id pub-id-type="pmid">18024863</pub-id></element-citation></ref><ref id="b88-ijms-14-15885"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Katsaros</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Park</surname><given-names>J.W.</given-names></name><name><surname>Fracchioli</surname><given-names>S.</given-names></name><name><surname>Vezzani</surname><given-names>C.</given-names></name><name><surname>de la Longrais</surname><given-names>I.A.R.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Rubin</surname><given-names>S.C.</given-names></name><etal></etal></person-group><article-title>The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>4225</fpage><lpage>4231</lpage><pub-id pub-id-type="pmid">12874030</pub-id></element-citation></ref><ref id="b89-ijms-14-15885"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Pathak</surname><given-names>P.S.</given-names></name><name><surname>Fukumura</surname><given-names>D.</given-names></name></person-group><article-title>Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells</article-title><source>Clin. Cancer Res</source><year>2004</year><volume>10</volume><fpage>701</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">14760093</pub-id></element-citation></ref><ref id="b90-ijms-14-15885"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>D.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name></person-group><article-title>VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma</article-title><source>Gynecol. Oncol</source><year>2004</year><volume>94</volume><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">15350351</pub-id></element-citation></ref><ref id="b91-ijms-14-15885"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bermudez</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Saunders</surname><given-names>B.O.</given-names></name><name><surname>Cheng</surname><given-names>J.Q.</given-names></name><name><surname>Nicosia</surname><given-names>S.V.</given-names></name><name><surname>Kruk</surname><given-names>P.A.</given-names></name></person-group><article-title>VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent</article-title><source>Gynecol. Oncol</source><year>2007</year><volume>106</volume><fpage>526</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">17559911</pub-id></element-citation></ref><ref id="b92-ijms-14-15885"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Barnes</surname><given-names>L.</given-names></name><name><surname>Cheresh</surname><given-names>D.</given-names></name></person-group><article-title>Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis</article-title><source>J. Cell Biol</source><year>2004</year><volume>167</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">15504909</pub-id></element-citation></ref><ref id="b93-ijms-14-15885"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>D.</given-names></name><name><surname>Nagy</surname><given-names>J.A.</given-names></name><name><surname>Manseau</surname><given-names>E.J.</given-names></name><name><surname>Dvorak</surname><given-names>H.F.</given-names></name></person-group><article-title>Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>1278</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">9515816</pub-id></element-citation></ref><ref id="b94-ijms-14-15885"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oikawa</surname><given-names>T.</given-names></name><name><surname>Onozawa</surname><given-names>C.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name><name><surname>Morita</surname><given-names>I.</given-names></name><name><surname>Murota</surname><given-names>S.</given-names></name></person-group><article-title>Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis <italic>in vivo</italic></article-title><source>Biol. Pharm. Bull</source><year>1994</year><volume>17</volume><fpage>1686</fpage><lpage>1688</lpage><pub-id pub-id-type="pmid">7537574</pub-id></element-citation></ref><ref id="b95-ijms-14-15885"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Thaker</surname><given-names>P.H.</given-names></name><name><surname>Lin</surname><given-names>Y.G.</given-names></name><name><surname>Spannuth</surname><given-names>W.</given-names></name><name><surname>Landen</surname><given-names>C.N.</given-names></name><name><surname>Merritt</surname><given-names>W.M.</given-names></name><name><surname>Jennings</surname><given-names>N.B.</given-names></name><name><surname>Langley</surname><given-names>R.R.</given-names></name><name><surname>Gershenson</surname><given-names>D.M.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><etal></etal></person-group><article-title>Impact of vessel maturation on antiangiogenic therapy in ovarian cancer</article-title><source>Am. J. Obstet. Gynecol</source><year>2008</year><volume>198</volume><pub-id pub-id-type="doi">10.1016/j.ajog.2007.12.028</pub-id></element-citation></ref><ref id="b96-ijms-14-15885"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erber</surname><given-names>R.</given-names></name><name><surname>Thurner</surname><given-names>A.</given-names></name><name><surname>Katsen</surname><given-names>A.D.</given-names></name><name><surname>Groth</surname><given-names>G.</given-names></name><name><surname>Kerger</surname><given-names>H.</given-names></name><name><surname>Hammes</surname><given-names>H.P.</given-names></name><name><surname>Menger</surname><given-names>M.D.</given-names></name><name><surname>Ullrich</surname><given-names>A.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name></person-group><article-title>Combined inhibition of VEGF and PDGF signalling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell surviving mechanisms</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><fpage>338</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">14657001</pub-id></element-citation></ref><ref id="b97-ijms-14-15885"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassus</surname><given-names>H.</given-names></name><name><surname>Sihto</surname><given-names>H.</given-names></name><name><surname>Leminen</surname><given-names>A.</given-names></name><name><surname>Nordling</surname><given-names>S.</given-names></name><name><surname>Joensuu</surname><given-names>H.</given-names></name><name><surname>Nupponen</surname><given-names>N.N.</given-names></name><name><surname>Butzow</surname><given-names>R.</given-names></name></person-group><article-title>Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma</article-title><source>Br. J. Cancer</source><year>2004</year><volume>91</volume><fpage>2048</fpage><lpage>2055</lpage><pub-id pub-id-type="pmid">15583695</pub-id></element-citation></ref><ref id="b98-ijms-14-15885"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Fieber</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Eriksson</surname><given-names>U.</given-names></name></person-group><article-title>Tissue plasminogen activator is a potent activator of PDGF-C.C</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>3793</fpage><lpage>3802</lpage><pub-id pub-id-type="pmid">15372073</pub-id></element-citation></ref><ref id="b99-ijms-14-15885"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazlauskas</surname><given-names>A.</given-names></name><name><surname>Cooper</surname><given-names>J.A.</given-names></name></person-group><article-title>Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins</article-title><source>Cell</source><year>1989</year><volume>58</volume><fpage>1121</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">2550144</pub-id></element-citation></ref><ref id="b100-ijms-14-15885"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrae</surname><given-names>J.</given-names></name><name><surname>Gallini</surname><given-names>R.</given-names></name><name><surname>Betsholtz</surname><given-names>C.</given-names></name></person-group><article-title>Role of platelet-derived growth factors in physiology and medicine</article-title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>1276</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">18483217</pub-id></element-citation></ref><ref id="b101-ijms-14-15885"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Board</surname><given-names>R.</given-names></name><name><surname>Jayson</surname><given-names>G.C.</given-names></name></person-group><article-title>Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics</article-title><source>Drug Resist. Updat</source><year>2005</year><volume>8</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15939344</pub-id></element-citation></ref><ref id="b102-ijms-14-15885"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valius</surname><given-names>M.</given-names></name><name><surname>Kazlauskas</surname><given-names>A.</given-names></name></person-group><article-title>Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor’s mitogenic signal</article-title><source>Cell</source><year>1993</year><volume>73</volume><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">7682895</pub-id></element-citation></ref><ref id="b103-ijms-14-15885"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname><given-names>S.R.</given-names></name><name><surname>Escobedo</surname><given-names>J.A.</given-names></name><name><surname>Williams</surname><given-names>L.T.</given-names></name></person-group><article-title>Role of phosphatidylinositol kinase in PDGF receptor signal transduction</article-title><source>Science</source><year>1989</year><volume>243</volume><fpage>1191</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">2466336</pub-id></element-citation></ref><ref id="b104-ijms-14-15885"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldin</surname><given-names>C.H.</given-names></name><name><surname>Ostman</surname><given-names>A.</given-names></name><name><surname>Ronnstrand</surname><given-names>L.</given-names></name></person-group><article-title>Signal transduction via platelet-derived growth factor receptors</article-title><source>Biochim. Biophys. Acta</source><year>1998</year><volume>1378</volume><fpage>79</fpage><lpage>113</lpage></element-citation></ref><ref id="b105-ijms-14-15885"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>S.M.</given-names></name><name><surname>Bucana</surname><given-names>C.D.</given-names></name><name><surname>Killion</surname><given-names>J.J.</given-names></name><name><surname>Gershenson</surname><given-names>D.</given-names></name><name><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines</article-title><source>Gynecol. Oncol</source><year>2004</year><volume>93</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">15047217</pub-id></element-citation></ref><ref id="b106-ijms-14-15885"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matei</surname><given-names>D.</given-names></name><name><surname>Graeber</surname><given-names>T.G.</given-names></name><name><surname>Baldwin</surname><given-names>R.L.</given-names></name><name><surname>Karlan</surname><given-names>B.Y.</given-names></name><name><surname>Rao</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>D.D.</given-names></name></person-group><article-title>Gene expression in epithelial ovarian carcinoma</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>6289</fpage><lpage>6298</lpage><pub-id pub-id-type="pmid">12214269</pub-id></element-citation></ref><ref id="b107-ijms-14-15885"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>S.M.</given-names></name><name><surname>Fan</surname><given-names>D.</given-names></name><name><surname>Killion</surname><given-names>J.J.</given-names></name><name><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma</article-title><source>Clin. Cancer Res</source><year>2004</year><volume>10</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">14871965</pub-id></element-citation></ref><ref id="b108-ijms-14-15885"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matei</surname><given-names>D.</given-names></name><name><surname>Emerson</surname><given-names>R.E.</given-names></name><name><surname>Lai</surname><given-names>Y.C.</given-names></name><name><surname>Baldridge</surname><given-names>L.A.</given-names></name><name><surname>Rao</surname><given-names>J.</given-names></name><name><surname>Yiannoutsos</surname><given-names>C.</given-names></name><name><surname>Donner</surname><given-names>D.D.</given-names></name></person-group><article-title>Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>2060</fpage><lpage>2069</lpage><pub-id pub-id-type="pmid">16331269</pub-id></element-citation></ref><ref id="b109-ijms-14-15885"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>K.</given-names></name><name><surname>Pahler</surname><given-names>J.</given-names></name><name><surname>Bergers</surname><given-names>G.</given-names></name><name><surname>Hanahan</surname><given-names>D.</given-names></name></person-group><article-title>Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><pub-id pub-id-type="doi">10.1371/journal.pmed.0050019</pub-id></element-citation></ref><ref id="b110-ijms-14-15885"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uren</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>J.C.</given-names></name><name><surname>Gholami</surname><given-names>N.S.</given-names></name><name><surname>Pierce</surname><given-names>J.H.</given-names></name><name><surname>Heidaran</surname><given-names>M.A.</given-names></name></person-group><article-title>The alpha PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis</article-title><source>Biochem. Biophys. Res. Commun</source><year>1994</year><volume>204</volume><fpage>628</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">7980524</pub-id></element-citation></ref><ref id="b111-ijms-14-15885"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>K.</given-names></name><name><surname>Sjöblom</surname><given-names>T.</given-names></name><name><surname>Rubin</surname><given-names>K.</given-names></name><name><surname>Heldin</surname><given-names>C.H.</given-names></name><name><surname>Ostman</surname><given-names>A.</given-names></name></person-group><article-title>PDGF receptors as cancer drug targets</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">12781361</pub-id></element-citation></ref><ref id="b112-ijms-14-15885"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colvin</surname><given-names>J.S.</given-names></name><name><surname>Bohne</surname><given-names>B.A.</given-names></name><name><surname>Harding</surname><given-names>G.W.</given-names></name><name><surname>McEwen</surname><given-names>D.G.</given-names></name><name><surname>Ornitz</surname><given-names>D.M.</given-names></name></person-group><article-title>Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor</article-title><source>Nat. Genet</source><year>1996</year><volume>12</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">8630492</pub-id></element-citation></ref><ref id="b113-ijms-14-15885"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaffer</surname><given-names>C.L.</given-names></name><name><surname>Dopheide</surname><given-names>B.</given-names></name><name><surname>Savagner</surname><given-names>P.</given-names></name><name><surname>Thompson</surname><given-names>E.W.</given-names></name><name><surname>Williams</surname><given-names>E.D.</given-names></name></person-group><article-title>Aberrant fibroblast growth factor receptor signaling in bladder and other cancers</article-title><source>Differentiation</source><year>2007</year><volume>75</volume><fpage>831</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">17697126</pub-id></element-citation></ref><ref id="b114-ijms-14-15885"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshenawy</surname><given-names>H.A.</given-names></name></person-group><article-title>Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin’s lymphoma</article-title><source>Ann. Diagn. Pathol</source><year>2010</year><volume>14</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">20850693</pub-id></element-citation></ref><ref id="b115-ijms-14-15885"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>N.</given-names></name><name><surname>Ornitz</surname><given-names>D.M.</given-names></name></person-group><article-title>Evolution of the <italic>Fgf</italic> and <italic>Fgfr</italic> gene families</article-title><source>Trends Genet</source><year>2004</year><volume>20</volume><fpage>565</fpage><lpage>569</lpage></element-citation></ref><ref id="b116-ijms-14-15885"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N.</given-names></name><name><surname>Grose</surname><given-names>R.</given-names></name></person-group><article-title>Fibroblast growth factor signaling: From development to cancer</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">20094046</pub-id></element-citation></ref><ref id="b117-ijms-14-15885"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korc</surname><given-names>M.</given-names></name><name><surname>Friesel</surname><given-names>R.E.</given-names></name></person-group><article-title>The role of fibroblast growth factors in tumor growth</article-title><source>Curr. Cancer Drug Targets</source><year>2009</year><volume>9</volume><fpage>639</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">19508171</pub-id></element-citation></ref><ref id="b118-ijms-14-15885"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lappi</surname><given-names>D.A.</given-names></name></person-group><article-title>Tumor targeting through fibroblast growth factor receptors</article-title><source>Semin. Cancer Biol</source><year>1995</year><volume>6</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">8562905</pub-id></element-citation></ref><ref id="b119-ijms-14-15885"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gorry</surname><given-names>M.C.</given-names></name><name><surname>Post</surname><given-names>J.C.</given-names></name><name><surname>Ehrlich</surname><given-names>G.D.</given-names></name></person-group><article-title>Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family</article-title><source>Gene</source><year>1999</year><volume>230</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">10196476</pub-id></element-citation></ref><ref id="b120-ijms-14-15885"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byron</surname><given-names>S.A.</given-names></name><name><surname>Gartside</surname><given-names>M.G.</given-names></name><name><surname>Wellens</surname><given-names>C.L.</given-names></name><name><surname>Goodfellow</surname><given-names>P.J.</given-names></name><name><surname>Birrer</surname><given-names>M.J.</given-names></name><name><surname>Campbell</surname><given-names>I.G.</given-names></name><name><surname>Pollock</surname><given-names>P.M.</given-names></name></person-group><article-title>FGFR2 mutations are rare across histologic subtypes of ovarian cancer</article-title><source>Gynecol. Oncol</source><year>2010</year><volume>117</volume><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">20106510</pub-id></element-citation></ref><ref id="b121-ijms-14-15885"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carstens</surname><given-names>R.P.</given-names></name><name><surname>McKeehan</surname><given-names>W.L.</given-names></name><name><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name></person-group><article-title>An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing</article-title><source>Mol. Cell Biol</source><year>1998</year><volume>18</volume><fpage>2205</fpage><lpage>2217</lpage><pub-id pub-id-type="pmid">9528792</pub-id></element-citation></ref><ref id="b122-ijms-14-15885"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>I.A.</given-names></name><name><surname>Edmondson</surname><given-names>R.J.</given-names></name><name><surname>Bulmer</surname><given-names>J.N.</given-names></name><name><surname>Bolger</surname><given-names>B.S.</given-names></name><name><surname>Leung</surname><given-names>H.Y.</given-names></name><name><surname>Davies</surname><given-names>B.R.</given-names></name></person-group><article-title>Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>5878</fpage><lpage>5887</lpage><pub-id pub-id-type="pmid">11593393</pub-id></element-citation></ref><ref id="b123-ijms-14-15885"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneda</surname><given-names>J.</given-names></name><name><surname>Kuniyasu</surname><given-names>H.</given-names></name><name><surname>Crispens</surname><given-names>M.A.</given-names></name><name><surname>Price</surname><given-names>J.E.</given-names></name><name><surname>Bucana</surname><given-names>C.D.</given-names></name><name><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice</article-title><source>J. Natl. Cancer Inst</source><year>1998</year><volume>90</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">9521169</pub-id></element-citation></ref><ref id="b124-ijms-14-15885"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>D.P.</given-names></name><name><surname>Cai</surname><given-names>A.</given-names></name><name><surname>Wendt</surname><given-names>K.</given-names></name><name><surname>Young</surname><given-names>M.</given-names></name><name><surname>Gamero</surname><given-names>A.</given-names></name><name><surname>de Cesare</surname><given-names>S.</given-names></name></person-group><article-title>Angiogenic protein expression in advanced epithelial ovarian cancer</article-title><source>Clin. Cancer Res</source><year>1997</year><volume>3</volume><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">9815846</pub-id></element-citation></ref><ref id="b125-ijms-14-15885"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>C.V.</given-names></name><name><surname>Steffensen</surname><given-names>K.D.</given-names></name><name><surname>Olsen</surname><given-names>D.A.</given-names></name><name><surname>Waldstrøm</surname><given-names>M.</given-names></name><name><surname>Søgaard</surname><given-names>C.H.</given-names></name><name><surname>Brandslund</surname><given-names>I.</given-names></name><name><surname>Jakobsen</surname><given-names>A.</given-names></name></person-group><article-title>Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors</article-title><source>Anticancer Res</source><year>2012</year><volume>32</volume><fpage>3817</fpage><lpage>3825</lpage><pub-id pub-id-type="pmid">22993324</pub-id></element-citation></ref><ref id="b126-ijms-14-15885"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>I.A.</given-names></name><name><surname>Edmondson</surname><given-names>R.J.</given-names></name><name><surname>Leung</surname><given-names>H.Y.</given-names></name><name><surname>Davies</surname><given-names>B.R.</given-names></name></person-group><article-title>Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines</article-title><source>Growth Factors</source><year>2006</year><volume>24</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16393693</pub-id></element-citation></ref><ref id="b127-ijms-14-15885"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebben</surname><given-names>P.J.</given-names></name><name><surname>Kalli</surname><given-names>K.R.</given-names></name><name><surname>Cliby</surname><given-names>W.A.</given-names></name><name><surname>Hartmann</surname><given-names>L.C.</given-names></name><name><surname>Grande</surname><given-names>J.P.</given-names></name><name><surname>Singh</surname><given-names>R.J.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name></person-group><article-title>Elevated fibroblast growth factor 23 in women with malignant ovarian tumors</article-title><source>Mayo Clin. Proc</source><year>2005</year><volume>80</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">15948297</pub-id></element-citation></ref><ref id="b128-ijms-14-15885"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouanneau</surname><given-names>J.</given-names></name><name><surname>Moens</surname><given-names>G.</given-names></name><name><surname>Montesano</surname><given-names>R.</given-names></name><name><surname>Thiery</surname><given-names>J.P.</given-names></name></person-group><article-title>FGF-1 but not FGF-4 secreted by carcinoma cells promotes <italic>in vitro</italic> and <italic>in vivo</italic> angiogenesis and rapid tumor proliferation</article-title><source>Growth Factors</source><year>1995</year><volume>12</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">8527162</pub-id></element-citation></ref><ref id="b129-ijms-14-15885"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seghezzi</surname><given-names>G.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Ren</surname><given-names>C.J.</given-names></name><name><surname>Gualandris</surname><given-names>A.</given-names></name><name><surname>Pintucci</surname><given-names>C.</given-names></name><name><surname>Robbins</surname><given-names>E.S.</given-names></name><name><surname>Shapiro</surname><given-names>R.L.</given-names></name><name><surname>Galloway</surname><given-names>A.C.</given-names></name><name><surname>Rifkin</surname><given-names>D.B.</given-names></name><name><surname>Mignatti</surname><given-names>P.</given-names></name></person-group><article-title>Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis</article-title><source>J. Cell Biol</source><year>1998</year><volume>141</volume><fpage>1659</fpage><lpage>1673</lpage><pub-id pub-id-type="pmid">9647657</pub-id></element-citation></ref><ref id="b130-ijms-14-15885"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>M.</given-names></name><name><surname>Katoh</surname><given-names>M.</given-names></name></person-group><article-title>FGF signaling network in the gastrointestinal tract</article-title><source>Int. J. Oncol</source><year>2006</year><volume>29</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">16773196</pub-id></element-citation></ref><ref id="b131-ijms-14-15885"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akai</surname><given-names>J.</given-names></name><name><surname>Halley</surname><given-names>P.A.</given-names></name><name><surname>Storey</surname><given-names>K.G.</given-names></name></person-group><article-title>FGF-dependent Notch signaling maintains the spinal cord stem zone</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><fpage>2877</fpage><lpage>2887</lpage><pub-id pub-id-type="pmid">16287717</pub-id></element-citation></ref><ref id="b132-ijms-14-15885"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiss</surname><given-names>Y.</given-names></name></person-group><article-title>Angiopoietins</article-title><source>Recent Results Cancer Res.</source><year>2010</year><volume>180</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">20033375</pub-id></element-citation></ref><ref id="b133-ijms-14-15885"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcon</surname><given-names>B.L.</given-names></name><name><surname>Hashizume</surname><given-names>H.</given-names></name><name><surname>Koumoutsakos</surname><given-names>P.</given-names></name><name><surname>Chou</surname><given-names>J.</given-names></name><name><surname>Bready</surname><given-names>J.V.</given-names></name><name><surname>Coxon</surname><given-names>A.</given-names></name><name><surname>Oliner</surname><given-names>J.D.</given-names></name><name><surname>McDonald</surname><given-names>D.M.</given-names></name></person-group><article-title>Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels</article-title><source>Am. J. Pathol</source><year>2009</year><volume>175</volume><fpage>2159</fpage><lpage>2170</lpage><pub-id pub-id-type="pmid">19815705</pub-id></element-citation></ref><ref id="b134-ijms-14-15885"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papapetropoulos</surname><given-names>A.</given-names></name><name><surname>Fulton</surname><given-names>D.</given-names></name><name><surname>Mahboubi</surname><given-names>K.</given-names></name><name><surname>Kalb</surname><given-names>R.G.</given-names></name><name><surname>O’Connor</surname><given-names>D.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Altieri</surname><given-names>D.C.</given-names></name><name><surname>Sessa</surname><given-names>W.C.</given-names></name></person-group><article-title>Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway</article-title><source>J. Biol. Chem</source><year>2000</year><volume>275</volume><fpage>9102</fpage><lpage>9105</lpage><pub-id pub-id-type="pmid">10734041</pub-id></element-citation></ref><ref id="b135-ijms-14-15885"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrillo</surname><given-names>M.</given-names></name><name><surname>Scambia</surname><given-names>G.</given-names></name><name><surname>Ferrandina</surname><given-names>G.</given-names></name></person-group><article-title>Novel targets for VEGF-independent anti-angiogenic drugs</article-title><source>Expert Opin. Investig. Drugs</source><year>2012</year><volume>21</volume><fpage>451</fpage><lpage>472</lpage></element-citation></ref><ref id="b136-ijms-14-15885"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H.T.</given-names></name><name><surname>Khankin</surname><given-names>E.V.</given-names></name><name><surname>Karumanchi</surname><given-names>S.A.</given-names></name><name><surname>Parikh</surname><given-names>S.M.</given-names></name></person-group><article-title>Angiopoietin 2 is a partial agonist/antagonist of tie2 signaling in the endothelium</article-title><source>Mol. Cell Biol</source><year>2009</year><volume>29</volume><fpage>2011</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">19223473</pub-id></element-citation></ref><ref id="b137-ijms-14-15885"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Park</surname><given-names>J.W.</given-names></name><name><surname>Katsaros</surname><given-names>D.</given-names></name><name><surname>Fracchioli</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>O’Brien-Jenkins</surname><given-names>A.</given-names></name><name><surname>Randall</surname><given-names>T.C.</given-names></name><name><surname>Rubin</surname><given-names>S.C.</given-names></name><name><surname>Coukos</surname><given-names>G.</given-names></name></person-group><article-title>Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>3403</fpage><lpage>3412</lpage><pub-id pub-id-type="pmid">12810677</pub-id></element-citation></ref><ref id="b138-ijms-14-15885"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliner</surname><given-names>J.</given-names></name><name><surname>Min</surname><given-names>H.</given-names></name><name><surname>Leal</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>You</surname><given-names>E.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Meyer</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.J.</given-names></name><etal></etal></person-group><article-title>Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2</article-title><source>Cancer Cell</source><year>2004</year><volume>6</volume><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">15542434</pub-id></element-citation></ref><ref id="b139-ijms-14-15885"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M.</given-names></name><name><surname>Felcht</surname><given-names>M.</given-names></name><name><surname>Kruse</surname><given-names>K.</given-names></name><name><surname>Kretschmer</surname><given-names>S.</given-names></name><name><surname>Deppermann</surname><given-names>C.</given-names></name><name><surname>Biesdorf</surname><given-names>A.</given-names></name><name><surname>Rohr</surname><given-names>K.</given-names></name><name><surname>Benest</surname><given-names>A.V.</given-names></name><name><surname>Fiedler</surname><given-names>U.</given-names></name><name><surname>Augustin</surname><given-names>H.G.</given-names></name></person-group><article-title>Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation</article-title><source>J. Biol. Chem</source><year>2010</year><volume>285</volume><fpage>23842</fpage><lpage>23849</lpage><pub-id pub-id-type="pmid">20519501</pub-id></element-citation></ref><ref id="b140-ijms-14-15885"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Muñoz</surname><given-names>A.</given-names></name><name><surname>Mendiola</surname><given-names>C.</given-names></name><name><surname>Pérez-Ruiz</surname><given-names>E.</given-names></name><name><surname>Rodríguez-Sánchez</surname><given-names>C.A.</given-names></name><name><surname>Jurado</surname><given-names>J.M.</given-names></name><name><surname>Alonso-Carrión</surname><given-names>L.</given-names></name><name><surname>Ghanem</surname><given-names>I.</given-names></name><name><surname>de Velasco</surname><given-names>G.</given-names></name><name><surname>Quero-Blanco</surname><given-names>C.</given-names></name><name><surname>Alba</surname><given-names>E.</given-names></name></person-group><article-title>Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer</article-title><source>Oncology</source><year>2010</year><volume>79</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">21079407</pub-id></element-citation></ref><ref id="b141-ijms-14-15885"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGonigle</surname><given-names>K.F.</given-names></name><name><surname>Muntz</surname><given-names>H.G.</given-names></name><name><surname>Vuky</surname><given-names>J.</given-names></name><name><surname>Paley</surname><given-names>P.J.</given-names></name><name><surname>Veljovich</surname><given-names>D.S.</given-names></name><name><surname>Greer</surname><given-names>B.E.</given-names></name><name><surname>Goff</surname><given-names>B.A.</given-names></name><name><surname>Gray</surname><given-names>H.J.</given-names></name><name><surname>Malpass</surname><given-names>T.W.</given-names></name></person-group><article-title>Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>3731</fpage><lpage>3740</lpage><pub-id pub-id-type="pmid">21815133</pub-id></element-citation></ref><ref id="b142-ijms-14-15885"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudoh</surname><given-names>K.</given-names></name><name><surname>Takano</surname><given-names>M.</given-names></name><name><surname>Kouta</surname><given-names>H.</given-names></name><name><surname>Kikuchi</surname><given-names>R.</given-names></name><name><surname>Kita</surname><given-names>T.</given-names></name><name><surname>Miyamoto</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>Kato</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>T.</given-names></name><name><surname>Kikuchi</surname><given-names>Y.</given-names></name></person-group><article-title>Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers</article-title><source>Gynecol. Oncol</source><year>2011</year><volume>122</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">21601912</pub-id></element-citation></ref><ref id="b143-ijms-14-15885"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbe</surname><given-names>B.</given-names></name><name><surname>Graflund</surname><given-names>M.</given-names></name><name><surname>Horvath</surname><given-names>G.</given-names></name><name><surname>Swahn</surname><given-names>M.</given-names></name><name><surname>Boman</surname><given-names>K.</given-names></name><name><surname>Bangshöj</surname><given-names>R.</given-names></name><name><surname>Lood</surname><given-names>M.</given-names></name><name><surname>Malmström</surname><given-names>H.</given-names></name></person-group><article-title>Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer</article-title><source>Int. J. Gynecol. Cancer</source><year>2012</year><volume>22</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">22193643</pub-id></element-citation></ref><ref id="b144-ijms-14-15885"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agheli</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>S.C.</given-names></name><name><surname>Huang</surname><given-names>C.J.</given-names></name><name><surname>Wang</surname><given-names>J.C.</given-names></name></person-group><article-title>Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma</article-title><source>Anticancer Drugs</source><year>2009</year><volume>20</volume><fpage>525</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">19568002</pub-id></element-citation></ref><ref id="b145-ijms-14-15885"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesiano</surname><given-names>S.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Jaffe</surname><given-names>R.B.</given-names></name></person-group><article-title>Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization</article-title><source>Am. J. Pathol</source><year>1998</year><volume>153</volume><fpage>1249</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">9777956</pub-id></element-citation></ref><ref id="b146-ijms-14-15885"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Hofmann</surname><given-names>J.</given-names></name><name><surname>Zaloudek</surname><given-names>C.</given-names></name><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Hamilton</surname><given-names>T.</given-names></name><name><surname>Jaffe</surname><given-names>R.B.</given-names></name></person-group><article-title>Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer</article-title><source>Am. J. Pathol</source><year>2002</year><volume>161</volume><fpage>1917</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">12414537</pub-id></element-citation></ref><ref id="b147-ijms-14-15885"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>S.</given-names></name><name><surname>Terai</surname><given-names>Y.</given-names></name><name><surname>Morishige</surname><given-names>K.</given-names></name><name><surname>Tanabe-Kimura</surname><given-names>A.</given-names></name><name><surname>Sasaki</surname><given-names>H.</given-names></name><name><surname>Kanemura</surname><given-names>M.</given-names></name><name><surname>Tsunetoh</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Sakata</surname><given-names>M.</given-names></name><name><surname>Burger</surname><given-names>R.A.</given-names></name><etal></etal></person-group><article-title>Maintenance treatment with bevacizumab prolongs survival in an <italic>in vivo</italic> ovarian cancer model</article-title><source>Clin. Cancer Res</source><year>2008</year><volume>14</volume><fpage>7781</fpage><lpage>7789</lpage><pub-id pub-id-type="pmid">19047105</pub-id></element-citation></ref><ref id="b148-ijms-14-15885"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>R.A.</given-names></name><name><surname>Brady</surname><given-names>M.F.</given-names></name><name><surname>Bookman</surname><given-names>M.A.</given-names></name><name><surname>Fleming</surname><given-names>G.F.</given-names></name><name><surname>Monk</surname><given-names>B.J.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Mannel</surname><given-names>R.S.</given-names></name><name><surname>Homesley</surname><given-names>H.D.</given-names></name><name><surname>Fowler</surname><given-names>J.</given-names></name><name><surname>Greer</surname><given-names>B.E.</given-names></name><etal></etal></person-group><collab>Gynecologic Oncology Group</collab><article-title>Incorporation of bevacizumab in the primary treatment of ovarian cancer</article-title><source>N. Engl. J. Med</source><year>2011</year><volume>365</volume><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">22204724</pub-id></element-citation></ref><ref id="b149-ijms-14-15885"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poveda</surname><given-names>A.M.</given-names></name><name><surname>Selle</surname><given-names>F.</given-names></name><name><surname>Hilpert</surname><given-names>F.</given-names></name><name><surname>Reuss</surname><given-names>A.</given-names></name><name><surname>Pasic</surname><given-names>A.</given-names></name><name><surname>Savarese</surname><given-names>A.</given-names></name><name><surname>Vergote</surname><given-names>I.B.</given-names></name><name><surname>Witteveen</surname><given-names>P.</given-names></name><name><surname>Bamias</surname><given-names>A.</given-names></name><name><surname>Bollag</surname><given-names>D.</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name></person-group><article-title>Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD), or topotecan (TOP) + bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC). Analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomized phase III trial</article-title><source>Ann. Oncol</source><year>2012</year><volume>23</volume><pub-id pub-id-type="doi">10.1093/annonc/mds499</pub-id></element-citation></ref><ref id="b150-ijms-14-15885"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>T.</given-names></name><name><surname>Dhingra</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Tomar</surname><given-names>P.</given-names></name><name><surname>Malhotra</surname><given-names>M.</given-names></name><name><surname>Bhardwaj</surname><given-names>T.R.</given-names></name></person-group><article-title>Aflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors</article-title><source>Mini Rev. Med. Chem</source><year>2013</year><volume>13</volume><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">23317499</pub-id></element-citation></ref><ref id="b151-ijms-14-15885"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troiani</surname><given-names>T.</given-names></name><name><surname>Martinelli</surname><given-names>E.</given-names></name><name><surname>Orditura</surname><given-names>M.</given-names></name><name><surname>De Vita</surname><given-names>F.</given-names></name><name><surname>Ciardiello</surname><given-names>F.</given-names></name><name><surname>Morgillo</surname><given-names>F.</given-names></name></person-group><article-title>Beyond bevacizumab: New anti-VEGF strategies in colorectal cancer</article-title><source>Expert Opin. Investig. Drugs</source><year>2012</year><volume>21</volume><fpage>949</fpage><lpage>959</lpage></element-citation></ref><ref id="b152-ijms-14-15885"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>A.T.</given-names></name><name><surname>Ross</surname><given-names>L.</given-names></name><name><surname>Holash</surname><given-names>J.</given-names></name><name><surname>Nakanishi</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Hofmann</surname><given-names>J.I.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><name><surname>Jaffe</surname><given-names>R.B.</given-names></name></person-group><article-title>Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model</article-title><source>Clin. Can. Res</source><year>2003</year><volume>9</volume><fpage>5721</fpage><lpage>5728</lpage></element-citation></ref><ref id="b153-ijms-14-15885"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baffert</surname><given-names>F.</given-names></name><name><surname>Le</surname><given-names>T.</given-names></name><name><surname>Sennino</surname><given-names>B.</given-names></name><name><surname>Thurston</surname><given-names>G.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Hu-Lowe</surname><given-names>D.</given-names></name><name><surname>McDonald</surname><given-names>D.M.</given-names></name></person-group><article-title>Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling</article-title><source>Am. J. Physiol. Heart Circ. Physiol</source><year>2006</year><volume>290</volume><fpage>547</fpage><lpage>559</lpage></element-citation></ref><ref id="b154-ijms-14-15885"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freyer</surname><given-names>G.</given-names></name><name><surname>Isambert</surname><given-names>N.</given-names></name><name><surname>You</surname><given-names>B.</given-names></name><name><surname>Zanetta</surname><given-names>S.</given-names></name><name><surname>Falandry</surname><given-names>C.</given-names></name><name><surname>Favier</surname><given-names>L.</given-names></name><name><surname>Trillet-Lenoir</surname><given-names>V.</given-names></name><name><surname>Assadourian</surname><given-names>S.</given-names></name><name><surname>Soussan-Lazard</surname><given-names>K.</given-names></name><name><surname>Ziti-Ljajic</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours</article-title><source>Br. J. Cancer</source><year>2012</year><volume>107</volume><fpage>598</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">22790797</pub-id></element-citation></ref><ref id="b155-ijms-14-15885"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>R.L.</given-names></name><name><surname>Duska</surname><given-names>L.R.</given-names></name><name><surname>Ramirez</surname><given-names>P.T.</given-names></name><name><surname>Heymach</surname><given-names>J.V.</given-names></name><name><surname>Kamat</surname><given-names>A.A.</given-names></name><name><surname>Modesitt</surname><given-names>S.C.</given-names></name><name><surname>Schmeler</surname><given-names>K.M.</given-names></name><name><surname>Iyer</surname><given-names>R.B.</given-names></name><name><surname>Garcia</surname><given-names>M.E.</given-names></name><name><surname>Miller</surname><given-names>D.L.</given-names></name><etal></etal></person-group><article-title>Phase 1–2. study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>1109</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">21992853</pub-id></element-citation></ref><ref id="b156-ijms-14-15885"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>G.J.</given-names></name><name><surname>Heckel</surname><given-names>A.</given-names></name><name><surname>Colbatzky</surname><given-names>F.</given-names></name><name><surname>Handschuh</surname><given-names>S.</given-names></name><name><surname>Kley</surname><given-names>J.</given-names></name><name><surname>Lehmann-Lintz</surname><given-names>T.</given-names></name><name><surname>Lotz</surname><given-names>R.</given-names></name><name><surname>Tontsch-Grunt</surname><given-names>U.</given-names></name><name><surname>Walter</surname><given-names>R.</given-names></name><name><surname>Hilberg</surname><given-names>F.</given-names></name></person-group><article-title>Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</article-title><source>J. Med. Chem</source><year>2009</year><volume>52</volume><fpage>4466</fpage><lpage>4480</lpage><pub-id pub-id-type="pmid">19522465</pub-id></element-citation></ref><ref id="b157-ijms-14-15885"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilberg</surname><given-names>F.</given-names></name><name><surname>Roth</surname><given-names>G.J.</given-names></name><name><surname>Krssak</surname><given-names>M.</given-names></name><name><surname>Kautschitsch</surname><given-names>S.</given-names></name><name><surname>Sommergruber</surname><given-names>W.</given-names></name><name><surname>Tontsch-Grunt</surname><given-names>U.</given-names></name><name><surname>Garin-Chesa</surname><given-names>P.</given-names></name><name><surname>Bader</surname><given-names>G.</given-names></name><name><surname>Zoephel</surname><given-names>A.</given-names></name><name><surname>Quant</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>4774</fpage><lpage>4782</lpage><pub-id pub-id-type="pmid">18559524</pub-id></element-citation></ref><ref id="b158-ijms-14-15885"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du Bois</surname><given-names>A.</given-names></name><name><surname>Huober</surname><given-names>J.</given-names></name><name><surname>Stopfer</surname><given-names>P.</given-names></name><name><surname>Pfisterer</surname><given-names>J.</given-names></name><name><surname>Wimberger</surname><given-names>P.</given-names></name><name><surname>Loibl</surname><given-names>S.</given-names></name><name><surname>Reichardt</surname><given-names>V.L.</given-names></name><name><surname>Harter</surname><given-names>P.</given-names></name></person-group><article-title>A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies</article-title><source>Ann. Oncol</source><year>2010</year><volume>21</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">19889612</pub-id></element-citation></ref><ref id="b159-ijms-14-15885"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedlander</surname><given-names>M.</given-names></name><name><surname>Hancock</surname><given-names>K.C.</given-names></name><name><surname>Rischin</surname><given-names>D.</given-names></name><name><surname>Messing</surname><given-names>M.J.</given-names></name><name><surname>Stringer</surname><given-names>C.A.</given-names></name><name><surname>Matthys</surname><given-names>G.M.</given-names></name><name><surname>Ma</surname><given-names>B.</given-names></name><name><surname>Hodge</surname><given-names>J.P.</given-names></name><name><surname>Lager</surname><given-names>J.J.</given-names></name></person-group><article-title>A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer</article-title><source>Gynecol. Oncol</source><year>2010</year><volume>119</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">20584542</pub-id></element-citation></ref><ref id="b160-ijms-14-15885"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamberg</surname><given-names>P.</given-names></name><name><surname>Verweij</surname><given-names>J.</given-names></name><name><surname>Sleijfer</surname><given-names>S.</given-names></name></person-group><article-title>(Pre-)Clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor</article-title><source>Oncologist</source><year>2010</year><volume>15</volume><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">20511320</pub-id></element-citation></ref><ref id="b161-ijms-14-15885"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matulonis</surname><given-names>U.A.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Ivy</surname><given-names>P.</given-names></name><name><surname>Tyburski</surname><given-names>K.</given-names></name><name><surname>Krasner</surname><given-names>C.</given-names></name><name><surname>Zarwan</surname><given-names>C.</given-names></name><name><surname>Berkenblit</surname><given-names>A.</given-names></name><name><surname>Campos</surname><given-names>S.</given-names></name><name><surname>Horowitz</surname><given-names>N.</given-names></name><name><surname>Cannistra</surname><given-names>S.A.</given-names></name><etal></etal></person-group><article-title>Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer</article-title><source>J. Clin. Oncol</source><year>2009</year><volume>27</volume><fpage>5601</fpage><lpage>5606</lpage><pub-id pub-id-type="pmid">19826113</pub-id></element-citation></ref><ref id="b162-ijms-14-15885"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahade</surname><given-names>M.</given-names></name><name><surname>Caparelli</surname><given-names>F.</given-names></name><name><surname>Hoff</surname><given-names>P.M.</given-names></name></person-group><article-title>Cediranib: A VEGF receptor tyrosine kinase inhibitor</article-title><source>Future Oncol</source><year>2012</year><volume>8</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">22830398</pub-id></element-citation></ref><ref id="b163-ijms-14-15885"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedge</surname><given-names>S.R.</given-names></name><name><surname>Kendrew</surname><given-names>J.</given-names></name><name><surname>Hennequin</surname><given-names>L.F.</given-names></name><name><surname>Valentine</surname><given-names>P.J.</given-names></name><name><surname>Barry</surname><given-names>S.T.</given-names></name><name><surname>Brave</surname><given-names>S.R.</given-names></name><name><surname>Smith</surname><given-names>N.R.</given-names></name><name><surname>James</surname><given-names>N.H.</given-names></name><name><surname>Dukes</surname><given-names>M.</given-names></name><name><surname>Curwen</surname><given-names>J.O.</given-names></name><etal></etal></person-group><article-title>AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>4389</fpage><lpage>4400</lpage><pub-id pub-id-type="pmid">15899831</pub-id></element-citation></ref><ref id="b164-ijms-14-15885"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matei</surname><given-names>D.</given-names></name><name><surname>Sill</surname><given-names>M.W.</given-names></name><name><surname>Lankes</surname><given-names>H.A.</given-names></name><name><surname>DeGeest</surname><given-names>K.</given-names></name><name><surname>Bristow</surname><given-names>R.E.</given-names></name><name><surname>Mutch</surname><given-names>D.</given-names></name><name><surname>Yamada</surname><given-names>S.D.</given-names></name><name><surname>Cohn</surname><given-names>D.</given-names></name><name><surname>Calvert</surname><given-names>V.</given-names></name><name><surname>Farley</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial</article-title><source>J. Clin. Oncol</source><year>2011</year><volume>29</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">21098323</pub-id></element-citation></ref><ref id="b165-ijms-14-15885"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>N.</given-names></name><name><surname>Mandai</surname><given-names>M.</given-names></name><name><surname>Okamoto</surname><given-names>T.</given-names></name><name><surname>Yamaguchi</surname><given-names>K.</given-names></name><name><surname>Yamamura</surname><given-names>S.</given-names></name><name><surname>Oura</surname><given-names>T.</given-names></name><name><surname>Baba</surname><given-names>T.</given-names></name><name><surname>Hamanishi</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>H.S.</given-names></name><name><surname>Matsui</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling</article-title><source>Cancer Sci</source><year>2010</year><volume>101</volume><fpage>2658</fpage><lpage>2663</lpage><pub-id pub-id-type="pmid">21040214</pub-id></element-citation></ref><ref id="b166-ijms-14-15885"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauerschlag</surname><given-names>D.O.</given-names></name><name><surname>Schem</surname><given-names>C.</given-names></name><name><surname>Tiwari</surname><given-names>S.</given-names></name><name><surname>Egberts</surname><given-names>J.H.</given-names></name><name><surname>Weigel</surname><given-names>M.T.</given-names></name><name><surname>Kalthoff</surname><given-names>H.</given-names></name><name><surname>Jonat</surname><given-names>W.</given-names></name><name><surname>Maass</surname><given-names>N.</given-names></name><name><surname>Meinhold-Heerlein</surname><given-names>I.</given-names></name></person-group><article-title>Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice</article-title><source>Anticancer Res</source><year>2010</year><volume>30</volume><fpage>3355</fpage><lpage>3360</lpage><pub-id pub-id-type="pmid">20944108</pub-id></element-citation></ref><ref id="b167-ijms-14-15885"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>S.M.</given-names></name><name><surname>Penson</surname><given-names>R.T.</given-names></name><name><surname>Matulonis</surname><given-names>U.</given-names></name><name><surname>Horowitz</surname><given-names>N.S.</given-names></name><name><surname>Whalen</surname><given-names>C.</given-names></name><name><surname>Pereira</surname><given-names>L.</given-names></name><name><surname>Tyburski</surname><given-names>K.</given-names></name><name><surname>Roche</surname><given-names>M.</given-names></name><name><surname>Szymonifka</surname><given-names>J.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name></person-group><article-title>A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma</article-title><source>Gynecol. Oncol</source><year>2013</year><volume>128</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">22885865</pub-id></element-citation></ref><ref id="b168-ijms-14-15885"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlan</surname><given-names>B.Y.</given-names></name><name><surname>Oza</surname><given-names>A.M.</given-names></name><name><surname>Richardson</surname><given-names>G.E.</given-names></name><name><surname>Provencher</surname><given-names>D.M.</given-names></name><name><surname>Hansen</surname><given-names>V.L.</given-names></name><name><surname>Buck</surname><given-names>M.</given-names></name><name><surname>Chambers</surname><given-names>S.K.</given-names></name><name><surname>Ghatage</surname><given-names>P.</given-names></name><name><surname>Pippitt</surname><given-names>C.H.</given-names><suffix>Jr.</suffix></name><name><surname>Brown</surname><given-names>J.V.</given-names><suffix>III</suffix></name><etal></etal></person-group><article-title>Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer</article-title><source>J. Clin. Oncol</source><year>2012</year><volume>30</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">22184370</pub-id></element-citation></ref><ref id="b169-ijms-14-15885"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polverino</surname><given-names>A.</given-names></name><name><surname>Coxon</surname><given-names>A.</given-names></name><name><surname>Starnes</surname><given-names>C.</given-names></name><name><surname>Diaz</surname><given-names>Z.</given-names></name><name><surname>DeMelfi</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Bready</surname><given-names>J.</given-names></name><name><surname>Estrada</surname><given-names>J.</given-names></name><name><surname>Cattley</surname><given-names>R.</given-names></name><name><surname>Kaufman</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>8715</fpage><lpage>8721</lpage><pub-id pub-id-type="pmid">16951187</pub-id></element-citation></ref><ref id="b170-ijms-14-15885"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>D.</given-names></name><name><surname>Secord</surname><given-names>A.A.</given-names></name></person-group><article-title>Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer</article-title><source>Int. J. Gynecol. Cancer</source><year>2012</year><volume>22</volume><fpage>348</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">22266932</pub-id></element-citation></ref><ref id="b171-ijms-14-15885"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquier</surname><given-names>E.</given-names></name><name><surname>Carré</surname><given-names>M.</given-names></name><name><surname>Pourroy</surname><given-names>B.</given-names></name><name><surname>Camoin</surname><given-names>L.</given-names></name><name><surname>Rebaï</surname><given-names>O.</given-names></name><name><surname>Briand</surname><given-names>C.</given-names></name><name><surname>Braguer</surname><given-names>D.</given-names></name></person-group><article-title>Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway</article-title><source>Mol. Cancer Ther</source><year>2004</year><volume>3</volume><fpage>1301</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">15486197</pub-id></element-citation></ref><ref id="b172-ijms-14-15885"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchan</surname><given-names>J.R.</given-names></name><name><surname>Jayaram</surname><given-names>D.R.</given-names></name><name><surname>Supko</surname><given-names>J.G.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Bubley</surname><given-names>G.J.</given-names></name><name><surname>Sukhatme</surname><given-names>V.P.</given-names></name></person-group><article-title>Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition</article-title><source>Int. J. Cancer</source><year>2005</year><volume>113</volume><fpage>490</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">15455390</pub-id></element-citation></ref><ref id="b173-ijms-14-15885"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jubb</surname><given-names>A.M.</given-names></name><name><surname>Hurwitz</surname><given-names>H.I.</given-names></name><name><surname>Bai</surname><given-names>W.</given-names></name><name><surname>Holmgren</surname><given-names>E.B.</given-names></name><name><surname>Tobin</surname><given-names>P.</given-names></name><name><surname>Guerrero</surname><given-names>A.S.</given-names></name><name><surname>Kabbinavar</surname><given-names>F.</given-names></name><name><surname>Holden</surname><given-names>S.N.</given-names></name><name><surname>Novotny</surname><given-names>W.F.</given-names></name><name><surname>Frantz</surname><given-names>G.D.</given-names></name><etal></etal></person-group><article-title>Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer</article-title><source>J. Clin. Oncol</source><year>2006</year><volume>24</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16365183</pub-id></element-citation></ref><ref id="b174-ijms-14-15885"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowlati</surname><given-names>A.</given-names></name><name><surname>Gray</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>D.H.</given-names></name><name><surname>Schiller</surname><given-names>J.H.</given-names></name><name><surname>Brahmer</surname><given-names>J.</given-names></name><name><surname>Sandler</surname><given-names>A.B.</given-names></name></person-group><article-title>Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC)</article-title><source>J. Clin. Oncol</source><year>2006</year><volume>24</volume><fpage>7027</fpage></element-citation></ref><ref id="b175-ijms-14-15885"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>N.S.</given-names></name><name><surname>Penson</surname><given-names>R.T.</given-names></name><name><surname>Duda</surname><given-names>D.G.</given-names></name><name><surname>di Tomaso</surname><given-names>E.</given-names></name><name><surname>Boucher</surname><given-names>Y.</given-names></name><name><surname>Ancukiewicz</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>K.S.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Krasner</surname><given-names>C.N.</given-names></name><name><surname>Moses</surname><given-names>M.A.</given-names></name><etal></etal></person-group><article-title>Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma</article-title><source>Clin. Ovarian Cancer Other Gynecol. Malig</source><year>2011</year><volume>4</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21833345</pub-id></element-citation></ref><ref id="b176-ijms-14-15885"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duda</surname><given-names>D.G.</given-names></name><name><surname>Willett</surname><given-names>C.G.</given-names></name><name><surname>Ancukiewicz</surname><given-names>M.</given-names></name><name><surname>di Tomaso</surname><given-names>E.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Czito</surname><given-names>B.G.</given-names></name><name><surname>Bentley</surname><given-names>R.</given-names></name><name><surname>Poleski</surname><given-names>M.</given-names></name><name><surname>Lauwers</surname><given-names>G.Y.</given-names></name><name><surname>Carroll</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer</article-title><source>Oncologist</source><year>2010</year><volume>15</volume><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">20484123</pub-id></element-citation></ref><ref id="b177-ijms-14-15885"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>A.G.</given-names></name><name><surname>Batchelor</surname><given-names>T.T.</given-names></name><name><surname>Zhang</surname><given-names>W.T.</given-names></name><name><surname>Chen</surname><given-names>P.J.</given-names></name><name><surname>Yeo</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Jennings</surname><given-names>D.</given-names></name><name><surname>Wen</surname><given-names>P.Y.</given-names></name><name><surname>Lahdenranta</surname><given-names>J.</given-names></name><name><surname>Ancukiewicz</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>5296</fpage><lpage>5300</lpage><pub-id pub-id-type="pmid">19549889</pub-id></element-citation></ref><ref id="b178-ijms-14-15885"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>A.X.</given-names></name><name><surname>Sahani</surname><given-names>D.V.</given-names></name><name><surname>Duda</surname><given-names>D.G.</given-names></name><name><surname>di Tomaso</surname><given-names>E.</given-names></name><name><surname>Ancukiewicz</surname><given-names>M.</given-names></name><name><surname>Catalano</surname><given-names>O.A.</given-names></name><name><surname>Sindhwani</surname><given-names>V.</given-names></name><name><surname>Blaszkowsky</surname><given-names>L.S.</given-names></name><name><surname>Yoon</surname><given-names>S.S.</given-names></name><name><surname>Lahdenranta</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study</article-title><source>J. Clin. Oncol</source><year>2009</year><volume>27</volume><fpage>3027</fpage><lpage>3035</lpage><pub-id pub-id-type="pmid">19470923</pub-id></element-citation></ref><ref id="b179-ijms-14-15885"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>R.J.</given-names></name><name><surname>Bukowski</surname><given-names>R.M.</given-names></name></person-group><article-title>Targeted therapy for metastatic renal cell carcinoma</article-title><source>J. Clin. Oncol</source><year>2006</year><volume>24</volume><fpage>5601</fpage><lpage>5608</lpage><pub-id pub-id-type="pmid">17158546</pub-id></element-citation></ref><ref id="b180-ijms-14-15885"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grepin</surname><given-names>R.</given-names></name><name><surname>Guyot</surname><given-names>M.</given-names></name><name><surname>Jacquin</surname><given-names>M.</given-names></name><name><surname>Durivault</surname><given-names>J.</given-names></name><name><surname>Chamorey</surname><given-names>E.</given-names></name><name><surname>Sudaka</surname><given-names>A.</given-names></name><name><surname>Serdjebi</surname><given-names>C.</given-names></name><name><surname>Lacarelle</surname><given-names>B.</given-names></name><name><surname>Scoazec</surname><given-names>J.Y.</given-names></name><name><surname>Negrier</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: The role of CXCL cytokines</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>1683</fpage><lpage>1694</lpage><pub-id pub-id-type="pmid">21909141</pub-id></element-citation></ref><ref id="b181-ijms-14-15885"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebos</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>C.R.</given-names></name><name><surname>Cruz-Munoz</surname><given-names>W.</given-names></name><name><surname>Bjarnason</surname><given-names>G.A.</given-names></name><name><surname>Christensen</surname><given-names>J.G.</given-names></name><name><surname>Kerbel</surname><given-names>R.S.</given-names></name></person-group><article-title>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>232</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">19249681</pub-id></element-citation></ref><ref id="b182-ijms-14-15885"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>M.</given-names></name><name><surname>Avraham</surname><given-names>I.</given-names></name><name><surname>Dor</surname><given-names>Y.</given-names></name><name><surname>Bachar-Lustig</surname><given-names>E.</given-names></name><name><surname>Itin</surname><given-names>A.</given-names></name><name><surname>Jung</surname><given-names>S.</given-names></name><name><surname>Chimenti</surname><given-names>S.</given-names></name><name><surname>Landsman</surname><given-names>L.</given-names></name><name><surname>Abramovitch</surname><given-names>R.</given-names></name><name><surname>Keshet</surname><given-names>E.</given-names></name></person-group><article-title>VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">16413490</pub-id></element-citation></ref><ref id="b183-ijms-14-15885"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favaro</surname><given-names>E.</given-names></name><name><surname>Amadori</surname><given-names>A.</given-names></name><name><surname>Indraccolo</surname><given-names>S.</given-names></name></person-group><article-title>Cellular interactions in the vascular niche: Implications in the regulation of tumor dormancy</article-title><source>Acta Pathol. Microbiol. Immunol. Scand.</source><year>2008</year><volume>116</volume><fpage>648</fpage><lpage>659</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-ijms-14-15885" position="float"><label>Figure 1</label><caption><p>Angiogenesis activation from growth factors within the tumor microenvironment.</p></caption><graphic xlink:href="ijms-14-15885f1"></graphic></fig><fig id="f2-ijms-14-15885" position="float"><label>Figure 2</label><caption><p>Schematic overview of the VEGF pathway.</p></caption><graphic xlink:href="ijms-14-15885f2"></graphic></fig><fig id="f3-ijms-14-15885" position="float"><label>Figure 3</label><caption><p>Schematic overview of the PDGF pathway.</p></caption><graphic xlink:href="ijms-14-15885f3"></graphic></fig><fig id="f4-ijms-14-15885" position="float"><label>Figure 4</label><caption><p>An overview of the FGF signaling pathway.</p></caption><graphic xlink:href="ijms-14-15885f4"></graphic></fig><fig id="f5-ijms-14-15885" position="float"><label>Figure 5</label><caption><p>An overview of the Ang signaling pathway.</p></caption><graphic xlink:href="ijms-14-15885f5"></graphic></fig></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/LrgpV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000195 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000195 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= LrgpV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |